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Introduction and outline of thesis
Invasive aspergillosis : a disease of medical progress
In 1842, John Hughes Bennett was the first to describe a case of pneumomycosis, in which 
the sputum and cavities of a patient with phthisis were found to contain a fungus. By then, 
the fungus Aspergillus had already been described and catalogued by the Italian biologist 
and priest Micheli in 1729. The name “Aspergillus” was derived in reference to the 
sporulating head of the Aspergillus conidia which resembled the aspergillum used by priests 
to sprinkle holy water during church services. Bennett gave the earliest description of 
pulmonary aspergillosis, without recognizing this fungus as being Aspergillus “... and which 
led me to suppose that a vegetable structure must occasionally be developed in the matter of 
tubercle found in the lungs. I am now enabled to put the truth of this supposition beyond 
doubt, whilst circumstances render it highly probable, if  not certain, that in the individual to
whom I am about to refer, these fungi were developed before death.... They appeared to me
somewhat analogous to the Penicilium glaucum or those fungi so often found covering 
disorganized animal matter...” [1].
In the subsequent years, emergence of similar cases led to eventual recognition of this 
fungus as being an Aspergillus [2, 3]. For a considerable time, most recorded observations 
have found the fungus in diseased lungs of patients who suffered from tuberculosis or 
emphysema. The predisposition of the fungus to reside in diseased lung cavities led to the 
opinion that the nature of the fungal invasion was saprophytic and a secondary phenomenon. 
Around the 1890s, pulmonary aspergillosis was seen as a trade disease by the French. 
Disease clusters were reported in pigeon handlers and workers in contact with grains, soil 
and hair [4, 5]. The absence of pre-exisiting pulmonary disease in these cases (which now in 
retrospect were probably due to hypersensitivity pneumonitis) had led some to propose that 
Aspergillus might possess the propensity to cause primary infection [6].
The turn of the of the twentieth century saw physicians faced with the challenge of 
distinguishing aspergillosis from tuberculosis, given that the former can super-infect TB- 
diseased lung tissues. Up to the 1940s the lack of resolution on roentgen films and the 
relative low yield on routine culture characteristic of either pathogen had continued to pose 
diagnostic difficulty [7]. The second half of the twentieth century saw key advances in 
development of cancer chemotherapeutics on the hemato-oncology front. Nitrogen mustard, 
anti-folates, thiopurines, methotrexate and Vinca alkaloids were developed over time and 
progressively used in treatment of hematological malignancies. At around the same time in 
the mid 1950s, reports began emerging on cases of secondary mycoses in autopsies of
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leukemic patients [8, 9]. Subsequent autopsy series confirmed observations that in patients 
undergoing treatment for leukemia and lymphoma, the disease spectrum was seeing a 
changing pattern with rising incidence of secondary mycoses, and that invasive aspergillosis 
was assuming increasing importance as a cause of morbidity and mortality [10]. It was 
striking that the patients most at risk were those who were profoundly immunocompromised, 
either from their advanced primary disease or iatrogenically from their potent 
chemotherapeutic regimens.
Meanwhile, bone marrow transplantation was being actively explored as a viable treatment 
option for a range of hematological diseases in the 1960-70s. By the 1980s, refinement in 
conditioning regimens and resultant satisfactory remission rates eventually heralded the era 
and practice of hematopoietic cell transplantation (HCT). These have been landmark 
advances in treatment of hematological malignancies and other related diseases leading to 
improved patient survival, but this in turn generated ever increasing numbers of patients with 
profound compromised immunity. The use of traditional conditioning regimens and even non- 
myeloablative regimens led to significant immunosuppression in the recipient and thus 
vulnerability to fungal infections, which would have been innocuous in a healthy host. This is 
perpetuated in the post-transplant period with the development of graft-versus-host disease 
(GVHD), or use of immune-suppressive anti-graft rejection medication. Hence, along with 
increased numbers of immunocompromised patients as a result of advancements of medical 
therapeutics in hemato-oncology and transplantation, the incidence of invasive aspergillosis 
has risen over the recent decades [11].
Innate recognition of Aspergillus
As described above, the pathogenesis of invasive aspergillosis is intrinsically linked to the 
competency of the host immune system and its ability to recognize and destroy the 
pathogen. The innate immune system plays an essential role in host defence against 
Aspergillus. It recognizes conserved polysaccharide moieties found on the pathogen cell 
wall, called pathogen associated molecular patterns (PAMPs) through an array of pattern 
recognition receptors (PRRs) found in the host immune cells. Several classes of PRRs have 
been described, among which Toll-like receptors (TLRs), and C-type lectin receptors (CLRs) 
e.g. Dectin-1 have been shown to play an important role in antifungal immunity.
Lemaitre et al was the first to discover a receptor on the cell membrane of the hematocyte in 
Drosophilia which played a major role in host defense. That receptor was named Toll protein,
12
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and thereafter, 10 Toll-like receptors (TLRs) have been described in humans based on their 
homology with the Toll protein. Upon initial identification of the Drosophila Toll gene, the 
group demonstrated that Drosophila strains which lacked the Toll receptor succumbed to 
overwhelming infection by Aspergillus fumigatus [12]. The subsequent discovery of TLRs in 
humans led to an explosion of research on PRRs of the human innate immune system [13] 
and their role in mediating host defense against microbial infections [14]. A wealth of 
information is now available on the biological function of PRRs, as well as the numerous 
signaling pathways involved, especially in bacterial and viral infections. However, progress in 
understanding immune recognition of fungal moulds such as Aspergillus has lagged behind. 
This may be because mould infections invariably affect select cohorts of patients who are 
immunocompromised, albeit they are the cause of significant mortality and morbidity [15].
The immune response to fungal pathogens is determined by the interaction of PRRs 
expressed on host immune cells and PAMPs exposed on the fungal cell wall [16]. Depending 
on the Aspergillus morphotype (i.e. hyphae or conidia), different PAMPs are exposed on the 
fungal cell wall, which in turn determine ligand recognition by host PRRs. Therefore, altered 
expression of PRRs on host immune cells and PAMP exposure on the fungal cell wall can 
result in initiation of different immune responses. Although vigorous research over recent 
years has greatly improved our understanding of fungal recognition by the host defence, 
much still needs to be learned on the specific Aspergillus PAMPs that are involved in 
immune recognition and of the immunomodulatory capacity of Aspergillus.
Thesis objectives
The aim of this thesis is to attempt to further elucidate the host-pathogen interaction in 
Aspergillus infection and to eventually translate this knowledge from the bench to the 
bedside in the management of invasive aspergillosis.
A successful pathogen is one that is able to survive and evade detection by the host innate 
immune system. In Chapter 2 of this thesis, we first reviewed the general strategies 
employed by various fungal pathogens to circumvent host defense in order to enhance 
chances of survival in the host and the propensity to cause disease.
Little is known on the immunomodulatory capacity of Aspergillus. In Chapter 3, we studied 
the capacity of A. fumigatus morphotypes (conidia and hyphae) to modulate the host immune
13
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responses. Since TLR2 and TLR4 have been known to be pivotal in recognizing A. fumigatus 
[17-19], the modulatory effects of Aspergillus on TLR2 and TLR4 signaling pathways were 
specifically examined. TLRs are activated upon detection of specific PAMPs, which are 
intrinsic components of the pathogen cell wall. Whether and which of these Aspergillus cell 
wall components modulate the TLR2- and TLR4-dependent pathways was investigated in 
Chapter 4.
Because Aspergillus spores are air-borne and ubiquitously present, they are continuously 
being inhaled into the respiratory tract [20]. A healthy host can usually deal with inhaled 
spores and thwart germination of invasive hyphae due to the effective anti-fungal properties 
of alveolar macrophages and neutrophils. However, in an immunocompromised host, the 
Aspergillus conidia can evade the weakened defense, partly through suppression of 
inflammation. In Chapter 5, we studied how melanin on the surface of the Aspergillus conidia 
may have a role in the modulating the host immune response.
T helper (Th)-cells are important components of anti-fungal defence, and the balance 
between Th1 and Th2 responses has been generally perceived as critical in determining 
outcome to invasive fungal diseases [21]. However, the recent discovery of a novel member 
of the CD4+ effector T-cell family (Th17 cells) producing especially IL-17, has provided novel, 
but conflicting insights into anti-fungal immunity, with both protective or deleterious effects 
being proposed for Th17. These findings were based on observations in mice models. Little 
is known regarding the role of IL-17 in host defense against Aspergillus infections in humans. 
In Chapter 6, we studied the IL-17 host response to A. fumigatus in human cells and in 
patients with invasive aspergillosis.
Dectin-1 is a CLR present on human immune cells and in recent years, this PRR has been a 
topic of intense research [22]. Dectin-1 recognizes the ß-1,3-glucan motif on the Aspergillus 
cell wall and results from in-vitro and murine models have suggested that Dectin-1 is pivotal 
in host defense against invasive aspergillosis [23, 24]. However, little is known regarding the 
clinical significance in invasive aspergillosis. In Chapter 7, using a recently identified single 
nucleotide polymorphism (SNP) in the Dectin-1 gene that results in a truncated inactive 
protein [25], we tested the hypothesis if the presence of the SNP conferred susceptibility to 
invasive aspergillosis in a cohort of patients at risk of the disease.
The eventual aim in studying pathogenesis of infection is to attempt to translate this 
knowledge from the bench to the bedside to aid in clinical management. Without doubt,
14
Introduction and outline of thesis
cytokines play a pivotal role in mediating host immune response to infections. In Chapters 8
& 9, we investigated whether the profiling of inflammatory cytokines and other biomarkers 
such as C-reactive protein, or galactomannan released from the Aspergillus cell wall, might 
be used as appropriate surrogates for disease status in a large cohort of aspergillosis 
patients in a clinical trial.
A summary of our findings and conclusions of the thesis are presented in Chapter 10.
15
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Abstract
A successful pathogen is one that is able to effectively survive and evade detection by the 
host innate immune defense. Fungal pathogens have adopted strategies which evade host 
defense and eventually cause disease in at-risk patients. Shielding of stimulatory surface 
recognition molecules, shedding of decoy components, induction of anti-inflammatory 
signals, complement evasion and resilient survival capacity are successful evasion 
mechanisms employed by fungal pathogens. Understanding these complex pathways of 
immune evasion can potentially contribute to development of novel therapeutic strategies 
against fungal infections.
Key words: innate immunity, escape mechanisms, Toll-like receptor
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Introduction
Fungal pathogens are invariably ubiquitous, and they often colonize the human host. Most of 
the time colonization is harmless under normal circumstances and perceived virulence low. 
In the immunocompetent, opportunistic fungal pathogens are systemically eradicated by the 
host innate immune defense. However, during immunosuppression induced either by 
disease or iatrogenically, opportunistic pathogenic fungi have the capability to proliferate and 
eventually establish an ensuing disease. The reported mortality and morbidity from invasive 
fungal infections under such circumstances in the compromised host can be substantial [1, 
2].
The human innate immune system is the body’s first line of defense against the foreign 
pathogen and is pivotal in determining outcome of such a confrontation. The ability of the 
pathogen to invade the human host relies on its capacity to evade and circumvent host 
defense mechanisms. These strategies, innovative yet simple, aid the fungus’ survival in the 
host. As the pathophysiology of fungal infections is slowly unraveled, we begin to understand 
the mechanisms leading to the presence and persistence of the fungal pathogen in the host. 
In this review, citing examples from our current understanding on the biology of Candida, 
Aspergillus, Cryptococcus and other fungal species, we shall attempt to illustrate how fungal 
pathogens avoid recognition or interfere with host innate systems to enhance their viability 
during the course of infection.
Attachment to and colonization of body surfaces
The skin and mucous membranes provide an anatomical barrier to fungi such as Candida 
spp. As a prelude to potential invasion, colonization requires a successful means of 
adherence to epithelial surfaces. To counteract removal by ciliary clearance on mucous 
membranes, Candida spp expresses attachment factors (so-called adhesins) -  surface 
proteins covalently linked to the ß-glucan of the cell wall, to aid adherence to epithelial 
surfaces. Adhesins, such as the agglutinin-like sequence (ALS) protein and hyphal wall 
protein-1 (HWP1), participate in biofilm formation by facilitating cell-to-surface and cell-to-cell 
adherence [3, 4]. Clinically, implanted medical devices like central venous catheters provide 
an entry for microbial penetration through a break in epithelial surface. The formation of an 
overlying biofilm may shield the embedded Candida spp from therapeutic levels of antifungal 
medications and provide a safe harbour for genetic variation to arise. This facilitates the
20
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emergence of resistance and forms a nidus for persistence or re-infection unless the implant 
is fully removed [5, 6].
Immune recognition and surveillance of fungal pathogens
The activation of the host defense depends on appropriate detection of the invading 
pathogen. The mechanism responsible for the recognition is regulated by host pattern- 
recognition receptors (PRRs) that recognize conserved pathogen-associated molecular 
patterns (PAMPs) expressed by microbes, but not by the host. This has been an area of 
intense research in recent years and the interested reader is encouraged to refer to 
comprehensive reviews on this topic [7-9]. Upon recognition of microbial ligands by PRRs, 
the innate defense system is activated. Firstly, a direct anti-fungal response resulting in 
either a phagocytic process or secretion of microbicidal compounds, and secondly, a 
facilitative role through the production of proinflammatory mediators such as cytokines and 
chemokines is initiated (Fig. 1). Finally, antigen uptake and presentation for the triggering of 
the adaptive immune system is induced [10].
The role of recognition of fungal pathogens has first been ascribed to a major class of PRRs, 
the Toll-like receptors (TLRs). TLRs are expressed on various immune and non-immune cell 
types. Within the TLR family, TLR2 and TLR4 have been highlighted as being involved in 
recognition of Candida and Aspergillus. Fungal wall components -  zymosan, 
phospholipomannan and glucoronoxylomannan (GXM) have been identified as ligands (or 
specific PAMPs) for TLR2, while GXM and O-linked mannan are ligands for TLR4 [11, 12]. 
Nonetheless, there have been differences in reports on the relative importance and role of 
either receptors in mediating recognition of yeast and hyphal form of fungal pathogens. The 
decreased resistance to invasive candidiasis in TLR2 -/- mice in a single study [13] was not 
supported by other studies that reported increased resistance to infection and a reduced 
fungal burden in TLR2 -/- mice [14, 15]. These latter studies attributed the observation to 
TLR2 as inducing the host immunity towards an ‘anti-inflammatory’-type response. Likewise, 
studies with TLR4 -/- mice had either demonstrated increased [14, 16] or similar susceptibility 
[17] to C. albicans infections as compared to wild-type animals. Most of these differences are 
likely attributable to differences in the cell lines employed or variation in methodologies in the 
respective studies. In addition TLR6 and TLR9 are also been reported to have 
supplementary roles in Candida recognition [14, 18]. Recognition of A. fumigatus conidia and 
hyphae have been attributed to both TLR2 and TLR4 although the relative importance of the 
role of each receptor differ depending on the morphologic stadium of the fungus [14, 19-21].
21
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ß-glucan
F igure 1. Pattern recognition of fungal pathogen and representative signaling pathways.
Specific pathogen-associated molecular patterns (PAMPs) on the surface of fungal cell wall engage their 
respective pattern-recognition receptor (pRr) like TLR2, TLR4 and dectin-1 receptor on immune cells. Complex 
signaling pathways are activated involving adaptors and protein kinases (see below) resulting in the release of 
transcription factor to the nucleus to regulate expression of inflammatory cytokines
Adaptors: myeloid differentiation primary response gene 88 (MyD88), Toll/interleukin-1 receptor (TIR) adaptor 
protein (TIRAP), TIR-containing adaptor-inducing interferon ß (TRIF), TRIF-related adaptor molecule (TRAM), 
caspase recruitment domain 9 (CARD9)-B-cell chronic lymphocytic leukaemia/lymphoma 10 (Bcl10)-mucosal- 
associated lymphoid tissue translocation gene 1 (MALT1) complex
Protein kinase: spleen tyrosine kinase (Syk)
IRF, Interferon regulatory factor 
NF-kB, nuclear factor-kappa B 
IkB, inhibitor of NF-kB
A second class of PRRs involved in the recognition of fungi is the C-type lectin receptors 
(CLR). Recently, the CLR receptor, Dectin-1, has been demonstrated to mediate specific 
recognition of ß-glucans found in the cell walls of Candida and Aspergillus spp [22-24]. 
Dectin-1 and TLR2 may collaborate to augment proinflammatory cytokine production. 
Phagocytosis of (blasto)conidia can also be mediated by either Dectin-1 or TLR2 [25, 26]. 
Though Dectin-1-deficient mice have shown increased susceptibility to disseminated
22
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candidemia [27], the actual importance of this receptor has been debated in another study 
that did not validate its anti-Candida effects using independently-developed dectin-1 -/- mice 
model [28]. Other CLRs, like the macrophage mannose receptor and DC-SIGN have also 
been implicated by recognizing N-linked branched mannan structures of fungi [11, 29, 30].
The main cells in the host innate immune system which are responsible for immune 
surveillance against fungal pathogens are the circulating neutrophils and monocytes as well 
as tissue macrophages. Dendritic cells are involved in antigen-presentation and aid initiation 
of host adaptive immunity [10]. The major PRRs involved in fungal recognition : TLR2, TLR4 
and Dectin-1 are found in all the above-mentioned cell populations [9]. The relative 
importance of these respective professional phagocytes in contributing to the body’s innate 
armour depends on the invading pathogen and its morphotype. Against Candida, neutrophils 
form an important frontline of the host defense. Organs of granulocytopenic mice yielded 
increased fungal burden following in vivo challenge with C. albicans [31, 32]. C. albicans 
yeasts exposed to blood components including monocytes but devoid of neutrophils still 
retained the capacity to germinate [33]. Nonetheless macrophages and monocytes also play 
important roles especially in the absence of adequate neutrophil function [34, 35]. Against A. 
fumigatus, it is believed that macrophages and monocytes form the first line of defence 
against inhaled conidia, while neutrophils target hyphal growth [10, 36]. Targeted non- 
phagocytic oxidative and non-oxidative modes of hyphal damage by neutrophils have been 
demonstrated for C. albicans and A. fumigatus [37-39].
Clinically, occurrence of invasive fungal infection is usually associated with a quantitative or 
qualitative deficiency in host immunity, especially with opportunistic pathogens like 
Aspergillus and Cryptococcus. Nonetheless, acquisition of disease is also determined by 
pathogen virulence and its ability to effectively evade host immune defense. The following 
are strategies are employed by fungal pathogens to evade host defense mechanisms (Fig. 
2):
1. Shielding of stimulatory PAMPs
2. Modulation of inflammatory signals
3. Shedding of decoy components
4. Persistence in intracellular environments
5. Complement evasion
23
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A Stimulatory PAMP like ß-(1,3)-glucan 
shielded with cell wall
Dectin-1 receptors
a-(1,3)-glucan
F igure 2. Fungal strategies for overcoming innate defense system
( a ) Avoiding engagement of dectin-1 receptors by shielding of surface proinflammatory ß-(1,3)-glucans or an 
alternative non-stimulatory a-(1,3)-glucan cell wall
Stealth mechanisms: shielding proinflammatory PAMPs
One important escape mechanism of the fungal pathogen is to shield its proinflammatory 
PAMPs from recognition by PRRs (Fig. 2a). Dectin-1 has been proposed as a pivotal PRR 
for recognition of fungal pathogens, by sensing ß-glucans, a common conserved component 
in the fungal cell wall [40, 41]. C. albicans is a polymorphic fungi which is able to switch its 
phenotype between yeast and filamentous forms pending environmental pressures. After 
budding, the bud scars of Candida yeast wall expose the otherwise concealed ß-glucan 
predisposing to Dectin-1 recognition. It has been demonstrated that during hyphal growth, C. 
albicans ß-glucans are obscured from recognition by Dectin-1 by outer wall components [24, 
42]. Dectin-1 also promotes fungicidal activity of human neutrophils [43], which are the 
important effector cells against hyphal morphologies. We postulate that ß-glucan shielding in 
hyphal growth, and the subsequent inability of Dectin-1 to detect the fungus, protects these 
larger morphologies from being internalized. In dendritic cells, hyphal forms also 
preferentially induced a T-helper cell type 2 (Th2) rather than a protective T-helper cell type 1 
(Th1) immune response [44, 45]. Hence, immune cells respond differently to yeast and 
hyphal forms.
24
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Similar to Candida in which surface mannans shield ß-glucan from recognition by Dectin-1, in 
Histoplasma capsulatum the a-(1,3)-glucan present in its outer layer cell wall contributes to 
pathogenesis by shielding its immunostimulatory ß-glucans. Proinflammatory tumor necrosis 
factor-a (TNF-a) production by phagocytic cells was demonstrated to be elevated in 
Histoplasma strains which lack a-(1,3)-glucan in contrast to strains which display in-situ a- 
(1,3)-glucan. Conversely, the TNF-a level became suppressed with depletion of host Dectin- 
1 receptor for ß-glucan [46]. Likewise, as Paracoccidioides brasiliensis transforms into its 
pathogenic yeast form, a change in its cell wall glucan polymer linkage occurs from ß-(1,3) to 
a-(1,3)-glucan [47]. Shielding of ß-glucan exposure is one possible mechanism of immune 
evasion, as a-(1,3)-glucan is not recognized and does not stimulate any known PRR. 
Cryptococcus neoformans simply masks its surface PAMPs through the production of an 
extracellular capsule of GXM which results in down-regulation of proinflammatory TNF-a and 
interleukin-1beta (IL-1 ß) production [48].
Another means of avoiding immune recognition is illustrated by Coccidioides posadasii, a 
fungal respiratory pathogen, that is recognized by the host by its immunodominant spherule 
outer wall glycoprotein (SOWgp). During endospore differentiation, the fungus secretes a 
metalloproteinase (Mep1) which digests SOWgp [49]. The resultant down-regulation of 
SOWgp during endospore formation enables the fungus to evade phagocytosis and killing at 
its vulnerable endospore stage of development [50].
One way of masking its signature from the host immune system is the ability of the fungus to 
exist in different morphotypes and to reversibly switch from one form to another during the 
course of infection [10, 51]. These polymorphic states are associated with phenotypic 
switching and results in differential recognition by PRRs. This capability has likely evolved to 
optimize the survival of fungi in different environments.
As exemplified earlier in experiments in which the C. albicans filament, unlike its yeast-form, 
is able to escape immune recognition by dectin-1 [24], differential recognition of C. albicans 
blastoconidia and hyphae via TLR-mediated cytokine production has also been 
demonstrated. Whereas C. albicans blastoconidia activate both TLR2 and TLR4 in peripheral 
blood mononuclear cells and peritoneal macrophages, the hyphal form, which is responsible 
for tissue-invasive disease, fails to be recognized by TLR4, the receptor which activates 
interferon-gamma (IFN-y) production, a critical cytokine in determining a successful outcome 
against candidiasis [52]. Phenotypic switching during germination, as such, may be an 
important escape mechanism for the organism. Likewise, TLR4-mediated signals are lost
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during A. fumigatus germination: whereas A. fumigatus conidia induce signals from TLR2 
and TLR4; during tissue invasion, the conidia germinate into hyphae with loss of TLR4 
stimulation, leading to a less pronounced stimulation of proinflammatory cytokines [21]. 
TLR4-mediated proinflammatory effects have been demonstrated to be important in the 
protection against invasive aspergillosis [14].
Modulation of inflammatory signals
The activation of TLR2 versus TLR4 differs in terms of nett pro- and anti-inflammatory 
cytokine effect, with the induction of proinflammatory cytokines that is weaker after TLR2 
than TLR4 engagement [53] (Fig. 2b). Activation of dendritic cells using TLR4 agonists 
specifically induced Th1-inducing cytokine responses, while TLR2 stimulation induced a 
more pronounced anti-inflammatory Th2 response [54].
PAMP PAMP
( b ) Preferential activation of TLR2 over TLR4 by certain fungal morphotypic PAMP stimulates a Th2 humoral 
response over a Th1 dependent antifungal proinflammatory cytokine production.
The balance between Th1/Th2 responses is perceived as critical in determining the outcome 
to infection [55-57] as each effector arm evokes a distinct immune response. On the one 
hand, the Th1 pathway produces proinflammatory cytokines like IFN-y that induce cell- 
mediated immune responses needed for phagocyte activation and cytotoxicity -  important 
against intracellular and fungal pathogens. The Th2 pathway, on the other hand, represented 
by cytokines such as IL-4, IL-5 and IL-10, stimulates a humoral response and in turn inhibits 
the Th1-dependent cellular mechanisms [58]. During anti-fungal responses, Th2 cytokines
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can inhibit monocyte anti-hyphal activity and oxidative burst [57]. Moreover, it has been 
demonstrated that C. albicans can evade the host defense through TLR2-derived signals: 
TLR2-deleted macrophages have been found to have enhanced anti-Candida capabilities 
[59] and in-vivo, TLR2 -/- mice are relatively more resistant to disseminated C. albicans 
infection [14, 15]. Hence the tissue-invasive hyphal forms of C. albicans and A. fumigatus, by 
means of evading TLR4 in favor of a predominant TLR2 activation, are able to tilt the balance 
towards a Th2 response.
Similar immunosuppressive potential has also been exhibited by C. neoformans.
The capsule of C. neoformans, which is its main virulence factor, consists mainly of the 
polysaccharide GXM which has been shown to be a potent inducer of the anti-inflammatory 
cytokine IL-10 in human monocytes and a pro-Th2 cytokine profiling [60, 61]. Interestingly, 
the melanin pigment, commonly produced in pathogenic fungal species, has been linked to 
fungal virulence and its immunomodulatory effect has been studied in C. neoformans. 
Melanized strains of C. neoformans induce higher pulmonary IL-4 levels polarizing the host 
towards a Th2 immune response [62].
Likewise, Blastomyces dermatitidis which causes a progressive pulmonary and systemic 
mycosis, has the capability to induce ‘relative immunosuppression’ by limiting the production 
of proinflammatory cytokine TNF-a [63]. It does so through a Blastomyces surface adhesin 
and established virulence factor BAD1 which binds to complement receptor 3 on 
macrophages, whose physiological role is to regulate excess TNF-a production during 
clearance of apoptotic cells [64]. The resultant ligation suppresses TNF-a release which 
would have been detrimental to the survival of B. dermatitidis.
Shedding of decoy components
Other strategies of evasion have been highlighted for Pneumocystis, the cause of the 
opportunistic Pneumocystis jiroveci (formerly mentioned carinii) pneumonia (PCP) mainly in 
AIDS patients. Glycoprotein A (gpA) complex is the principal protein antigen on the surface 
of Pneumocystis, which is heavily glycosylated with mannose, glucose and galactose- 
containing carbohydrate moieties [65]. These structures are recognized by mannose 
receptors (MR) on alveolar macrophages (AMs). By prematurely shedding its gpA as a 
decoy, Pneumocystis seeks to competitively block MR on AMs and impair their phagocytic 
function [66]. In addition, Pneumocystis has been shown to induce the depletion of MR from
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the surface of AMs and consequently block the non-opsonic uptake by surface-expressed 
mannose receptor [67] (Fig. 2c).
( c ) Shedding of surface protein gpA by Pneumocystis as decoy to competitively inhibit mannose receptor (MR). 
Pneumocystis also induces MR loss from macrophages. This blocks non-opsonic uptake by surface-attached MR.
Escape from phagocytic response
To escape from immune surveillance and phagocytosis, fungi may resort to hiding in 
sanctuary sites within the host (Fig. 2d). These niches can be host cells that are functionally 
non-phagocytic by designation, such as the host epithelial or endothelial cells, in which the 
pathogen is protected from the hostile external environment.
It has been demonstrated that A. fumigatus conidia can bind and become internalized by 
human epithelial cell lines [67]. Although the invasion index may be lower than professional 
phagocytes, the internalized conidia within epithelial cells remained viable for relatively 
longer periods compared to conidia within macrophages [68]. Following inhalation, 
Aspergillus conidia which become internalized by airway epithelial cells can limit the induced 
levels of proinflammatory cytokines IL-6 and IL-8 [69]. A. fumigatus conidia endocytosed by 
type II pneumocytes can hide within late endosomes. The conidia eventually germinate with 
the potential to disseminate [70].
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( d ) Post-phagocytosis intracellular persistence and immune escape. Upon internalization by immune or non- 
phagocytic cells, Candida or Aspergillus can resist intracellular killing, germinate and eventually escape.
C. albicans can induce its own uptake via endocytosis by endothelial cells through N- 
cadherin, a surface protein [68]. C. neoformans can induce its own endocytosis by 
microvascular endothelial cells and subsequently cross the blood-brain barrier to cause 
meningitis [69]. These findings provide evidence that fungal pathogens may use their 
internalization by non-phagocytic cells to hide from detection by professional phagocytes, 
and when the opportunity presents, disseminate from its reservoir within the host.
Persistence despite adversity
In confronting macrophages, some fungal pathogens have also developed the capability to 
resist phagocytosis as exemplified by C. neoformans, which can undergo phenotypic 
switching to a mucoid colony variant that produces a larger capsular polysaccharide GXM 
(with altered biophysical and biochemical properties) thus reducing the phagocytic efficacy of 
alveolar macrophages [70].
For pathogenic strains which fail to evade host recognition, phagocytosis by immune cells 
does not mean inevitable demise and the end of its life cycle as the fungus may still be able 
to persist, despite the adverse environment of the phagolysosome. Some strains of C. 
albicans can resist intracellular killing, develop hyphal forms and eventually escape from the
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macrophage [71]. Against the oxygen free radicals and reactive nitrogen molecules such as 
nitric oxide (NO) produced by monocytes and macrophages upon confrontation, C. albicans 
possesses a highly specific, readily inducible anti-NO defense mechanism involving NO­
scavenging flavohemoglobin genes which converts NO to less toxic molecules [72]. Detailed 
morphologic studies have demonstrated that despite phagocytosis by macrophages, with 
rapid recruitment of lysosomes to fuse with the phagosome, Candida yeast may still form 
germ tubes, propagate and escape from the host cell [73]. Phagocytosis induces C. albicans 
within the macrophage to adopt a self-preserving state: a slower growth rate, alternative 
carbon utilization and an oxidative stress response as for a ‘hibernation mode’ for continued 
survival in the harsh environment until it re-declares its presence with the eventual demise of 
the macrophage [74]. Phagocytic activity alone may be inadequate to contain the pathogen 
[75] and should be augmented by Th1-type cytokines like IFN-y for effective microbial killing 
capacity.
Likewise, C. neoformans may be viewed as practicing a form of intracellular parasitism [76]. 
It has been observed that the yeast can survive and replicate within phagocytic cells during 
chronic infection [77, 78]. In addition to resisting intracellular killing, it is thought that C. 
neoformans upon being phagocytosed, induces disordered lysosomal trafficking and 
extensive host cell cytoplasmic vacuolation with eventual host cell disruption [76]. 
Histoplasma capsulatum, another facultative intracellular fungus, is known to be able to 
persist in the host for long periods after initial infection and re-activate when immunity wanes 
by surviving within macrophages [79, 80]. After phagocytosis, Histoplasma is able to inhibit 
phagolysosome fusion and actively modulate phagosomal pH to optimize its survival within 
phagosomes [81, 82]. In addition, Histoplasma can also inhibit the release of toxic 
superoxide radicals detrimental to its survival [83].
Evasion of complement system
The complement system represents another arm of the host innate immunity. This consists 
of intricate cascades involving serum proteins via three biochemical pathways -  the classical, 
alternative and lectin activating pathways -  resulting in antimicrobial activity via 
opsonophagocytosis and recruitment of inflammatory cells. The lectin pathway is thought to 
play a minor anti-fungal role. Aspergillus and Candida are known to trigger complement 
activation through C3 deposition on fungal surface facilitating opsonization and production of 
chemoattractant C5a, which recruits leukocytes to site of infection [84-86]. Pigmentation on 
A. fumigatus conidial surface has been shown to affect virulence by limiting C3 complement
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deposition [87] and neutrophil activation. Physiologically, the complement system is kept in 
check against excessive activation by regulatory proteins, such as Factor H (alternative 
pathway), Factor H-like protein 1 (FHL-1) and C4 binding protein (C4BP) for the classical 
pathway. In attempting immune evasion, C. albicans, and more recently, A. fumigatus have 
shown ability to bind Factor H, FHL-1 and C4BP on their surface to down-regulate the 
complement cascade [88-91] (Fig. 2e). Moreover the thick fungal cell wall is largely resistant 
to direct lysis by the terminal membrane-attack complex of the complement system [92].
M
Complement activation
( e ) Binding of complement-inhibitory C4 binding protein (C4BP) and Factor H on fungal surface
Conclusion
The defense mechanisms in the immunocompetent host are generally effective against 
fungal pathogens. However, it is not rare that the integrity of the innate immune system is 
breached: iatrogenically with medical procedures (e.g. central catheters, major surgery) or 
immunosuppressive therapy (e.g. chemotherapy/ transplant regimens leading to neutropenia 
and immune depletion). Despite the varied capabilities possessed by the fungal pathogen to 
evade host detection, it remains to be highlighted that a normal host defense is generally 
effective against most fungal infections and a permissive immune suppressive state has first
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to exist before the host becomes susceptible to opportunistic pathogens. In endemic 
mycoses however, immune suppression may not be a pre-requisite and the pathogen’s 
capability to evade host immune detection may yet determine eventual disease acquisition. 
In the face of significant morbidity and mortality rates, however, treatment options for 
invasive fungal infections remain generally limited by the range of anti-microbial medications 
which act against the few established drug targets known to date.
In the recent years, increased knowledge on the mechanisms of fungal recognition by the 
host immune system has become available. In addition to understanding how the host 
defense is activated, it also becomes clear that fungal pathogens do possess strategies to 
evade recognition and inhibit anti-fungal defenses, as presented in this review. As more is 
understood of the pathogenesis of fungal diseases from the perspectives of immunology, 
infectious diseases and microbiology, it is hoped that this knowledge will help direct the 
development of future therapeutics and minimize risk of disease in the ever-increasing 
population of immunocompromised patients seen in medical practice today.
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Abstract
Toll-like receptor (TLR)-based signaling pathways in the host may be modulated by 
pathogens during the course of infection. We describe a novel immunomodulatory 
mechanism in which Aspergillus fumigatus conidia induce attenuation of TLR2- and TLR4- 
mediated interleukin (IL)-6/IL-1 ß proinflammatory responses in human mononuclear cells 
with suppression of IL-1 ß mRNA transcription. Background TLR2 and TLR4 mRNA 
transcription were not influenced. A. fumigatus conidia induced TLR2 internalization and 
uptake into the phagosome with resultant decreased surface receptor expression. A. 
fumigatus hyphae, on the other hand, selectively down-regulated TLR4-mediated response. 
These novel immunosuppressive effects may facilitate the invasiveness of A. fumigatus.
Key words: innate immunity, Toll-like receptor, phagocytosis
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Background
Opportunistic fungal infections remain a significant cause of mortality and morbidity in 
immunocompromised patients. Aspergillus fumigatus is one of the most common mold 
infections worldwide [1]. Acquisition of invasive aspergillosis arises from inhalation of 
airborne conidia which, in the absence of competent immune containment, is followed by 
germination, development of hyphae, and invasive disease.
Mononuclear phagocytes constitute an important component of host defense against A. 
fumigatus and also are the precursors of tissue macrophages involved in immune 
surveillance against invasive pulmonary aspergillosis [2, 3]. Their ability to detect specific 
pathogen-associated molecular patterns (PAMPs) of Aspergillus conidia involves expression 
of pattern recognition receptors (PRRs), and the main families of these are the Toll-like 
receptors (TLRs) and the lectin receptors (LRs). TLR2 and TLR4 have been reported to 
mediate recognition of various cell-wall components of Aspergillus [4-7] and Dectin-1, a C- 
type lectin receptor, is the major PRR involved in the recognition of ß-glucans [3, 8, 9]. 
Although infection experiments in TLR-deficient mice have provided evidence for 
involvement of TLR2 and TLR4 in host defense against A. fumigatus [4, 10], the relative 
importance of both receptors and other TLRs still remain to be determined. In addition, the 
inflammatory response triggered through TLR2 and TLR4 strongly depends on the 
Aspergillus morphotype. For example, while conidium recognition was mediated by both 
TLR2 and TLR4, TLR4-mediated signaling was lost in recognition of hyphae [11]. This 
inability to recognize and fight the most dangerous morphotype could represent an immune 
evasion mechanism [12]. On the other hand, very little is known whether fungal pathogens 
can also modulate TLR-mediated host defense, by decreasing the capacity of host cells to 
respond to TLR2 and TLR4 ligands.
The aim of the present study was to study the capacity of A. fumigatus to modulate the host 
immune response triggered by TLRs. The effects of Aspergillus modulation of TLR2 and 
TLR4 activation was specifically examined, given that these receptors mediate the major 
pathways implicated in anti-fungal host defense.
Materials and methods 
Reagents
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TLR2 ligand lipopeptide (S)-(2,3-bis(palmitoyloxy)-(2RS)-propyl)-N-palmitoyl-(R)-Cys-(S)- 
Ser(S)-Lys4-OH, trihydrochloride (Pam3Cys) was purchased from EMC Microcollections 
(Tübingen, Germany). TLR4 ligand lipopolysaccharide (LPS; E. coli serotype 055:B5) was 
purchased from Sigma Chemical Co (St Louis, MO, USA). An extra purification step of LPS 
was performed as previously described [13]. Cytochalasin B was purchased from BIOMOL 
International and dissolved to 5 mg/ml in dimethyl sulfoxide (DMSO). Laminarin, a specific 
inhibitor of Dectin-1, and mannan, a competitive inhibitor of the mannose receptor pathway 
[14], were kindly provided by Dr David Williams (University of Tennessee, USA). Bartonella 
LPS (anti-TLR4) was obtained as previously described [15]. 3-(1-methyl-1H-indol-3yl- 
methylene)-2-oxo-2,3dihydro-1H-indole-5-sulphonamide (Calbiochem) was used for 
pharmacological inhibition of Dectin-1-associated adaptor molecule Syk.
A. fumigatus
The strain V05-27, a previously characterized clinical isolate of A. fumigatus [11], was grown 
on Sabouraud glucose agar supplemented with chloramphenicol, for 4-7 days at 35°C. 
Abundant conidia were produced under these conditions. Conidia were harvested by gently 
scraping the surface of the slants and suspending them in phosphate-buffered saline (PBS) 
with 0.05% Tween 80. To remove hyphae and debris, the conidial suspension was filtered 
through 4 layers of sterile gauze. To yield hyphal fragments, conidia were added to 5 ml of 
yeast nitrogen base (Difco Laboratories), in a final concentration of 108 microorganisms/ml. 
After 18 h at 37°C, the tubes were centrifuged at 1550 g for 10 min, and the pellet, almost 
exclusively containing mycelia, was washed twice in Hanks’ balanced salt solution (HBSS) 
without Ca2+ and Mg2+ and resuspended in PBS. Aliquots of the conidial suspension and 
mycelium were heat-killed for 60 min at 56°C. Nonviable conidia and hyphal fragments were 
centrifuged at 4000 g for 15 min, resuspended and vortexed vigorously. Finally, both 
suspensions were washed 3 times with HBSS without Ca2+ and Mg2+ to remove released A. 
fumigatus components and kept frozen at -80°C until use. Viability was checked by culture in 
Sabouraud glucose broth and no growth was observed after heat treatment. The Aspergillus 
materials were prepared in an LPS-free fashion. For the experiments, 107 microorganisms/ml 
of A. fumigatus conidia or hyphae were used for priming, unless otherwise indicated.
Stimulation assays
Venous blood was drawn into EDTA tubes from healthy volunteers after informed consent. 
Peripheral blood mononuclear cells (PBMC) were isolated by density centrifugation on Ficoll- 
Hypaque (Pharmacia Biotech, Uppsala, Sweden). Cells were washed twice in saline, 
counted and the number adjusted to 5x106 cells/ml. A 100 ^l volume of PBMC, suspended in 
culture medium (RPMI 1640 DM; ICN Biomedicals, Costa Mesa, CA) supplemented with 10
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^g/ml gentamicin, 10 mM L-glutamine, and 10 mM pyruvate was added to flat-bottomed 96- 
well plates (Greiner, Netherlands).
PBMC were pre-incubated with A. fumigatus conidia, hyphae or RPMI (as unprimed control). 
After 24 h at 37oC, the culture supernatants were replaced with fresh culture medium 
containing the secondary stimulus, consisting of either TLR2 ligand (Pam3Cys 10 ^g/ml), or 
TLR4 ligand (LPS 1 ng/ml). The supernatants were collected after 24 h of incubation at 37oC 
and stored at -20oC until cytokine assay. To block phagocytosis, PBMC were pre-incubated 
with 1 ^g/ml of cytochalasin B for 30 minutes at 37oC before stimulation with A. fumigatus 
components as described above. For receptor-blocking experiments, mannan (200 ^g/ml), 
laminarin (200 ^g/ml) or Bartonella LPS (20 ^g/ml) fractions were pre-incubated with the 
PBMC for 1 hour at 37oC prior to stimulation with Aspergillus. Dectin-1-mediated intracellular 
pathways were inhibited by pre-incubation of cells with a Syk-inhibitor (50 nMol/L) for 30 
minutes before incubation with A. fumigatus. The experiments were performed in the 
absence or presence of inhibitors with PBMC of the same volunteers.
Differentiation of monocyte-derived macrophages (MDM) was performed as previously 
described [16]. In brief, monocytes were isolated by adherence following PBMC isolation, 
washed and resuspended in freshly prepared RPMI with 10% human human serum, and 
supplemented with pyruvate, L-glutamine and gentamicin. The cells were maintained in a 
humidified atmosphere (5% CO2) at 37oC for 6 days to permit differentiation with the medium 
refreshed after 3 days. The procedure for stimulation assays involving MDM was similar as 
for PBMC.
Cytokine measurements
Interleukin (IL) 6 and IL-1ß concentrations were measured by use of commercial sandwich 
ELISA kits (Pelikine Compact, CLB, Amsterdam, Netherlands) according to the 
manufacturer's instructions. Human tumor necrosis factor alpha (TNF-a) was determined by 
specific ELISA as described elsewhere [17].
Quantitative PCR
To determine TLR2 and TLR4 mRNA expression, RNA was extracted from PBMC primed 
with A. fumigatus conidia or hyphae for 24 h. For IL-1 ß and TNF mRNA expression, PBMC 
were primed with A. fumigatus and then stimulated with Pam3Cys, LPS or RPMI as 
described above for 4 h. RNA was extracted from 107 PBMC by using 1 ml TRIzol reagent 
(Sigma, St. Louis, MO). Subsequently, 200 ^l chloroform and 500 ^l 2-propanol (Merck, 
Darmstadt, Germany) were used to separate the RNA from DNA and proteins. Finally, after
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washing with 75% ethanol, the RNA was dissolved in 50 ^l of diethylpyrocarbonate (DEPC) 
water.
To obtain cDNA, we reverse-transcribed 1 ^g DNase-treated total RNA with oligo(dT) 
primers (0.01 ^g/ml) in a reverse transcription-PCR mixture with a total volume of 20 ^l. 
Quantitative real-time PCR to monitor DNA synthesis was performed using the Bio-Rad 
iCycler and SYBR Green. The following primers were used (5’-3’): 
GAATCCTCCAATCAGGCTTCTCT (forward) and GCCCTGAGGGAATGGAGTTTA 
(reverse) for TLR2, GGCATGCCTGT GCT GAGTT (forward) and 
CTGCT ACAACAGATACTACAAGCACACT (reverse) for TLR4,
GCCCTAAACAGATGAAGTGCTC (forward) and GAACCAGCATCTTCCTCAG (reverse) for 
IL-1ß, TGGCCCAGGCAGTCAGA (forward) and GGTTTGCTACAACATGGGCTACA 
(reverse) for TNF-a and ATGAGTATGCCTGCCGTGTG (forward) and 
CCAAATGCGGCATCTTCAAAC (reverse) for ß2 microglobulin (B2M) (Biolegio, The 
Netherlands). Quantification of the PCR signals for each sample was performed by 
comparing the cycle threshold values, in duplicate, of the gene of interest with the cycle 
threshold values for the B2M as housekeeping gene. All primers were validated according to 
the protocol. Mean relative mRNA expression was calculated using Pfaffl method. Values are 
expressed as ratio of fold increase to mRNA levels of unprimed cells.
TLR2 and TLR4 expression by flow  cytometry
From PBMC, CD14+ monocytes were isolated by positive selection with anti-CD14 
microbeads as per manufacturer’s instructions (Miltenyi Biotec, Germany). Following 
incubation with A. fumigatus conidia, hyphae or RPMI control for 24 h, cells were cooled to 
4oC, washed 2 times in 0.5% bovine serum albumin/PBS and incubated for 15 min with the 
following monoclonal antibodies (mAb) : anti-TLR2-FITC and anti-TLR4-PE (eBioscience, 
San Diego, CA). The cells were washed 2 more times and then analyzed on a FACSCalibur 
flow cytometer (BD Biosciences, San Jose, CA).
Phagocytosis of Aspergillus  conidia and TLR2 internalization
Blankophor staining [18] was used to differentiate phagocytosed Aspergillus conidia from 
bound conidia. A. fumigatus conidia were incubated with monocytes obtained via adherence 
from PBMC for 30 min at 37oC. To permit phagocytosis, monocytes were washed at 4oC and 
Blankophor stain was added. The fresh mount was then visualized using a Leica 
fluorescence microscope. To visualize internalization of surface TLR2, monocytes were 
allowed to adhere onto fibronectin and the cells were pre-incubated with Alexa488-labelled 
TLR2 specific mAb (eBioscience, San Diego, CA) or its isotype control. A. fumigatus conidia
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were added and phagocytosis was assessed after 30 min at 37oC. At the end the samples 
were washed and fixed in 4% paraformaldehyde and visualized using an Olympus FV1000 
confocal microscope.
Statistical analysis
Results from at least 3 sets of experiments were pooled and analyzed using SPSS 16.0 
statistical software. Data given as means + SE and the Wilcoxon signed rank test was used 
to compare differences between groups (unless otherwise stated). The level of significance 
was set at p < 0.05.
Results 
A. fumigatus conidia and hyphae differentially modulate the host proinflammatory 
cytokine response induced by TLR2 and TLR4.
Following pre-incubation of PBMC with heat-killed A. fumigatus conidia and hyphae, a dose- 
dependent cytokine response was observed following Pam3Cys (TLR2)- or LPS (TLR4) 
stimulation, as indicated by the IL-6 production. A differential and inverse dose-dependent 
cytokine response was observed following pre-incubation with A. fumigatus hyphae and 
subsequent TLR2-stimulation (Figs. 1a & 1b). As 107 microorganisms/ml of A. fumigatus 
conidia and hyphae yielded strongest responses during most TLR-stimulations, subsequent 
experiments were performed using 107 microorganisms/ml of conidia and hyphae.
Overall, pre-incubation of PBMC with heat-killed A. fumigatus conidia significantly attenuated 
IL-6 production in response to TLR2 and TLR4 stimulation (Figs. 1c & 1d). Similarly, IL-1ß 
production induced by TLR2 was also strongly inhibited by A. fumigatus conidia. In contrast, 
the TNF -a response was not influenced after pre-incubation of cells with heat-killed A. 
fumigatus conidia.
On the other hand, pre-incubation with heat-killed A. fumigatus hyphae had a limited 
immunomodulatory effect. Pre-incubation with Aspergillus hyphae attenuated the TLR4- 
induced IL-6 and TNF-a production but increased the TLR2-induced TNF production (Figs. 
1e & 1f). TLR4 stimulation with LPS did not induce detectable levels of secreted IL-1 ß in cells 
pre-incubated with either RPMI or Aspergillus. This failure to release IL-1 ß into the 
environment is a known phenomenon due to initiation of macrophage differentiation [19, 20].
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F igure 1. Effects of pre-incubation of PBMC (panels 1a-h) or MDM (panels 1 i-j) with heat- killed Aspergillus 
conidia (panels 1a-f), hyphae (panels 1i-j), or live conidia (1g-h) on host TLR2 (PaiTbCys)- and TLR4 (LPS)- 
mediated pro-inflammatory response, as compared to corresponding unprimed control (  RpMI). Dose-dependent 
IL-6 response to TLR2-agonist and TLR4-agonist [panels 1 a & b]. Live Aspergillus conidia [panels 1 g & h] 
yielded similar IL-6 attenuation (as heat-killed components) but TLR4-induced TNF-a response was attenuated 
with germination and hyphal development (as anticipated with HK hyphae, panel 1f). The data are the cumulative 
results of at least 3 sets of experiments and expressed as means +/- SEM; * p < 0.05 compared to respective 
unprimed PBMC control.
There was no elevation of lactate dehydrogenase (LDH) levels in the samples containing the 
Aspergillus fractions as compared to controls, excluding a role of cellular toxicity in these 
effects (data not shown).
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Live Aspergillus conidia exerted similar effects (Figs. 1g & 1h) as heat-killed conidia, with an 
attenuation of TLR2- and TLR4-induced IL-6 responses. However, contrary to heat-killed 
conidia, live conidia decreased the TLR4-mediated TNF-a production. This response was 
similar to that displayed by heat-killed hyphae (Fig. 1f). This differential TNF-a response 
following stimulation with heat-killed or live conidia may be explained by the hyphal 
development from the live conidia during the course of experiment.
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The modulatory effects of A. fumigatus conidia on monocyte-derived macrophages (MDM) 
were similar to those on FBMC. Following pre-incubation with conidia, the IL-6 production in 
response to TLR2 and TLR4 stimulation was attenuated (Figs. 1i & 1j).
IL-1 ß and TNF-a mRNA expression
IL-1 ß mRNA expression was utilized as a representative surrogate to assess IL-1 ß/IL-6 
transcription as the process is known to be tightly regulated [21]. In parallel with the 
attenuation of secreted IL-1ß by PBMC, A. fumigatus conidia markedly reduced IL-1 ß mRNA 
transcription induced by TLR2 or TLR4 ligands (ratio of 0.34 x and 0.42 x relative to 
unprimed controls respectively; Fig. 2). Notably, FBMC incubated with conidia alone also 
displayed attenuation of IL-1 ß mRNA transcription. This strengthened the evidence of the 
immunomodulatory potential of Aspergillus conidia. Aspergillus hyphae also inhibited TLR4- 
induced IL-1 ß mRNA, while TLR2-induced IL-1 ß mRNA transcription was not affected. 
Cytokine mRNA expression was consistent with trends of measured secreted cytokines.
46
Modulation of TLR responses by Aspergillus
As with the pattern of cytokine stimulation, TNF-a mRNA expression was distinct from that of 
IL-1 ß mRNA (Fig. 2). Aspergillus hyphae slightly amplified TNF-a mRNA expression induced 
by TLR2 ligation which eventually translated into elevated TNF-a levels detectable in the 
supernatants (Fig. 1b).
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F igure 2. IL-1 ß and TNF-a mRNA expression in FBMC pre-incubated with A. fumigatus components for 24 h, 
followed by RFMI, TLR2 ligand or TLR4 ligand stimulation for 4 h. IL-1 ß mRNA expression was suppressed by 
Aspergillus conidia whether in the absence (RFMI) or presence of secondary stimulation (Pam3Cys and LFS). 
The data are the cumulative results of 3 sets of experiments and expressed as means +/- SEM; * p < 0.05 
relative to ratio of fold increase in the mRNA levels of unprimed cells.
Taken together, these results indicate that Aspergillus conidia alter TLR2- and TLR4- 
mediated signaling resulting in down-regulation of cytokine production and this is 
corroborated by mRNA measurements. Aspergillus hyphae also induced attenuation of 
TLR4-mediated signaling though there was a tendency towards increased TLR2 response.
Role of Aspergillus conidia uptake fo r the immunomodulatory effects
In order to assess whether phagocytosis of conidia was involved in the modulation of TLR- 
induced activation, cytochalasin B, an inhibitor of actin polymerization, was added to FBMC 
prior to priming with conidia or hyphae. Cytochalasin B reversed the inhibition of TLR2- 
induced IL-6 levels (Fig. 3a) and IL-1ß (data not shown). Interestingly, the effects of 
Aspergillus on TLR4-induced IL-6 were not influenced by cytochalasin B, i.e. these effects 
were independent of phagocytosis (Fig. 3b).
Role of other PRRs in immunomodulation induced by A. fumigatus
In order to assess the role of the various FRRs involved in the recognition of A. fumigatus, 
we blocked the given receptor prior to Aspergillus incubation using specific inhibitors. This 
was followed by TLR2 or TLR4 ligand stimulation as described above. IL-6 production was 
used as a representative read-out parameter.
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F igure 3. IL-6 production after TLR2- or TLR4-stimulation by FBMC pre-incubated with A. fumigatus conidia or 
hyphae in the presence or absence (Control) of cytochalasin B (Cyto B), as compared to corresponding unprimed 
FBMC (RFMI). Inhibiting phagocytosis reversed TLR2- (a) but not TLR4-induced IL-6 attenuation (b). The data 
are the cumulative results of 3 sets of experiments and expressed as means +/- SEM; * p < 0.05 as compared to 
respective unprimed FBMC following secondary stimulation.
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F igure 4. IL-6 production after TLR2- or TLR4-stimulation by FBMC pre-incubated with A. fumigatus conidia or 
hyphae in the presence or absence (Control) of specified inhibitor, as compared to corresponding unprimed 
FBMC (RFMI). Inhibitors used were mannan (blocks mannose receptor), laminarin (blocks Dectin-1) and 
Bartonella LFS (TLR4 antagonist). TLR4-mediated attenuation of IL-6 by A. fumigatus hyphae was reversed using 
mannan (b). Modulatory effects were not reversed by blocking Dectin-1 receptor or TLR4 (c -  f). The data are the 
cumulative results of 3 sets of experiments and expressed as means +/- SEM; * p < 0.05 as compared to 
respective unprimed FBMC.
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Blockade of MR by mannan had no effect on IL-6 attenuation by Aspergillus conidia, but did 
have an effect on hyphal modulation of LFS-induced IL-6 (Figs. 4a & 4b). No effects of 
Dectin-1 blockade with laminarin (Figs. 4c & 4d) and of TLR4 blockade with Bartonella LFS 
(Figs. 4e & 4f), were observed on Aspergillus-induced modulation of TLR responses. 
Chemical blockage of the Dectin-1 adaptor molecule Syk, using a specific chemical inhibitor 
did not have an effect on the immunomodulation (data not shown).
Taken together, the results indicate that cytokine production following TLR2- and TLR4- 
stimulation is down-regulated by Aspergillus conidia, an immunomodulatory process that is 
phagocytosis-dependent via TLR2-mediated pathway, and largely independent of other FRR 
such as TLR4, MR and Dectin-1. A. fumigatus hyphae induced downregulation of TLR4- 
mediated signaling which was MR dependent.
Modulation of TLR2 and TLR4 transcription and expression by A. fumigatus
One possible mechanism through which Aspergillus may modulate cytokine responses is by 
directly influencing TLR2 and TLR4 expression. We first assessed whether the amount of 
TLR mRNA transcription in FBMC was modulated after incubation with A. fumigatus conidia 
and hyphae. In the presence of A. fumigatus conidia, there is a minimal reduction in TLR2 
and TLR4 mRNA transcription relative to unprimed cells (Fig. 5). Likewise, in FBMC primed 
with hyphae, both TLR2 and TLR4 mRNA expression were not significantly altered.
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Figure 5. Relative TLR2 and TLR4 mRNA expression in FBMC following incubation with Aspergillus conidia and 
hyphae. The data are the cumulative results of 3 sets of experiments and expressed as means +/- SEM. The 
values are not statistically significant.
49
Chapter 3
Flow cytometry was performed on positively-selected CD14+ monocytes incubated with A. 
fumigatus conidia and hyphae. This methodology was employed because of binding of 
conidia to monocytes, which affected scatter characteristics and possibly altered CD14 
expression upon exposure to Aspergillus [22]. After stimulation with A. fumigatus conidia, 
surface TLR2 expression was significantly reduced on the monocytes as compared to TLR4 
(Table 1).
These data, together with the minimally influenced mRNA expression, suggest that A. 
fumigatus conidia induced depletion of surface TLR2 expression on FBMC by inducing 
receptor engagement and internalization, rather than inhibiting TLR transcription.
Mean Fluorescence Intensity
TLR2a TLR4a
RFMI 85+17 48+14
A.fumigatus conidia 42+15 33+5
p valueb 0.03* 0.05
A.fumigatus hyphae 83+20 43+15
p valueb 0.46 0.25
Table 1. Expression of surface TLR2 and TLR4 on CD14+ monocytes following incubation with either A. 
fumigatus conidia or hyphae or unprimed control (RFMI).
a Values are the cumulative results of 3 sets of experiments and expressed as mean+standard deviation of mean 
geometric fluorescence intensities by flow cytometric analysis.
p value versus corresponding RFMI control (Wilcoxon)
* statistically significant
Internalization of TLR2 follow ing phagocytosis of Aspergillus  conidia
An alternative explanation to decreased surface TLR2 expression as observed above could 
be due to adherence of Aspergillus conidia to surface TLR2 binding sites, thereby blocking 
access to anti-TLR2 mAb (in Table 1). Blankophor staining was utilized to distinguish 
between ingested and adherent conidia. As seen in Figures 6a & b, following incubation of 
Aspergillus conidia with monocytes, all phagocytosed conidia remain unstained in contrast to 
conidia in the external milieu. This indicates that interference of TLR2-bound conidia on the 
cell surface with anti-TLR2mAb is very unlikely. In addition, using confocal microscopy, we 
demonstrated the internalization of surface TLR2 into the phagosome together with the A. 
fumigatus conidia (Figs. 6c & 6d).
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F igure 6. [Fanel a] Direct microscopic view of monocyte with 3 phagocytosed Aspergillus conidia and an 
adherent conidium in the external milieu (white arrow). [Fanel b] With Blankophor stain of the same field, only the 
above externalized conidium (white arrow) was fluorescent. [Fanels c & d] Light and fluorescent view of monocyte 
labelled with Alexa488-TLR2 mAb on confocal microscopy depicting localization of TLR2 on cell surface. [Fanels 
e & f] Following phagocytosis of Aspergillus conidia (asterisk), concurrent internalization of TLR2 with the 
phagosome was observed.
Discussion
In the present study, we show that A. fumigatus conidia have a modulatory potential to 
selectively attenuate TLR2/TLR4-induced proinflammatory IL-1 ß and IL-6 cytokine production 
in mononuclear phagocytic cells. The modulatory effects were observed in FBMC and MDM, 
and could be induced with both heat-killed and live conidia. The immunomodulatory effects of 
Aspergillus conidia on TLR responses are apparent at the transcriptional level with inhibition 
of cytokine mRNA. Down-regulation of the TLR2-mediated pathway involved internalization 
of the receptor together with Aspergillus conidia into the phagosome, resulting in decreased 
expression of TLR2 on the cell membrane. Aspergillus hyphae displayed a propensity to 
selectively down-modulate TLR4-mediated responses, an effect partly mediated by the MR.
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The above observed TLR2- and TLR4-mediated phenomena were not attributable to altered 
receptor mRNA transcription.
As Aspergillus conidia are the primary morphotype infecting the host, it is possible that the 
conidial form, by its ability to decrease the host pro-inflammatory response via TLR 
suppression, endows an early advantage to the fungus to enhance its chances of survival 
and compromise initial attempts by the host defense to contain germination. Hyphal 
development further induces selective loss of TLR4-mediated pro-inflammatory response 
capacity. However, one has to acknowledge that these effects are most likely relevant only in 
immunocompromised patients, as host defense in immunocompetent individuals are usually 
effective against invasive Aspergillus infection.
Conidial and hyphal forms of A. fumigatus are able to differentially modulate host response 
and generate distinct cytokine responses. Notably, while A. fumigatus conidia attenuated 
both TLR2/TLR4-induced responses (IL-1 ß and IL-6 concentrations), its hyphae retained or 
even accentuated TLR2-induced response (TNF-a production and mRNA concentration) 
while suppressing the TLR4 activity. The diminished extracellular cytokine quantifications 
were corroborated by mRNA measurements. Diminished hyphae-induced TLR4-mediated 
proinflammatory signaling is consistent with our earlier observations that A. fumigatus 
hyphae could induce loss of TLR4-mediated proinflammatory signals while sparing those of 
TLR2 [11]. In light of this differential response, recent data have suggested that activation of 
TLR2 in the absence of TLR4 signals (as observed here with A. fumigatus hyphae) may 
preferentially favor a Th2-type response to the advantage of the pathogen [23, 24].
Nonetheless, while it might be tempting to speculate that observations described above are 
means of an immune escape mechanism employed by the pathogen to evade the host 
innate defense, these data may need to be interpreted in the context of the other modulatory 
consequences of Aspergillus infection [22]. For instance, we also noted a trend towards 
increased TNF-a production induced by A. fumigatus hyphae via TLR2 which may be a 
compensatory response to the TLR4-associated attenuation. The immunomodulatory effects 
on cytokine production by A. fumigatus conidia are also not generalized but significantly 
more profound for IL-1 ß and IL-6, while TNF-a production remains largely unaffected. It 
appears that TNF-a synthesis may be compensated by alternative mechanisms, such as 
induction through lectin-receptors like Dectin-1 or mannose receptors [25, 26]. Our results 
also suggest that there are differences in the pathways leading to TNF-a and IL-1 ß 
transcription, and that these pathways are differentially regulated by the respective
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Aspergillus morphotype. The concept that Aspergillus conidia and hyphae do induce 
differential immune response has recently been suggested [22, 27]. Cortez et al showed that 
the conidia can induce a differential expression of genes implicated in host defense and 
immunomodulation [22]. The diminished IL-6/IL-1 ß response reported in our study may be 
biologically significant as these cytokines orchestrate host proinflammatory antimicrobial 
response, including neutrophil recruitment [28, 29]. In addition, altered levels of these 
proinflammatory cytokines affect the Th1/Th2 equilibrium which may result in an attenuated 
host phagocytic and cytotoxic response [30].
We have demonstrated that the inhibition of TLR2-mediated responses by Aspergillus 
conidia was due to induction of TLR2 engagement and internalization, rather than mediation 
via other FRRs like MR, TLR4 or Dectin-1. This is supported by recent studies which point to 
TLR2 involvement in phagocytosis of A. fumigatus conidia [31, 32]; as well as demonstration 
of internalization and recruitment of TLR2 in phagosomes. However, contrary to the notion 
that phagocytosis is often coupled with elaboration of proinflammatory cytokine response as 
seen in Candida and Gram-positive bacteria [33], our findings suggest that in the case of A. 
fumigatus conidia, phagocytosis may conversely result in surface receptor depletion and 
consequently decreased receptor-mediated signaling. However, we also noted that use of 
laminarin (a Dectin-1 receptor-specific inhibitor) did not reverse the inhibitory effect induced 
by conidial phagocytosis involving TLR2 pathway. Our finding here counters prior 
observations that the Dectin-1 receptor is intrinsically involved in phagocytosis of A. 
fumigatus conidia and supports the notion that Dectin-1-independent phagocytosis of 
Aspergillus is effective [31, 34].
Our observations have also implicated a possible immunomodulatory role for the MR, 
another C-type lectin receptor. Despite its reported ability to recognize fungi like C. albicans, 
Cryptococcus neoformans and Pneumocystis, little is known on the role of MR as a FRR for 
A. fumigatus [35-37]. This is intriguing given that terminal mannose, fucose or N-acetyl 
glucosamine are established ligands for MR [38] and such mannose-based moieties 
constitute a major component of the Aspergillus cell wall [39]. Though MR has been 
implicated in the phagocytosis of fungi, it did not seem to play a significant role in the 
inhibitory effects on TLR2 signals that are mediated through phagocytosis of Aspergillus 
conidia [40, 41]. However, we show that mannan reversed TLR4-mediated attenuation of IL- 
6 production following pre-incubation with A. fumigatus hyphae. It is thus very likely that a 
ligand of the MR on the Aspergillus cell wall is involved in the modulatory capability of the 
fungus. This is supported by the emerging data suggesting an immunoregulatory role for MR 
in curtailing the proinflammatory response [42-44].
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A. fumigatus remains the most important filamentous fungal pathogen with significant 
attributable morbidity and mortality in at-risk patient cohorts [1, 45]. We have attempted to 
show how A. fumigatus may alter the host response, in particular, the TLR-mediated host 
defense, during the course of infection. The observations reported here demonstrate how a 
pathogen may intrinsically induce down-regulation of selective host pro-inflammatory 
responses to its advantage. However, the absence of invasive infection in healthy 
individuals, despite the ubiquitous presence of Aspergillus, attests for the effective antifungal 
mechanisms usually inherent in the healthy host. On top of the above-reported modulatory 
effects induced by the pathogen, further immune deficiencies in the compromised host will 
provide the ‘second hit’ leading to disease development. Though the latter undoubtedly 
remains the major determining factor in acquisition of invasive disease, it is believed that this 
instrinsic immune modulatory potential of A. fumigatus contributes to the nett deficit in 
proinflammatory response to skew the Th1/Th2 equilibrium towards the advantage of the 
pathogen.
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Abstract
Aspergillus fumigatus conidia attenuates host proinflammatory response through modulation 
of Toll-like receptor (TLR)2 and TLR4 signaling, but the precise mechanisms that mediate 
this effect are not known. In the present study, the role of the Aspergillus cell wall 
polysaccharide constituents for the modulation of host capability to mount a proinflammatory 
response was studied. Aspergillus cell wall fractions and its major components showed 
differential capabilities in modulating host TLR-mediated cytokine production. Beta-glucan 
specifically suppressed TLR4-induced response, while alpha-glucan inhibited 
proinflammatory cytokine production induced through TLR2- and TLR4-stimulation. 
Galactomannan diminished TLR4-mediated response, while its inhibitory effects on TLR2- 
signalling were limited. Chitin, on the other hand, did not have significant immunomodulatory 
capability. It is likely that the ability of the fungal cell wall to alter the immune signature of the 
pathogen contributes to its virulence and the pathogenesis of the infection.
Key words: innate immunity; beta-glucan; chitin; galactomannan; alpha-glucan.
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Introduction
Fungi are ubiquitous organisms with limited virulence in the immunocompetent host. 
Suppression of the immune system, however, predisposes the host to opportunistic fungal 
infection. Furthermore, fungal pathogens have also evolved capabilities to evade recognition 
by the immune system and circumvent host anti-fungal defense mechanisms to enhance its 
chances of survival [1]. As such, management of invasive fungal diseases in the 
immunocompromised still presents a major challenge.
Invasive aspergillosis remains the most common opportunistic mold infection in susceptible 
patients and is associated with significant rates of mortality and morbidity [2, 3]. However, 
much remains to be learnt on the pathogenicity of Aspergillus fumigatus and host response. 
The Aspergillus cell wall maintains cellular integrity against environmental stress [4], and has 
been linked to pathogenesis and virulence of the fungus [5]. The cell wall is relatively well- 
characterized and consists of linked polysaccharide polymers. The major components of the 
A. fumigatus cell wall consist of ß-glucan, chitin, galactomannan and a-glucan [6, 7]. Being in 
contact with the external milieu, these polysaccharide components can be sensed as 
pathogen-associated molecular patterns by pattern recognition receptors such as Toll-like 
receptors (TLR) on host innate immune cells, and this triggers the anti-fungal inflammatory 
responses. Both TLR2 and TLR4, as well as the C-type lectin receptor, Dectin-1, are 
involved in the recognition of A. fumigatus [8-11]. Little had been known on whether the fungi 
can modulate TLR-mediated host defense mechanisms as a means of immune evasion and 
to facilitate the invasiveness of the pathogen. Recently, we described a novel immune 
escape mechanism of A.fumigatus via modulation of host TLR2- and TLR4-signaling 
pathways [12]. However, the molecular mechanisms responsible for this immunosuppressive 
effect are not well understood. Characterization of fungal cell wall components that interact 
with the host (innate) immune cells may hold the key to understanding the observed immune 
escape mechanisms. In the present study, we aim to elucidate the role that the A. fumigatus 
cell wall and its major components play in modulation of the host TLR-based signaling 
pathways.
Materials and methods 
Reagents
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TLR2 ligand tripalmitoyl S-glycerol-Cys-(Lys)4 (Pam3Cys) was purchased from EMC 
Microcollections (Tübingen, Germany). TLR4 ligand Escherichia coli lipopolysaccharide 
(LPS; E. coli serotype 055:B5) was purchased from Sigma Chemical Co (St Louis, MO, USA) 
and was used after an additional purification step [13]. Glucan phosphate (MW 1.55 x 105 
g/mol) was a gift from Dr David Williams (University of Tennessee, USA) [14] and its capacity 
to function as Dectin-1 inhibitor was previously described [15].
A. fumigatus preparation
The A. fumigatus strain DAL CBS144-89 was a previously described clinical isolate and was 
grown in liquid medium containing 2% glucose and 1% mycopeptone [16]. For experiments 
involving intact A. fumigatus conidia, fixation was performed in 4% paraformaldehyde (PFA). 
Otherwise A. fumigatus conidia at different growth stadia (dormant, enlarged and 
germinating) were obtained from culture in liquid medium. The conidia were collected by 
filtration, and washed extensively with sterile water. Subsequently, the conidia were 
resuspended in a buffer containing 50 mM Tris-HCl, pH 7.5, 50 mM EDTA and 1 mM 
phenylmethylsulfonyl fluoride and were disrupted in a Dyno-mill cell homogenizer (W. A. 
Bachofen AG, Basel, Switzerland) in the presence of 1-mm-diameter glass beads at 4°C. 
The mass of disrupted cellular material was removed from the glass beads by pipette, 
transferred to another tube and centrifuged (8000x g for 10 min). Pellets of disrupted cellular 
material from A. fumigatus conidia at the above mentioned growth stadia were washed three 
times with the same buffer and suspensions were stored at -20°C [17].
Alkali treatment for fractionation of A.fumigatus cell wall
Alkali-insoluble (AI) cell wall component. Fractionation and digestion steps of the obtained 
disrupted cell suspensions as mentioned were performed as previously described with minor 
modifications [17]. To remove non-covalently bound cell wall protein, the suspensions were 
boiled twice in buffer containing 50mM Tris-HCl, pH 7.4, 50mM EDTA, 2% sodium dodecyl 
sulfate and 40mM ß-mercaptoethanol (SDS/ME) and then incubated twice in 200 ml of 1M 
NaOH at 65°C for 30 min. The supernatant, consisting of the alkali-soluble fraction, was 
transferred to another tube for further treatment (see below). The pellet, which constituted 
the alkali-insoluble cell wall fraction, was washed five times with water and once with 50 mM 
Tris-HCl, pH 7.4 buffer and stored as described below. The AI fraction consisted of ß-glucan, 
chitin and galactomannan [7, 18].
Alkali-soluble (AS) cell wall component. Following treatment with NaOH, the supernatant, 
which contained the alkali-soluble cell wall constituents, was adjusted to pH 5.0 by addition
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of glacial acetic acid [19]. The AS component consisted of a-glucan and galactomannan [18, 
20].
Both AI and AS fractions of dormant, enlarged and germinating conidial cell wall were 
dialyzed, quantified and freeze-dried fractions were stored at -20°C until use. Before assay, 
AI and AS fractions were re-suspended in 0.05% Tween 20 in phosphate buffered saline for 
use in the experiments.
Isolated cell wall components
Purified a-glucan consisting of alternating 1,3- and 1,4-linked glucose residues (Nigeran) was 
obtained from Sigma Aldrich (Zwijndrecht, Netherlands). Purified A. fumigatus 
galactomannan (GM) was from Bio-Rad Laboratories (Marnes-la-Cocquette, France). 
Particulate ß-1,3-glucan (MW > 1.5x105 g/mol) was prepared as previously described [21, 
22]. Native chitin purified from Candida albicans cell wall [23] was a kind gift from Dr Neil 
Gow (University of Aberdeen, U.K.).
Stimulation assays
Stimulation assays were performed as previously described [12]. Peripheral blood 
mononuclear cells (PBMC) from healthy donors were isolated by density centrifugation on 
Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden). Cells were washed, counted and the 
number adjusted to 5x106 cells/ml. A 100 l^ volume of PBMC, suspended in culture medium 
(RPMI 1640 DM; ICN Biomedicals, Costa Mesa, CA) supplemented with 10 g^/ml 
gentamicin, 10 mM L-glutamine, and 10 mM pyruvate was added to flat-bottomed 96-well 
plates (Greiner, Netherlands).
PBMC were pre-incubated with incremental amounts of AI and AS cell wall fractions of A. 
fumigatus arrested at different growth stages, intact conidia or carrier in RPMI (as unprimed 
control). Where indicated, the Dectin-1 receptor was blocked using 200 g^/ml of glucan 
phosphate by pre-incubating PBMC for 1 h at 37oC prior to addition of the respective cell wall 
fractions or components [15]. After 24 h, the culture supernatants were replaced with fresh 
culture medium containing the secondary stimulus, consisting of either TLR2 ligand 
(Pam3Cys 10 ^g/ml), or TLR4 ligand (LPS 2 ng/ml). The supernatants were collected after 
24 h of incubation at 37oC and stored at -20oC until cytokine assay.
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Mice experiments
Male C57BL/6 mice (Charles River Laboratories) were used for the experiments. The mice 
were fed sterilized laboratory chow (Hope Farms, Woerden, the Netherlands) and water ad 
libitum. The experiments were approved by the Ethics Committee on Animal Experiments of 
Radboud University Nijmegen. Similar to the setup in the in-vitro experiments above, the 
mice were injected intravenously with either inactivated A. fumigatus conidia (1x107 
microorganisms/mouse) in a 100 l^ volume of PBS or PBS alone at Day -1. On Day 0, E. coli 
LPS (3^g/mouse in a 100 l^ volume) was injected intravenously into all mice. At +3 h, the 
mice were bled for cytokine measurement.
Cytokine measurements
Interleukin (IL) 6 concentration was measured by use of a commercial sandwich ELISA kit 
(Pelikine Compact, CLB, Amsterdam, Netherlands) in accordance to the manufacturer's 
instructions. The lower detection limit was 8 pg/ml. Mouse IL-6 levels were measured by a 
commercial ELISA (Biosource, Camarillo, CA; detection limit 16 pg/ml).
Statistical analysis
Results from 3 sets of experiments (involving n > 5 subjects) were pooled and analyzed 
using SPSS  16.0 statistical software. Data are provided as means + standard errors of the 
means (SEM) and the Wilcoxon signed rank test was used to make two-group comparison 
on the extent of modulation induced by the respective cell wall fraction/component against 
the unprimed control viz. the carrier. The level of significance was set at p < 0.05.
Results
A. fumigatus conidia modulates IL-6 response in-vitro and in-vivo
In view of our earlier study, in which we had used heat-killed conidia from a different A. 
fumigatus strain [12], we re-validated our earlier findings using PFA-fixed intact A. fumigatus 
conidia at 106 microorganisms/ml under similar assay conditions. After pre-incubating PBMC 
with intact conidia, we reproduced the inhibitory effects of heat-killed A. fumigatus conidia on 
TLR2- and TLR4-mediated IL-6 production (Fig. 1a). Likewise, we observed similar 
modulatory effects in the mice model. Mice primed with A. fumigatus conidia showed an 
attenuated IL-6 response by 30% to LPS (Fig. 1b). This demonstrated that intact Aspergillus 
conidia significantly inhibit TLR-mediated cytokine production both in-vitro and in-vivo.
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F igure 1. Effect of pre-incubation of PBMC with intact PFA-fixed conidia on host TLR2 (Pam3Cys)- and TLR4 
(LPS)-induced IL-6 production, as compared to corresponding unprimed control (carrier). (b) Mice response to 
LPS following intravenous injection with either inactivated A. fumigatus conidia or carrier (PBS) following 24 hours 
earlier. Mouse serum IL-6 was assayed at +3 hours after LPS. The data are the cumulative results from 3 sets of 
experiments and expressed as means + standard errors of the means; * p < 0.05 compared to respective carrier 
(black bar).
Modulatory effects of the AI fraction of conidial cell wall arrested at different growth 
stadia
It is perceivable that the Aspergillus cell wall constituents may vary in the dormant, enlarged 
and germinating conidia. Consequently, the immunomodulatory capacity may be dictated by 
the growth morphology. Therefore, the effects of AI and AS cell wall fractions from dormant, 
enlarged and germinating conidia were studied.
Irrespective of the conidial growth phase, the AI fraction (consisting of ß-glucan, chitin and 
galactomannan) did not influence TLR2-stimulated production of IL-6 (Fig. 2a). However, a 
strong and significant dose-dependent inhibition of TLR4-mediated IL-6 response was 
observed as compared to controls (carrier). In addition, it was demonstrated that the TLR4-
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inhibitory effect is exerted most strongly by the AI fraction from germinating conidia, followed 
by enlarged conidia over dormant conidia (Fig. 2b).
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F igure 2. IL-6 production in response to TLR2 (a) and TLR4 (b) stimulation after pre-incubation of PBMC with 
alkali-insoluble (AI) cell wall fractions obtained from dormant, enlarged and germinating A. fumigatus conidia. A 
dose-dependent attenuation effect on IL6 levels is seen via TLR4 and most evident in AI fraction from germinating 
conidia. The data are the cumulative results from 3 sets of experiments and expressed as means +  standard 
errors of the means; * p < 0.05 between IL-6 levels induced by the respective cell wall fraction at specified dose 
compared to that of carrier alone (black bar).
*
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Modulatory effects of alkali-soluble (AS) fraction of conidial cell wall at different stadia
Galactomannan and a-glucan constitute the AS fraction. Only at the highest amounts, and 
irrespective of the conidial morphologies from which the fraction was derived, the AS fraction
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significantly attenuated TLR2-mediated IL-6 production (Fig. 3a). This fraction also 
significantly reduced the production of proinflammatory IL-6 through TLR4 and this was most 
evident for the AS fraction obtained from the germinating A. fumigatus conidia (Fig. 3b).
In the above experiments involving AI and AS fractions of the Aspergillus conidial cell wall, 
lactate dehydrogenase (LDH) levels were undetectable (lower detection limit 16 U/L). This 
was indicative that cellular toxicity was not a cause of the inhibitory effects observed.
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F igure 3. The effect of pre-incubation of PBMC with alkali-soluble (AS) cell wall fractions from A. fumigatus 
conidia at the different growth stadia on TLR2- (a) and TLR4-signalling pathways (b). Both pathways were 
significantly attenuated by the AS fraction. The data are the cumulative results from 3 sets of experiments and 
expressed as means +  standard errors of the means; * p < 0.05 between cytokine levels induced by respective 
cell wall fraction at specified dose compared to that of carrier alone (black bar).
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The role that individual cell wall components play in cytokine modulation
At doses of 1^ g/ml and 10^ g/ml, ß-glucan significantly reduced IL-6 production via TLR4 in a 
dose-dependent manner. This suggests that down-regulation of TLR4-induced pro- 
inflammatory cytokine production by the AI fraction is partly due to the ß-glucan constituent. 
In contrast, ß-glucan had no immunomodulatory effect on TLR2 stimulation of cytokines (Fig. 
4a). This finding is consistent with the absence of modulatory activity on TLR2 response as 
seen with the AI fraction (Fig. 2a).
Chitin had no modulatory effect on both TLR2- or TLR4-mediated inflammatory response 
(Fig. 4c). Galactomannan significantly diminished TLR4-mediated host response. Its 
modulation of the TLR2 response, though present, was weaker and evident only at the 
higher dose of 10^ g/ml (Fig. 4b).
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F igure 4. The role of individual Aspergillus cell wall components in modulating host TLR2 and TLR4 responses. 
Beta-glucan (a), galactomannan (b), chitin (c) and a-glucan (d) were pre-incubated with PBMC followed by TLR2 
and TLR4 stimulation. TLR2 signaling pathway was attenuated by a-glucan and galactomannan while TLR4 
signaling was diminished by a-, ß-glucan and galactomannan. Data are the cumulative results from at least 3 sets 
of experiments and expressed as means + standard errors of the means; * p < 0.05 between cytokine levels 
induced by the respective cell wall components at specified dose compared to that of carrier alone (black bar).
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Besides galactomannan, a-glucan is the other major constituent of the AS fraction. We 
observed that a-glucan had strong inhibitory effects on cytokine induction by both TLR2 and 
TLR4 (Fig. 4d) with the effect being stronger on the TLR4 stimulation pathway. These data 
corroborated with the findings that were observed with the AS cell wall fraction (Fig. 3) and 
demonstrate the immunomodulatory capabilities inherent in a-glucan and galactomannan 
which have not been previously described.
Table 1 provides a summary on the net modulatory effect induced by the AI and AS fractions 
as well as the individual modulatory effects of the respective cell wall polysaccharide 
components as observed in our study.
TLR2 TLR4
Alkali-soluble 
(AS) fraction
inhibition inhibition
a-glucan inhibition inhibition
Galactomannan limited
inhibition
inhibition
TLR2 TLR4
Alkali-insoluble 
(AI) fraction
no change inhibition
ß-glucan no change inhibition
Galactomannan limited
inhibition
inhibition
Chitin no change no change
Table 1. Summary of the net immunomodulatory effects of the alkali-insoluble and alkali-soluble fractions and 
contribution from the individual cell wall components.
Discussion
The present study demonstrates that the Aspergillus conidial cell wall constituents play a key 
role in the modulation of host innate immune responses through the TLR2 and TLR4 
pathways. This modulatory capacity of A. fumigatus is of significance in-vivo as it is also 
observed in the mice model in-vivo. We have recently shown that A. fumigatus modulates the 
host TLR responses by directly decreasing the capacity of the host cells to respond to TLR2 
and TLR4 ligation, a mechanism that can be interpreted as a means to evade detection by 
host immune system or to interfere with the resultant signaling pathways [12]. For TLR2, this 
was partly attributed to receptor internalization after ingestion of Aspergillus conidia, resulting 
in decreased receptor availability on cell surface for ligation. However, the observations 
involving TLR4 could not be accounted for, and the molecular mechanisms responsible for 
these effects were not known. In the present study we found that a-glucan plays an important 
role in the TLR2-mediated attenuation of the immune response, and that the TLR4-
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attenuative effect is due to the combination of a-, ß-glucan, and galactomannan components 
of the Aspergillus cell wall.
The primary role of the Aspergillus cell wall is to protect the fungus against the hostile 
environment. The cell wall also harbors hydrolytic and toxic molecules which are requisites 
for tissue invasion with germination and hyphal growth [7]. In addition the polysaccharide 
moieties which constitute the Aspergillus cell wall dictate the immune signature of the conidia 
depending on their state i.e. dormant, enlarged or germinating. With the exception of ß- 
glucan [11, 24], little is known about the immunomodulatory activities of the other major cell 
wall components of A. fumigatus, such as galactomannan, a-glucan and chitin. We have 
shown that AI fraction of the A. fumigatus cell wall (consisting mainly of ß-glucan, 
galactomannan and chitin) almost exclusively attenuated host TLR4 signaling. This effect 
was exerted by both the ß-glucan and galactomannan components. Chitin appeared to be 
immunologically inert. The AS fraction (consisting of a-glucan and galactomannan), however, 
modulated both the TLR2 and TLR4 pathway. Modulation of TLR2 and TLR4 pathways by 
the AS fraction may be attributable to a combination of a-glucan and galactomannan, both 
having TLR-modulatory potential. Table 1 provides an overview on the net modulatory effect 
induced by AI and AS fractions of A. fumigatus cell wall incorporating the contributions from 
the respective cell wall components.
The concept that the conidial cell wall participates in host-pathogen interaction by influencing 
proinflammatory signaling pathway is not totally unanticipated [25]. Beta-glucan, a major 
constituent of the fungal cell wall, has been recognized as possessing immune modulating 
properties and has been recently identified as the ligand for the C-type lectin receptor (CLR) 
Dectin-1 present on host immune cells [26, 27]. Beta-glucan has been reported to be able to 
skew the host’s pro-inflammatory innate response [28], which may be perceived as an 
immune escape mechanism [1]. In our hands, ß-glucan had a specific TLR4-suppressive 
effect and this was independent of the Dectin-1 receptor as blocking Dectin-1 with glucan 
phosphate did not reverse the inhibitory effects of A. fumigatus (data not shown). This 
observation was consistent with findings of our previous study in which laminarin (another 
Dectin-1 receptor inhibitor) did not influence the modulatory effects induced by intact A. 
fumigatus conidia. The absence of ß-glucan inhibitory effects on TLR2 signaling was 
consistent with the net effect exerted by the AI fraction. Variant effects of ß-glucan on TLR 
signaling have been reported by others [29-31].This is attributable, in part, to the purity and 
size of the ß-glucan used [26]. Another important aspect which may account for this 
difference is that most of the above stimulation studies were performed with ß-glucan
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derivative added simultaneously with the TLR ligands. In our study, however, cells were pre­
incubated with ß-glucan (or Aspergillus cell wall fraction/component) for 24 h before 
stimulation with the respective TLR ligand. This was necessary as the intent had been to 
simulate and study the modulatory capacity induced by preceding infection with A. fumigatus.
In contrast to the relatively rich literature on the effects of ß-glucan, the immunological 
properties of a-glucan, galactomannan and chitin have been much less studied. While its role 
in the A. fumigatus conidial wall has not been ascribed until recently, a-glucan has been 
implicated as a means for immune evasion employed by Histoplasma capsulatum, in which 
a-glucan functioned as a shield to mask the more immunologically-active ß-glucan from 
recognition by the Dectin-1 receptor [32]. Our results reveal a novel immunomodulatory role 
of a-glucan but through modulation of TLR2 and TLR4 pathways. Nonetheless, the perceived 
importance of a-glucan in pathogenesis of invasive aspergillosis will require further in-depth 
experiments as in one study, an a-glucan synthase (AGS)-disrupted A. fumigatus strain did 
not display an altered virulence [20][. Similarly, the immunologic property of A. fumigatus cell 
wall galactomannan (consisting of galactofuranose chains linked to a mannan core) was 
previously not well-characterized [33]. This polysaccharide has been suggested to be 
involved in the pathogenicity of the fungus, as galactofuranose-deletant A. fumigatus mutant 
displayed attenuated virulence in a murine model of invasive aspergillosis [34]. It is tempting 
to speculate that this may be linked to the finding that galactomanan altered host 
proinflammatory signals as seen in our study. Despite forming the skeletal framework of the 
fungal cell wall, chitin seemed to lack the capacity to modulate TLR responses, which is 
consistent with reports that chitin synthase genes are non-essential for cell viability in A. 
fumigatus [35].
In interpreting the present results, one has to bear in mind that these findings were
generated with isolated cell wall components, whilst in-vivo, the polysaccharides in the
Aspergillus cell wall are linked to form a lattice-like layered framework and may possibly
induce a more complex biological effect. Besides ß-glucan [11], little is known on how the
other cell wall polysaccharide components are exposed on conidial surface during
germination to interact with the host immune cells and in turn, influence the signaling
pathways. In addition, modulatory effects may possibly vary depending on the extent of
bonding between the various cell wall components. Beta-glucan in the fungal cell wall can be
widely branched and linked to chitin, as may be galactomannan. Likewise, galactomannan
moieties may also consist of branches linked to a-glucan. Nevertheless, the modulatory
effects of the individual cell wall components as elicited seem consistent with the overall net
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effect induced by the AI and AS fractions (Table 1), which in turn, can account for our 
observations that A. fumigatus intact conidia attenuate both TLR2 and TLR4 signaling 
pathways but via different means [12]. It has been reported that ß-glucan can have variable 
immunomodulatory effects as determined by the molecular weight and number of covalent 
bonds between the polysaccharides and the effects may depend on the degree of 
ramification. It is unknown however, whether the alkali-treatment in yielding the AI and AS 
cell wall fractions could have partially altered biological activity of the respective cell 
fractions.
It is also interesting that AI and AS cell wall fractions obtained from the fungus at different 
stadia exhibited varying potencies in inducing modulation of host proinflammatory signals. 
Both AS and AI fractions obtained from germinating conidia were notably more potent in 
attenuating TLR4 response as compared to dormant and enlarged conidia at equivalent 
doses. The morphological transitions that occur as the conidia enlarge and germinate under 
appropriate conditions, suggest that the relative compositions of the fungal cell wall 
constituents i.e. a-, ß-glucans, galactomannan and chitin undergo quantitative (and possibly 
qualitative biochemical) changes. Based on the modulatory effects induced by the individual 
cell wall components, we speculate that the relative quantities of a- and ß-glucans are 
increased per unit mass in the germinating conidia (as compared to resting conidia). These 
changes would be consistent with the need to circumvent innate immune responses during 
the critical stage of conidial germination to facilitate pathogenesis in the host.
In conclusion, we have attempted to delineate the mechanisms through which A. fumigatus 
down-regulates selective host proinflammatory response via TLR suppression. This ability 
provides an early advantage to the fungus to enhance its chances of survival and 
compromise initial attempts by the host defense to contain germination [12]. However, it 
remains to be highlighted that invasive aspergillosis is an opportunistic infection involving 
patients with profoundly suppressed immune systems. A compromised immune system 
remains the pivotal requisite for this pathogen to cause disease; nonetheless, the 
immunomodulatory effects as described in the present study most likely facilitate the 
development of invasive disease in the susceptible host.
71
Chapter 4
The authors are grateful to Professor Marc van der Maarel and Ms Jolanda van Munster from 
the University of Groningen for providing assistance and technical advice on a-glucan. We 
thank Professor David Williams (University of Tennessee, USA) for providing us with the 
glucan phosphate and ß-glucan.
Acknowledgements
72
Aspergillus cell wall m odulates TLR responses
References
1. Chai LY, Netea MG, Vonk AG and Kullberg BJ. Fungal strategies for overcoming host innate 
immune response. Med Mycol 2009;47:227-36
2. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment 
practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000;79:250-60
3. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in 
adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal 
Therapy (PATH) Alliance registry. Clin Infect Dis 2009;48:265-73
4. Bowman SM, Free SJ. The structure and synthesis of the fungal cell wall. Bioessays 2006;28:799- 
808
5. Netea MG, Brown GD, Kullberg BJ and Gow NA. An integrated model of the recognition of Candida 
albicans by the innate immune system. Nat Rev Microbiol 2008;6:67-78
6. Latge JP, Mouyna I, Tekaia F, Beauvais A, Debeaupuis JP and Nierman W. Specific molecular 
features in the organization and biosynthesis of the cell wall of Aspergillus fumigatus. Med Mycol 
2005;43 Suppl 1:S15-22
7. Latge JP. The cell wall: a carbohydrate armour for the fungal cell. Mol Microbiol 2007;66:279-90
8. Wang JE, Warris A, Ellingsen EA, et al. Involvement of CD14 and toll-like receptors in activation of 
human monocytes by Aspergillus fumigatus hyphae. Infect Immun 2001;69:2402-6
9. Mambula SS, Sau K, Henneke P, Golenbock DT and Levitz SM. Toll-like receptor (TLR) signaling in 
response to Aspergillus fumigatus. J Biol Chem 2002;277:39320-6
10. Bellocchio S, Montagnoli C, Bozza S, et al. The contribution of the Toll-like/IL-1 receptor 
superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol 2004;172:3059-69
11. Steele C, Rapaka RR, Metz A, et al. The beta-glucan receptor dectin-1 recognizes specific 
morphologies of Aspergillus fumigatus. PLoS Pathog 2005;1:e42
12. Chai LY, Kullberg BJ, Vonk AG, et al. Modulation of Toll-like receptor 2 (TLR2) and TLR4 
responses by Aspergillus fumigatus. Infect Immun 2009;77:2184-92
13. Hirschfeld M, Weis JJ, Toshchakov V, et al. Signaling by toll-like receptor 2 and 4 agonists results 
in differential gene expression in murine macrophages. Infect Immun 2001;69:1477-82
14. Adams EL, Rice PJ, Graves B, et al. Differential high-affinity interaction of dectin-1 with natural or 
synthetic glucans is dependent upon primary structure and is influenced by polymer chain length and 
side-chain branching. J Pharmacol Exp Ther 2008;325:115-23
15. Willment JA, Marshall AS, Reid DM, et al. The human beta-glucan receptor is widely expressed 
and functionally equivalent to murine Dectin-1 on primary cells. Eur J Immunol 2005;35:1539-47
16. Fontaine T, Magnin T, Melhert A, Lamont D, Latge JP and Ferguson MA. Structures of the 
glycosylphosphatidylinositol membrane anchors from Aspergillus fumigatus membrane proteins. 
Glycobiology 2003;13:169-77
17. Fontaine T, Simenel C, Dubreucq G, et al. Molecular organization of the alkali-insoluble fraction of 
aspergillus fumigatus cell wall. J Biol Chem 2000;275:41528
18. Hearn VM, Sietsma JH. Chemical and immunological analysis of the Aspergillus fumigatus cell 
wall. Microbiology 1994;140 ( Pt 4):789-95
19. Mouyna I, Hartland RP, Fontaine T, et al. A 1,3-beta-glucanosyltransferase isolated from the cell 
wall of Aspergillus fumigatus is a homologue of the yeast Bgl2p. Microbiology 1998;144 ( Pt 11):3171- 
80
20. Beauvais A, Maubon D, Park S, et al. Two alpha(1-3) glucan synthases with different functions in 
Aspergillus fumigatus. Appl Environ Microbiol 2005;71:1531-8
21. Ensley HE, Tobias B, Pretus HA, et al. NMR spectral analysis of a water-insoluble (1-->3)-beta-D- 
glucan isolated from Saccharomyces cerevisiae. Carbohydr Res 1994;258:307-11
22. Lowman DW, Ferguson DA and Williams DL. Structural characterization of (1-->3)-beta-D-glucans 
isolated from blastospore and hyphal forms of Candida albicans. Carbohydr Res 2003;338:1491-6
23. Lenardon MD, Whitton RK, Munro CA, Marshall D and Gow NA. Individual chitin synthase 
enzymes synthesize microfibrils of differing structure at specific locations in the Candida albicans cell 
wall. Mol Microbiol 2007;66:1164-73
24. Hohl TM, Van Epps HL, Rivera A, et al. Aspergillus fumigatus triggers inflammatory responses by 
stage-specific beta-glucan display. PLoS Pathog 2005;1:e30
25. Bozza S, Clavaud C, Giovannini G, et al. Immune sensing of Aspergillus fumigatus proteins, 
glycolipids, and polysaccharides and the impact on Th immunity and vaccination. J Immunol 
2009;183:2407-14
26. Brown GD, Gordon S. Fungal beta-glucans and mammalian immunity. Immunity 2003;19:311-5
73
Chapter 4
27. Chen J, Seviour R. Medicinal importance of fungal beta-(1-->3), (1-->6)-glucans. Mycol Res 
2007;111:635-52
28. Nakagawa Y, Ohno N and Murai T. Suppression by Candida albicans beta-glucan of cytokine 
release from activated human monocytes and from T cells in the presence of monocytes. J Infect Dis 
2003;187:710-3
29. Huang H, Ostroff GR, Lee CK, Wang JP, Specht CA and Levitz SM. Distinct patterns of dendritic 
cell cytokine release stimulated by fungal beta-glucans and toll-like receptor agonists. Infect Immun 
2009;77:1774-81
30. Shah VB, Williams DL and Keshvara L. beta-Glucan attenuates TLR2- and TLR4-mediated 
cytokine production by microglia. Neurosci Lett 2009;458:111-5
31. Ferwerda G, Meyer-Wentrup F, Kullberg BJ, Netea MG and Adema GJ. Dectin-1 synergizes with 
TLR2 and TLR4 for cytokine production in human primary monocytes and macrophages. Cell 
Microbiol 2008;10:2058-66
32. Rappleye CA, Eissenberg LG and Goldman WE. Histoplasma capsulatum alpha-(1,3)-glucan 
blocks innate immune recognition by the beta-glucan receptor. Proc Natl Acad Sci U S A 
2007;104:1366-70
33. Morelle W, Bernard M, Debeaupuis JP, Buitrago M, Tabouret M and Latge JP. 
Galactomannoproteins of Aspergillus fumigatus. Eukaryot Cell 2005;4:1308-16
34. Schmalhorst PS, Krappmann S, Vervecken W, et al. Contribution of galactofuranose to the 
virulence of the opportunistic pathogen Aspergillus fumigatus. Eukaryot Cell 2008;7:1268-77
35. Mellado E, Dubreucq G, Mol P, et al. Cell wall biogenesis in a double chitin synthase mutant 
(chsG-/chsE-) of Aspergillus fumigatus. Fungal Genet Biol 2003;38:98-109
74
Chapter 5
Aspergillus fumigatus conidial melanin down- 
regulates host cytokine response
Louis Y.A. Chai, Mihai G. Netea, Janyce Sugui, Alieke G. Vonk, 
Wendy W.J. van de Sande, Adilia Warris, Kyung J. Kwon- 
Chung, Bart-Jan Kullberg
Chapter 5
76
M o du lato ry  role of Aspergillus m elanin
Abstract
Melanin biopigments have been linked to fungal virulence. Aspergillus fumigatus conidia are 
melanised and are weakly immunogenic. We show that melanin pigments on the surface of 
resting Aspergillus fumigatus conidia may serve to mask pathogen-associated molecular 
patterns (PAMPs)-induced cytokine response. The albino conidia induced significantly more 
proinflammatory cytokines in human peripheral blood mononuclear cells (PBMC), as 
compared to melanised wild-type conidia. Blocking Dectin-1 receptor, Toll-like receptor 4 or 
mannose receptor decreased cytokine production induced by the albino but not by the wild 
type conidia. Moreover, albino conidia stimulated less potently, cytokine production in PBMC 
isolated from an individual with defective Dectin-1, compared to the stimulation of cells 
isolated from healthy donors. These results suggest that ß-glucans, but also other stimulatory 
PAMPs like mannan derivatives, are exposed on conidial surface in the absence of melanin. 
Melanin may play a modulatory role by impeding the capability of host immune cells to 
respond to specific ligands on A. fumigatus.
Key words: ß-glucan, Dectin-1, melanin, mannose receptor, mannan, modulation
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Introduction
Aspergillus fumigatus is an opportunistic pathogen that causes life-threatening invasive 
disease in immunocompromised hosts [1]. Mononuclear phagocytes constitute an important 
component of host defense against A. fumigatus and also represent the precursor cell 
population of tissue macrophages involved in immune surveillance against invasive 
pulmonary aspergillosis [2-4]. Pathogen recognition and the subsequent host immune 
response have been attributed to pattern-recognition receptors (PRRs) such as Toll-like 
receptors (TLRs) and C-type lectin receptors (CLRs) on host immune cells. These PRRs 
recognize conserved structures on the invading fungus called pathogen-associated 
molecular patterns (PAMPs). Elucidation of conidial factors that contribute to pathogenicity of 
Aspergillus spp. is important. It has recently been shown that recognition of cell wall ß-glucan 
is one of the main stimulation pathways of host defense against aspergillosis [5]. In addition 
to the (ß-and-a)-glucans and galactomannan which are the main components of the 
Aspergillus conidial cell wall, there are also melanin nodules which are localized on the 
exterior surface of the cell wall [6].
Production of melanin has been associated with survival and virulence of fungal species 
such as Cryptococcus neoformans [7, 8], Exophilia dermatitidis [9, 10] and Aspergillus 
fumigatus [11, 12]. Aspergillus strains with melanised conidia have demonstrated an 
increased ability to scavenge reactive oxygen species and they are protected against 
oxidative damage by host leukocytes [13, 14]. However, to date, the immunomodulatory 
capacity of Aspergillus melanin remains to be elucidated.
Since melanin is localized on the exterior surface of conidia and therefore in contact with the 
external milieu and the host immune system, we explored the role of melanin in modulating 
host response to A. fumigatus.
Materials and methods 
Micro-organisms
A. fumigatus strain B-5233 is a wild type strain which produces melanised bluish green 
conidia, and was isolated from a patient with fatal invasive aspergillosis. The strain RGD-12, 
which produces albino conidia devoid of melanin, was obtained by deletion of the gene alb1 
in the strain B-5233. The alb1 gene codes for a polyketide synthase (pksP) in the 1,8- 
dihydroxynaphthalene (DHN)-melanin pathway involved in the biosynthesis of conidial 
pigment [12, 15].
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The strains were grown on Aspergillus minimal agar media for one week and resting conidia 
were harvested in 0.01% Tween20/PBS, washed with sterile distilled water and resuspended 
in Hanks’ balanced saline solution (HBSS) without Ca2+ and Mg2+ [12]. Conidia were heat- 
killed by incubation at 65oC for 1 h [16] and their viability was tested on malt agar. The 
treatment was repeated until no viable conidia were detected on malt plates. Conidia were 
kept at -20oC between heat-treatments.
Heat-killed Candida albicans blastoconidia, strain ATCC MYA-3573 (UC820), that was used 
as a positive control for its beta-glucan-mediated stimulation of Dectin-1, was characterized 
elsewhere [17, 18]. Experiments involving heat-killed C. albicans blastoconidia were 
performed in a similar manner as described above.
Extraction of melanin from A. fumigatus conidia
Melanin was extracted from conidia of A. fumigatus strain ATCC 204305, as previously 
described [19]. In brief, conidia were enzymatically lysed to form protoplasts. The protoplasts 
were incubated in the denaturant 4.0 M guanidine thiocyanate to generate dark particles, 
which were treated with proteinase K to remove residual proteins. The pellet was boiled in 
6.0 M HCL for 1 h to obtain pure melanin. Melanin concentration was quantified by weighing 
the dried mass [20].
Reagents
The Toll-like receptor (TLR)-4 antagonist Bartonella lipopolysaccharide (LPS) was obtained 
as previously described [21]. D-Mannose, in order to block the mannose receptor pathway 
[22], was purchased from Sigma Chemical Co (St. Louis, MO, USA). The Dectin-1 receptor 
antagonist, laminarin, was kindly provided by Dr David Williams (University of Tennessee, 
USA).
PBMC stimulation assays
Venous blood was drawn from the cubital vein of healthy volunteers, into 10-mL EDTA tubes 
after informed consent. Peripheral blood monocytes (PBMC) were isolated as described [23]. 
In brief, the PBMC fraction was obtained by density centrifugation on Ficoll-Hypaque 
(Pharmacia Biotech, Uppsala, Sweden). Cells were washed twice in saline, counted and the 
number was adjusted to 5 * 106 cells/mL. A 100 l^ volume of PBMC, suspended in culture 
medium (RPMI 1640 DM; ICN Biomedicals, Costa Mesa, CA) supplemented with 10 g^/ml 
gentamicin, 10mM L-glutamine and 10 mM pyruvate was added to 96-well plates with heat- 
killed conidia of A. fumigatus or melanin extract, in various concentrations, for 24 hours at 
37oC.
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For receptor-blocking experiments, laminarin (200 g^/ml), Bartonella LPS (160 g^/ml) or 
mannose (50mM) fractions were pre-incubated with PBMC for 1 h at 37o C prior to 
stimulation with Aspergillus conidia. The supernatants were collected at 24 hours and stored 
at -20oC until cytokine assay.
Cytokine assay
Interleukin-6 (IL-6), IL-10 and interferon-gamma (IFNy) were measured by a commercial 
ELISA kit (Pelikine Compact; Sanquin), according to the instructions of the manufacturer. 
Tumor necrosis factor-alpha (TNFa) was measured by commercial ELISA kit (R&D 
Systems). The detection limit was 8 pg/ml for IL-6, 4.7 pg/ml for IL-10, 3.1 pg/ml for IFNy and 
40 pg/ml for TNFa.
Statistics
Results from 3 sets of experiments were pooled and analyzed using SPSS  16.0 statistical 
software. Data are given as mean + standard error of the mean (SEM). Wilcoxon signed rank 
test was used and the level of significance was set at p < 0.05.
Results
Cytokine response to wild type (WT) melanised A. fumigatus and albino A. fumigatus 
Conidia
Samples containing 105 to106 of A. fumigatus conidia/ml poorly induced cytokine production 
(data not shown). However, 107/ml of albino conidia (defective in melanin) stimulated 
significantly higher cytokine productions as compared to the wild type (WT) melanised 
conidia of the same concentration. The albino conida elicited a significantly stronger IL-6 
response. TNFa and IL-10 response was also significantly elevated with albino conidia at 107 
conidia/ml. Its corresponding melanised WT conidia were weakly immunogenic (Figs. 1a & 
1b). Even at 107 conidia/ml, both WT and albino A. fumigatus conidia were weak inducers of 
IFNy with PBMC. The above representative cytokines were assayed as IL-6, TNFa and IFNy 
are distinct proinflammatory mediators which represent the effector arm of the host immune 
response against the fungal pathogen. IL-10, on the other hand, is an anti-inflammatory 
cytokine which regulates and limits anti-fungal immune response [3].
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Figure 1. Human PBMC response 
to wild-type (WT) melanised and 
albino A. fumigatus conidia (107/ml). 
Interleukin-6 (IL-6), tumor necrosis 
factor alpha (TNF-a) (Fig. 1a) and 
interleukin 10 (IL10), interferon­
gamma (IFN-gamma) levels as 
shown (Fig. 1b). A. fumigatus 
conidia were poorly immunogenic at 
the concentrations of 105 to 106 /ml 
(data not shown). Data was pooled 
from 3 sets of experiments and 
expressed as mean + SEM; n = 6 
subjects. * p < 0.05 in respective 
cytokine production between WT 
conidia and albino conidia.
Immunogenicity of melanin
Given the disparity in response between albino and melanised WT conidia, we investigated 
the immunogenic potential of melanin extracted from A. fumigatus conidia in PBMC. Similar 
to the wild-type conidia expressing melanin on their surface, purified melanin was poorly 
immunogenic for proinflammatory cytokine production with various concentrations ranging up 
to 1 mg/ml (Table 1).
Melanin RPMI 1mg/ml 0.1 0.01 0.001
dry-w e igh t
mg/m l mg/m l mg/m l
IL-6 pg/m l * 8 8 36 + 19 8 8
TNF-a pg/ml# 40 40 52 + 11 40 40
Table 1. Cytokines IL6 and TNFa production to melanin extracts, dose response relationship. Data was 
pooled from 3 sets of experiments and expressed as mean + SEM; n = 6 subjects.
* detection limit for IL-6 assay was 8 pg/ml
# detection limit for TNF-a assay was 40 pg/ml
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Selective inhibition of Dectin-1 receptor, TLR4 and mannose receptor (MR) pathway
IL-6 and TNFa responses to conidia of 107/ml from each strain were further analyzed in the 
presence of inhibitors that block the specific recognition pathways. Laminarin, the Dectin-1 
antagonist, significantly reduced the IL-6 and TNFa production in response to the albino 
conidia, while cytokine production induced by the wild-type melanised conidia was less 
affected (Figs. 2a & 2b). This observation indicates that ß-glucans on the albino conidia play 
a significant role in eliciting a proinflammatory cytokine response while the stimulatory role of 
ß-glucan in melanised conidia is less pronounced.
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F igure 2. PBMC pre-incubated with laminarin (blocks Dectin-1; Figs. 2a & b), Bartonella LPS (blocks TLR4; Figs. 
2c & d) and mannose (blocks mannose receptor pathway; Figs. 2e & f) and stimulated with albino and wild-type 
(WT) Aspergillus conidia. Data pooled from 3 sets of experiments and expressed as mean + SEM, n = 6 subjects. 
* p < 0.05 as compared to respective control (without specified inhibitor).
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Ex-vivo stimulation in Dectin-1'/_ PBMC
PBMC were isolated from a subject known to have a complete defect in Dectin-1 receptor 
expression, due to a homozygous mutation leading to a premature stop codon (Tyr 238 stop) 
[24]. Cytokine production following stimulation with 107 conidia/ml was compared to those of 
three control subjects. Since ß-glucans are known to be exposed on heat-killed cells of 
Candida albicans [16], we used heat-killed C. albicans blastoconidia 106/ml to stimulate 
PBMC pre-incubated with laminarin and validated the non-functional role of Dectin-1 in this 
subject (Figs. 3b & 3d). The melanin-defective albino conidia induced a lower cytokine 
production in cells of the Dectin-1-deficient individual, compared to those of control subjects, 
suggesting that ß-glucans are one of the components exposed on its surface of the albino 
conidia (Fig. 3a & 3c). However, even in the absence of dectin-1, conidia from the albino 
strain still induced more cytokine production than the wild-type. This observation 
corroborates with the hypothesis that in addition to ß-glucans, other PAMP components 
(such as mannans) are also exposed on the melanin-deficient albino conidia.
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F igure 3. PBMC response to albino and wild-type (WT) strains of A. fumigatus conidia in Dectin-1-deficient 
homozygous subject versus 3 control subjects. As compared to controls, the Dectin-1 deficient subject displayed 
a trend towards less IL6 and TNF-a production with the albino conidia (Figs. 3a & c) than WT conidia. Positive 
control using Candida albicans blastoconidia, heat-killed with exposed surface ß-glucans with and without Dectin- 
1 inhibitor, laminarin (Figs. 3b & d). Data pooled from 2 sets of experiments and expressed as mean + SEM.
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Discussion
In this study, we focused on the role of A. fumigatus conidial pigment in host-pathogen 
interactions. The airborne conidia that humans inhale are resting conidia bearing bluish 
green pigment on the conidial surface identified as DHN-melanin [12]. This melanin layer 
disappears as conidia swell to initiate germination. Since the host cells first interact with 
inhaled resting conidia, it is in our interest to elucidate the role of melanin in the pathobiology 
of A. fumigatus.
To our knowledge, this is the first study showing that conidial pigmentation of A. fumigatus 
modulates the host proinflammatory cytokine response. Compared to the melanised WT 
resting conidia, the albino resting conidia stimulated much stronger host defense 
mechanisms such as proinflammatory cytokine production. Our results suggest that the 
melanin layer shields fungal PAMPs such as ß-glucan, MR- and TLR-4 ligands from 
recognition by host PRRs thus preventing these PAMPS from eliciting an inflammatory 
response. This postulation is further strengthened by our demonstration that purified melanin 
was a very poor inducer of cytokine production, a pre-requisite characteristic for the 
assumption of its ‘masking’ role.
The evolutionary conservation of fungal melanin points to its role beyond that of rudimentary 
biopigmentation. Indeed, there has been considerable evidence linking fungal melanin 
biosynthesis to virulence [25]. Melanin has been shown to protect fungi in many ways. It 
offers a beneficial physiologic redox buffer [13], limits complement activation [12, 26], 
protects Aspergillus conidia against reactive oxygen intermediates (ROIs) released by host 
immune cells, and protects against killing by human monocytes [14, 27]. In addition to these 
effects, we demonstrated in this study that melanin localized on the surface of A. fumigatus 
conidia [6, 28] is also able to down-regulate host immune response by shielding of fungal 
PAMPs from recognition by host PRRs.
Previous reports on the decreased virulence of albino A. fumigatus mutants [11] may partly 
be explained by the propensity of these mutants for an accentuated proinflammatory immune 
response. Wild type A. fumigatus conidia, which initiate human disease in 
immunocompromised hosts, elicit a muted proinflammatory response in its resting state. 
Given the ubiquity of fungal spores in the environment, it is conceivable that the host defense 
does not elicit an unnecessary high cytokine-mediated inflammatory cascade in the immune 
competent host upon inhalation of Aspergillus conidia, as long as other protective 
mechanisms are active. On the other hand, increased levels of proinflammatory cytokines
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like TNFa, IL6 and IFN-y have been associated with an efficient response to Aspergillus 
infection, through induction of potent anti-fungal cellular responses to clear the pathogen 
[29]. A muted host proinflammatory response (especially with TNFa and IL-6), as seen with 
wild type melanised conidia, may hamper the effectiveness of the anti-fungal defense 
mechanisms, especially in the immunocompromised host.
Our experimental results are interpreted in light of the understanding that deletion of the alb1 
gene, and hence lack of polyketide synthase (pksP), resulted in cessation of melanin 
production. This was validated phenotypically by production of albino conidia instead of the 
greenish-blue conidia of the wild type. Nonetheless, it remains to be elucidated whether 
additional immunologically-active by-products are formed or silenced in the melanin-defective 
albino strain as a result of silencing pksP in the DHN-melanin pathway.
An additional point of interest is the identification of the fungal PAMPs which upon exposure 
to the albino conidia are responsible for the increased cytokine induction. Laminarin- 
mediated blockade of Dectin-1 receptor diminished proinflammatory cytokine production 
induced by the albino strain. This observation points to ß-glucan as being one of the PAMPs 
that are exposed on the surface of the non-melanized albino conidia. This has been 
corroborated recently by other groups, which had demonstrated a high concentration of 
accessible ß-glucan on the conidial surface of a pksP deletant strain or on swollen conidia [5, 
30]. However, our results suggest that in addition to ß-glucan, TLR4- and mannose receptor 
(MR) ligands are also exposed on albino conidia. The A. fumigatus ligands for the above­
mentioned PRRs have not been identified to date. Based on our current understanding 
extrapolated from C. albicans PAMPs [31], in which O- and W-linked mannan entities serve 
as ligands for TLR4 and MR respectively, it is likely that galactofuranose-containing 
galactomannan [32] may be one candidate PAMP on the A. fumigatus conidial wall which is 
exposed on the albino conidia. This is further supported by our demonstration that albino 
conidia were still able to induce higher levels of cytokines than the WT strain in host cells 
defective in dectin-1. Hence, in the absence of melanin, other conidial PAMPs can potentially 
engage host PRRs such as TLR4 and MR, next to engagement of Dectin-1 by ß-glucan 
which had been thought to be a major ligand on swollen A. fumigatus conidia [16].
In conclusion, we have demonstrated that the melanin layer plays an important role in 
attenuating host immune response to A. fumigatus conidia. This is likely to be achieved 
through the physical masking of the stimulatory effects of PAMPs like ß-glucan and mannan- 
containing PAMPs located on the resting conidial surface. In addition to its other known roles
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of protecting the pathogen against host phagocytes [14, 33] and limiting damage by the 
complement system [12], melanin may have an additional role as an important modulator of 
cytokine response to A. fumigatus conidia.
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Abstract
Both interferon-gamma-producing type 1 T helper (Th1)- and interleukin-17 (IL-17)-producing 
type 17 T helper (Th17) cells have been proposed to be involved in anti-fungal host defense. 
Although invasive aspergillosis is one of the most severe human fungal infections, little is 
known regarding the relative importance of the Th1 versus Th17 cellular immune pathways 
for the human anti-Asperg///us host defense. Using human peripheral blood mononuclear 
cells and a system consisting of monocyte-derived macrophages, we found that Asperg///us 
fum/gatus is a weak inducer of human IL-17 but induces a strong Th1 response. These data 
were validated by the very low IL-17 levels in bronchoalveolar lavage fluid and serum of 
patients with invasive aspergillosis. Surprisingly, live A. fum/gatus reduced IL-17 production 
induced by mitogenic stimuli. This effect was mediated through the propensity of A. 
fum/gatus to metabolize tryptophan and release kynurenine that modulates the inflammatory 
response through inhibition of the IL-17 production. In conclusion, A. fum/gatus does not 
stimulate production of IL-17 and human host defense against aspergillosis may not rely on 
potent Th17 responses.
Keywords : interferon-gamma, macrophages, kynurenine, IL-17, Asperg///us
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Introduction
Asperg///us fum/gatus, an opportunistic ubiquitous mold, causes invasive aspergillosis in 
immunocompromised hosts with high rates of mortality and morbidity [1, 2]. Until recently, the 
paradigm of the type 1 T helper (Th1) and type 2 T helper (Th2) cells was traditionally the 
model upon which knowledge of host immune response to fungal infection was based [3, 4]. 
These CD4+ T-cell subtypes mediate distinct immune responses. Th1 cells produce 
proinflammatory cytokines such as interferon-gamma (IFN-y) that induces protective 
antifungal defense mechanisms, whereas Th2 cells release IL-4 and IL-10 which evoke a 
humoral response and in turn down regulate Th1-dependent mechanisms [5]. It is the 
balance between Th1 and Th2 responses that has been perceived as critical in determining 
outcome of invasive fungal diseases [6].
However, the recent discovery in both mice and man of a novel member of the CD4+ effector 
T-cell family (Th17 cells) producing IL-17 has provided novel insights into the immune 
mechanisms that are responsible for both protection from infections and immunopathology in 
autoimmune diseases [7-9]. Differentiation of murine and human naive CD4+ T cells into 
either Th1, Th2 or Th17 cells depends on the cytokine milieu present at the time of initial 
engagement of the T-cell receptor and co- stimulatory receptors [10]. Homology between 
human and murine IL-17 is high and the major function of IL-17 is to promote recruitment and 
activation of neutrophils [11]. As a result of these effects, IL-17 is generally perceived as 
having a protective role against fungal infection, as demonstrated by an increased 
susceptibility to disseminated candidiasis of mice lacking the IL-17 receptor [12]. However, 
human Th17 cells have a different origin than those in mice [13], and the cytokines that direct 
Th17 development exert their effect differently in the two hosts [14].
Few and conflicting data are available regarding the potential role of IL-17 for the host 
defense against A. fum/gatus. On one hand, IL-17 was recently reported to hamper 
neutrophil-mediated killing of A. fum/gatus and the in-vivo clearance of the organism in non- 
immunosuppressed mice [15]. In contrast, other data suggest a protective role for IL-17 in 
host defense against A. fum/gatus. Neutralization of IL-17 early in host defense against A. 
fum/gatus infection in non-immunosuppressed mice resulted in an increased pulmonary 
fungal burden [16]. Very little is known regarding the role of IL-17 for the host defense 
against Asperg///us infections in humans.
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On this background and with the understanding that regulation of Th17 pathway may differ 
between murine and human cells, we studied the IL-17 host response to A. fum/gatus in 
human leukocytes and in patients with invasive aspergillosis.
Materials and methods 
Microorganisms
The A. fum/gatus strain V05-27 is a previously characterized clinical isolate [17]. Live conidia 
and heat-killed hyphae were obtained as previously described [18]. For the experiments 
involving Asperg///us-conditioned medium, live V05-27 A. fum/gatus (at concentrations as 
specified) were grown in RPMI 1640 DM (ICN Biomedicals, Costa Mesa, CA) supplemented 
with 10 g^/ml gentamicin, 10 mM L-glutamine, and 10 mM pyruvate at 37oC. After 3 days, the 
culture suspension was centrifuged and the supernatant was passed through a 0.2 ^m filter 
(Whatman GmbH, Dassel, Germany). In addition, conidia arrested at the different growth 
phases were prepared from A. fum/gatus B-5233, another well-characterized strain [19]. After 
incubation on Asperg///us minimal agar media for one week, both resting and germinating 
conidia (following incubation for 4 hours at 37oC in liquid broth yeast nitrogen base, Difco, 
Franklin Lakes, NJ)) were harvested in 0.01% Tween-20/phosphate-buffered saline, washed 
with sterile distilled water and resuspended in Hanks’ balanced saline solution without Ca2+ 
and Mg2+. Conidia were heat-inactivated by incubation at 65oC [20]. The treatment was 
repeated until no viable conidia were detected on malt agar plate. All specimens were kept 
frozen at -20oC until use.
Heat-killed Cand/da a/b/cans blastoconidia, strain ATCC MYA-3573 (UC820) were used as a 
positive control [21, 22]. Experiments involving heat-killed C. a/b/cans blastoconidia at a 
concentration of 106 microorganisms/ml were performed in a similar manner to that described 
above.
Reagents
Anti-CD3/anti-CD28-coated beads (to mimic action of antigen-presenting cells for T-cell 
activation) were purchased from Miltenyi-Biotech (Utrecht, the Netherlands) and used 
according to manufacturer’s instructions. Recombinant human IL-1 ß (rIL-1ß; 50ng/mL) from 
Biosource (Etten-Leur, the Netherlands), IL-6 (rIL-6; 50ng/mL) and IL-23 (rIL-23; 50ng/mL) 
from R&D Systems (Abingdon, UK) were used. Rabbit anti-human anti-interferon-gamma 
(anti-IFN-Y) (10^g/mL) was purchased from U-CyTech (Utrecht, the Netherlands) and
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corresponding isotype control, rabbit immunoglobulin G (IgG), from Jackson 
ImmunoResearch Laboratories (West Grove, PA). Kynurenine and tryptophan were 
purchased from Sigma-Aldrich (Zwijndrecht, the Netherlands). The Dectin-1 receptor 
antagonist, laminarin, was kindly provided by Dr David Williams (University of Tennessee, 
Knoxville, TN). Anti-human monoclonal antibody against mannose receptor CD206 (a-MR) 
and corresponding isotype control was purchased from BD Pharmingen (Breda, the 
Netherlands).
In-vitro cytokine production
Separation and stimulation of peripheral blood mononuclear cells (PBMC) was performed as 
described previously [23]. Briefly, venous blood was drawn into ethylenediaminetetraacetic 
acid tubes from healthy volunteers after informed consent. PBMC were isolated by density 
centrifugation on Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden). Cells were washed 
twice in saline, counted and the number adjusted to 5x106 cells/mL. For experiments 
involving monocyte-derived macrophages (MDM) [24], PBMC were maintained in culture 
medium (RPMI 1640 DM supplemented with gentamicin, L-glutamine, and pyruvate) in the 
presence of 10% human pooled serum in humidified atmosphere (5% CO2) at 37oC for 6-7 
days to permit differentiation with the lymphocyte component in-situ. Culture medium was 
refreshed after 3 days. Stimulation assays were performed in 96-well plates (Greiner, Alphen 
a/d Rijn, the Netherlands) using 100 l^ volume of PBMC or MDM with lymphocytes 
(abbreviated as MDM/lymphocytes), and the various stimuli to a total volume of 200 l^/well. 
For investigation of Th17 responses, the cells were incubated with the pathogen at 37oC for 3 
or 7 days [25]. After incubation, the supernatants were collected and stored at -20oC until 
assay.
Flow cytometry
MDM/lymphocytes were stimulated for 4-6 hours with 13-phorbol 12-myristate acetate (PMA) 
(50 ng/ml; Sigma) and ionomycine (1 g^/ml; Sigma) in the presence of Golgiplug (BD 
Biosciences, Breda, the Netherlands) according to manufacturer’s protocol. Cells were first 
stained extracellularly using an allophycocyanin-conjugated anti-CD4 antibody (BD 
Biosciences). Subsequently the cells were fixed and permeabilized with Cytofix/ Cytoperm 
solution (BD Biosciences) and then intracellularly stained with fluorescein isothiocyanate- 
conjugated anti-IL-17 (eBiosciences, Halle-Zoersel, Belgium). Samples were measured on a 
FACS Calibur and data were analyzed using the Flow Jo software (version 7.2.5.).
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Patients
Serum from hematology patients diagnosed with proven or probable invasive aspergillosis 
(IA) [26] and bronchoalveolar lavage (BAL) fluid of IA patients as per European Organization 
for Research and Treatment of Cancer (EORTC) criteria [27] were obtained before the 
initiation of appropriate treatment and in line with the respective institutional guidelines. 
Matched controls consisted of similar patient cohorts with underlying hematological 
malignancies who did not have IA.
Cytokine assay
Interleukin-6, IL-10 and IFN-y were measured by commercial ELISA kit (Pelikine Sanquin 
Compact, Amsterdam, the Netherlands), according to the instructions of the manufacturer. 
IL-17 was measured by the appropriate commercial ELISA kit (R&D Systems). Detection 
limits were 8 pg/ml (IL-6 and IL-10), 20pg/ml (IFN-y), and 16 pg/ml (IL-17) respectively.
Tryptophan and kynurenine measurement
Levels of tryptophan and kynurenine produced by A. fum/gatus in Asperg///us-conditioned 
medium were quantified by UV detection with high performance liquid chromatography 
(HPLC). This was performed on a SpectraSYSTEM autosampler and pump (Thermo 
Separation Products, San Jose, CA). Chromatographic separation was performed using an 
Inertsil 5 ODS-2 column (100mm x 3.0 I.D.) (Varian Inc., Middelburg, the Netherlands). 
Absorbance was monitored with a diode-array detector (UV6000LP, Thermo Separation 
Products, San Jose, CA) at wavelength of 280nm for tryptophan and 360nm for kynurenine
[28]. The mobile phase for isocratic elution was made by dissolving 40mM sodium acetate. 
The pH of the eluent was adjusted to pH 4.5 with a solution of 40mM citric acid and 2% 
acetonitrile of the total volume buffer was added. The continuous flow rate was 0.3 ml/min
[29]. For calibration, the standard was diluted in RPMI in the concentration range of 0-72 ^M 
for tryptophan, and 0-42 ^M for kynurenine. 50 ^L of the standard or sample was injected 
into the column for measurement.
Statistical analysis
Experiments were performed in duplicates. For the in-vitro experiments, results from 3 sets 
of separate experiments (involving 5 or more distinct healthy volunteers) were pooled and 
analyzed using SPSS  16.0 statistical software. Data given as means + standard errors of the 
means (SEM) and the Wilcoxon signed rank test was used to compare differences between 
groups (unless otherwise stated). The level of significance was set at p < 0.05.
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Results
Aspergillus fumigatus is a poor inducer of human IL-17 by PBMC and MDM
We investigated the capacity of A. fum/gatus to induce production of IL-17 by human PBMC. 
Incubation of live A. fum/gatus V05-27 conidia (at doses of 104 - 106 microorganisms/ml) with 
PBMC over 7 days induced little IL-17, in contrast to C. a/b/cans, a known inducer of IL-17 
(Fig. 1a) [25]. We also assessed the capacity of MDM/lymphocytes to mediate IL-17 
induction. However, IL-17 production upon incubation with live Asperg///us conidia was also 
nearly undetectable in this system (Fig. 1b). Flow cytometric analysis further corroborated 
the low propensity of live Asperg///us to induce IL-17, in contrast to C. a/b/cans, as illustrated 
by the absence of IL-17-producing CD4+ cells (Figs. 1c&d).
F igure 1. (a, b) Interleukin-17 (IL-17) -inducing capacity of 104-1 0 6 micro-organisms/ml Asperg///us fum/gatus in 
peripheral blood mononuclear cells (PBMC) and monocyte-derived macrophages (MDM)/lymphocytes systems 
over 7 days with Cand/da a/b/cans as positive control. (c, d) Flow cytometry of MDM/lymphocytes stimulated by A. 
fum/gatus and C. a/b/cans, respectively. The cells were labelled with anti-CD4-allophycocyanin and anti-IL-17- 
fluorescein isothiocyanate. Density plots show surface staining of CD4 (x-axis) and intracellular staining of IL-17 
(y-axis). Numbers on the plots represent percentage of cells bearing positivity for the respective markers. Results 
from a representative experiment are shown. (e, f) IL-17 and IL-6 induced by 105-1 0 7 micro-organisms/ml of heat- 
killed A. fum/gatus components: resting conidia, germinating conidia and hyphae in PBMC. Stimulation studies 
are cumulative from three sets of experiments. *P < 0 05 compared with control (RPMI-1640). Asperg///us: live A. 
fum/gatus conidia (unless otherwise stated), Cand/da: heat-killed C. a/b/cans blastoconidia (as positive control), 
HK: heat-killed.
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To validate these findings and to demonstrate that the above observed phenomenon was not 
strain-specific, we repeated the experiments using either heat-inactivated conidia of another 
well-characterized A. fumigatus strain B-5233 that were arrested at the resting and 
germinating growth stage, or with heat-killed V05-27 A. fumigatus hyphae. All of the above 
Aspergillus preparations showed limited IL-17 responses across the concentration range of 
105 to 107 microorganisms/ml (Fig. 1e). In contrast, the Aspergillus components induced a 
distinct dose-dependent trend in IL-6 production, excluding significant cellular toxicity as the 
cause of the limited IL-17 production (Fig. 1f). In line with this, lactate dehydrogenase levels 
in supernatants of cells stimulated with live Aspergillus were not elevated as compared to 
vehicle-stimulated controls. Hence, both live and heat-inactivated A. fumigatus at different 
stadia were poor inducers of IL-17 in human cells.
Aspergillus fumigatus induces strong Th1 responses
It has been described that host immune response to A. fumigatus is primarily T-helper type 1 
(Th1)-mediated, accompanied by the production of IFN-y [30, 31]. We have also 
demonstrated the propensity of live A. fumigatus to induce a robust IFN-y response in 
contrast to absence of IL-17, or the limited IL-6 and IL-10 production in the MDM/lymphocyte 
system (Fig. 2).
F igure 2. Interleukin-6 (IL-6), IL-10, interferon-y (IFN-y) and IL-1ß production by monocyte-derived macrophages 
(MDM) following stimulation by live Aspergillus fumigatus at incremental concentrations. IFN--y and IL-1ß 
responses are robust compared with IL-6 and IL-10. *P < 0 05 compared with RPMI-1640 control, n = 8 subjects.
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Live Aspergillus attenuates IL-17 production
As other studies have used mitogenic stimulation with anti-CD3/anti-CD28 antibodies to 
induce Th17 responses, live Aspergillus conidia were added to MDM/lymphocytes in the 
presence of anti-CD3/anti-CD28 beads. Surprisingly, IL-17 levels remained low in the 
presence of A. fumigatus compared with the mitogenic stimulation alone and even showed a 
dose-dependent inverse relationship to the concentration of the pathogen. Adding 
recombinant IL-6, IL-1ß and IL-23 to the anti-CD3/anti-CD28 T-cell activation failed to 
increase IL-17 induction by A. fumigatus (Figs. 3c&d). IFN-y production showed a trend 
towards inhibition by Aspergillus, but this was not as markedly attenuated as the IL-17 
response.
F igure 3. (a, b) Interferon-y (IFN-y) and interleukin-17 (IL-17) produced by monocyte-derived macrophages 
(MDM)/lymphocytes stimulated with anti-CD3/anti-CD28 beads alone and with incremental amounts of Aspergillus 
fumigatus or Candida albicans (positive control) over 3 days (c, d) In addition to anti-CD3/anti-CD28 beads, 
recombinant IL-6 (rIL-6) + rIL-1ß + rIL-23 were added to MDM/lymphocytes stimulated with A. fumigatus or C. 
albicans (positive control) over 3 days. *P < 0 05 compared with stimulated MDM/lymphocytes but without 
pathogen, n = 6 subjects. Aspergillus: live A. fumigatus conidia, Candida: heat-killed C. albicans blastoconidia, 
aCD3CD28: anti-CD3/anti-CD28-coated beads.
Weak IL-17 response is not linked to the pro-Th1-propensity of A. fumigatus
IFN-y can suppress Th17 responses and shift cellular responses towards a Th1 bias. We 
attempted to silence the Th1 response with anti-human IFN-y antibodies and investigate its 
effect on IL-17 induction by Aspergillus (Figs. 4a&b), although IFN-y production was 
effectively inhibited, there was no significant rescue of IL-17 production induced by anti- 
CD3/anti-CD28 antibodies in the presence of A. fumigatus. Hence, the weak IL-17 response 
seen in A. fumigatus is not related to its pro-Th1-inducing propensity.
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Figure 4. Interferon-Y (IFN-y ) and interleukin-17 (IL-17) 
from monocyte-derived macrophages
(MDM)/lymphocytes stimulated with anti-CD3/anti-CD28 
beads and incremental amounts of Aspergillus 
fumigatus or Candida albicans (positive control) in the 
presence of anti-IFN-y (a, b). *P < 0 05 compared with 
respective control (white bar) without anti-IFN-y, n = 6 
subjects. Aspergillus: live A. fumigatus conidia, 
Candida: heat-killed C. albicans blastoconidia (as 
positive control).
Secreted products from live Aspergillus attenuate IL-17 production
The inhibitory effects of Aspergillus on the IL-17 response induced by mitogens may be 
exerted directly through cell-cell contact, or indirectly through products released by 
Aspergillus. To investigate this, Aspergillus-conditioned medium was added to the activated 
cells. As observed in Fig. 5, IL-17 production was inhibited in a dose-dependent manner by 
the conditioned media on which live A. fumigatus conidia had grown. The IL-17-attenuating 
effects induced by Aspergillus-conditioned medium could not be assigned to shed ß-glucan 
or mannan-derivatives from the Aspergillus cell wall, as the addition of laminarin (inhibitor of 
Dectin-1, the ß-glucan receptor) and anti-MR antibodies (which block the mannose receptor) 
did not reverse the effects of the conditioned medium (data not shown).
The tryptophan metabolism pathway has recently been implicated for its role in regulating
Th17 response to fungal infection [32]. Tryptophan and kynurenine concentrations were
measured in the Aspergillus-conditioned media. Kynurenine concentrations in the
Aspergillus-conditioned media were increased (as compared to control) across the
concentration range of live A. fumigatus. This correlated with a drop in the concentration of
the substrate, tryptophan, in the conditioned medium (Table 1).
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The effect of kynurenine was assessed on the IL-17 production induced by anti-CD3/anti- 
CD28 antibodies. As depicted in Fig. 5c, kynurenine inhibited IL-17 production in a dose- 
dependent manner as compared to control stimulation.
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Figure 5. (a, b) Interferon-y (IFN-y) and interleukin-17 
(IL-17) produced by anti-CD3/anti-CD28-stimulated 
monocyte-derived macrophages (MDM)/lymphocytes 
over 3 days in the presence of conditioned medium in 
which the respective concentrations of live Aspergillus 
fumigatus had previously been grown over 72 hr. *P < 
0 05 compared with anti-CD3/anti-CD28-stimulated 
MDM/lymphocytes in the presence of conditioned 
medium in which no Aspergillus had been grown 
(control; first bar), n = 6 subjects. (c) IL-17 production 
by anti-CD3/anti-CD28-stimulated MDM/lymphocytes 
over 3 days in the presence of increasing 
concentrations of kynurenine compared with control 
(without kynurenine). *P < 0 05 compared with control, 
n = 6 subjects. Aspergillus: live A. fumigatus conidia, 
aCD3CD28: anti-CD3/anti-CD28-coated beads.
Conditioned medium
RPMI Control Live Aspergillus (microorganism/ml) 
104 105 106
Tryptophan (^M) 28.38 + 0.17 20.14 + 4.46 18.95 + 4.10 17.98 + 3.48
Kynurenine (^M) 0 0.12 + 0.01 0.18 + 0.05 0.26 + 0.04
Table 1. Tryptophan and kynurenine levels of conditioned media in which live A. fumigatus (of incremental 
concentrations) had been grown over 3 days as compared to levels in conditioned medium incubated over 3 days 
without Aspergillus (RPMI Control). Tryptophan and kynurenine levels were measured via high performance liquid 
chromatography (HPLC). The analysis was performed on 3 sets of assays and is presented as means+SD.
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IL-17 concentrations are low in patients with invasive aspergillosis
To assess the capacity of Aspergillus to stimulate Th17 responses in vivo, we measured IL- 
17 concentrations in clinical specimens of patients with invasive aspergillosis. This consisted 
of BALs from 17 distinct patients diagnosed with proven/probable IA and another 20 BALs 
from corresponding control patients (i.e. patients with similar background underlying disease, 
but without invasive aspergillosis). The same analysis was performed on the serum of 19 
patients with invasive aspergillosis (specimen obtained at the point of diagnosis of disease) 
and also 15 other control patients without IA. As seen in Fig. 6a, IL-17 levels are generally 
low in BALs of patients at risk of IA, and not higher than the concentrations found in patients 
without IA. Similarly, IL-17 concentrations were low in the circulation of patients with IA, and 
even decreased compared with controls (Fig. 6b).
F igure 6. (a) Interleukin-17 (IL-17) levels in bronchoalveolar lavage of patients diagnosed with proven/probable 
invasive aspergillosis (IA) compared with a corresponding patient cohort without IA (No IA): n = 17 in IA group 
(eight proven IA cases and nine probable IA cases), n = 20 in No IA group. (b) IL-17 levels in serum of IA patients 
(IA) and corresponding patient controls (No IA): n = 19 in IA group (eight proven IA cases and 11 probable IA 
cases), and n = 15 in No IA group. *P < 0 05 (unpaired t-test).
Discussion
In the present study we investigated the activation of T-helper cellular responses activated by 
A. fumigatus. We demonstrate that A. fumigatus induces a very limited Th17 response in 
humans, both in-vitro and in-vivo. In contrast, A. fumigatus induces robust stimulation of IFN- 
y production, implying that Th1 responses likely represent the cornerstone of T helper- 
dependent immunity against Aspergillus species.
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Few studies have investigated the role of IL-17 in host defense against Aspergillus infection. 
The studies performed to date involved murine knock-out models, and reported contradicting 
results, with some studies suggesting a deleterious role of IL-17 [15, 33], while others have 
suggested that IL-17 is beneficial for anti-Aspergillus host defense [16]. In addition, induction 
of Th17 cells in humans may differ from that of mice [34, 35]. No studies have assessed the 
induction of Th17 responses in human cells. Moreover, patients with IA represent a unique 
susceptible cohort who have primarily hematological malignancies and are profoundly 
immunocompromised: being recipients of high-dose, long-term steroid therapy, 
chemotherapy, stem-cell transplantation and having prolonged agranulocytosis. Such 
mitigating conditions are difficult to simulate in the above-studied mice models. Therefore, 
studies in primary human cells are the only viable alternative for the study of Th17 responses 
in humans. Because host immune responses to live and killed A. fumigatus are known to be 
different [20, 36], and in order to closely mimic the physiological conditions in which the host 
immune cells encounter the pathogen, the stimulation of MDM/lymphocytes and live A. 
fumigatus conidia was investigated.
In the present study we report that A. fumigatus is a poor inducer of IL-17 in both PBMC and 
in a macrophage/T-cell system. Based on the current understanding of Th-17 activation 
pathway in other fungal infections such as C. albicans [25], this can be attributed to either the 
absence of specific memory T-cells against A. fumigatus or to a sub-optimal induction of the 
endogenous cytokines necessary for the induction of a Th17 response (e.g. IL-23, IL-1ß, IL- 
6). However, even mimicking T-cell activation by the use of anti-CD3/anti-CD28 beads, as 
well as adding a ‘pro-Th17 cytokine cocktail’ consisting of IL-1 ß, IL-6 and IL-23 [34, 37, 38], 
failed to significantly augment IL-17 production in response to Aspergillus.
In contrast to the failure to induce IL-17 production, A. fumigatus induced robust Th1 IFN-y 
responses [3, 30, 39]. It has been suggested by some studies that Th1 and Th17 
differentiation can be mutually exclusive [10, 15]. If this would be indeed the case, the strong 
induction of IFN-y by Aspergillus, may inhibit the Th17 responses and account for the lack of 
IL-17 induction in the presence of a predominant Th1 response. However, when we 
neutralized IFN-y bioactivity with anti-human IFN-y antibodies, this failed to stimulate IL-17, 
arguing for an intrinsic incapacity to stimulate Th17 responses, rather than indirect effects 
through Th1 induction. Similar to Aspergillus, the inhibition of IFN-y during stimulation with C. 
albicans did not up-regulate IL-17 release, arguing against a major role of IFN-y as a 
modulator of Th17 responses in fungal infections.
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Interestingly, not only was A. fumigatus unable to induce much IL-17 production, it even 
actively inhibited the IL-17 release induced by mitogenic stimuli such as anti-CD3/anti-CD28 
antibodies. The tryptophan metabolism pathway has recently been implicated for its role in 
regulating Th17 response to fungal infection [32]. Tryptophan can be metabolized by the 
enzyme indoleamine 2,3-dioxygenase (IDO) into the catabolite kynurenine. IDO and 
kynurenine have been shown to inhibit Th17 differentiation in mice [33]. IDO is also involved 
in modulation of Th1 differentiation [40, 41]. Interestingly, A. fumigatus also possess an IDO- 
family enzyme [42], and we show that A. fumigatus can induce metabolization of tryptophan 
into kynurenine. We investigated whether kynurenine is able to modulate Th17 also in human 
cells, and we have indeed observed inhibitory effects. Therefore, it seems rational to 
hypothesize that the observed inhibitory effect of A. fumigatus on the induction of IL-17 is at 
least in part mediated through its effects on tryptophan metabolites, via the generation of the 
inhibitory product kynurenine. However, besides kynurenine, we cannot exclude that 
additional factors may also mediate inhibition of Th17 induction by Aspergillus. Nonetheless, 
in our hands, these additional IL-17-modulating effects were probably not linked to innate 
signaling via the macrophage receptor [43] or Dectin-1 ß-glucan receptor [16].
The importance of IL-17 in the pathogenesis of invasive aspergillosis remains to be proven. 
Recently it has been reported that IL-17 receptor-deficient mice, despite an initially elevated 
fungal burden, were eventually able to efficiently control aspergillosis [44]. This raises the 
question on the perceived non-redundancy of IL-17. From the clinical perspective, patients 
with hyper-IgE (HIE) syndrome are known to have deficiency of Th17 cells due to mutations 
in signal transducer and activator of transcription 3 (STAT-3) [45, 46] and are susceptible to 
secondary Aspergillus infection of pneumatoceles, but not to primary invasive aspergillosis 
[47]. Whilst colonization of pneumatoceles with Aspergillus in hyper IgE syndrome patients 
would seemingly support the notion of a protective role of IL-17 against fungal infections, one 
will need to keep in mind that the pathogenic mechanism behind an ‘opportunistic 
colonization’ of a lung cavity in a patient with hyper-IgE is perceivably distinct from that of 
invasive aspergillosis in a bone marrow transplant patient. Therefore, the clinical picture in 
Th17-defective patients with hyper-IgE syndrome does not dispute the notion that Th17 
responses may not be essential in the host defense against invasive aspergillosis.
In conclusion, we demonstrate that A. fumigatus is a poor inducer of IL-17 response in 
humans, and this may be at least partly attributable to the pathogen’s ability to metabolize 
tryptophan and secrete kynurenine which, in turn, down-regulates the Th17 pathway. The 
importance of IL-17 in the pathogenesis of invasive aspergillosis remains therefore in
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question, as Th1 response is likely the predominant T helper-dependent immunity mounted 
by the host against Aspergillus species. It is hence difficult to envisage a dominant role for IL- 
17 in host defense against Aspergillus at this juncture.
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Abstract
Background The C-type lectin receptor Dectin-1 which recognizes ß-glucan in the fungal cell 
wall has been shown to be a pivotal pathogen recognition receptor for anti-Asperg///us host 
defense in experimental studies. We assessed whether defective Dectin-1 receptor function 
due to the early stop codon polymorphism Y238X enhances susceptibility to invasive 
aspergillosis (IA) in at-risk patients.
Methods The presence of Dectin-1 Y238X polymorphism, which results in diminished 
Dectin-1 receptor expression and inability to bind ß-glucan, was evaluated in a cohort of 92 
IA patients, 108 controls without IA and their respective hematopoietic stem cell transplant 
(HSCT) donors. This was correlated with clinical outcome data. In addition, functional studies 
were performed to study the consequences of the Y238X Dectin-1 polymorphism.
Results An altered Dectin-1 function due to the Y238X polymorphism in the heterozygous 
state resulted in a trend towards susceptibility to IA (adjusted odds ratio [OR] 2.18, 95% 
confidence interval [CI] 0.98-4.80, p=0.06). Upon stratification, recipient Y238X status was 
associated with increased risk of IA in non-HSCT immunocompromised patients (adjusted 
OR 4.50, 95% CI 1.40-14.5, p=0.012), but no association was seen in the group of HSCT 
patients or their donors. The Y238X polymorphism did not influence clinical course of IA. 
Functional assays revealed that human peripheral blood mononuclear cells from individuals 
bearing the Y238X polymorphism responded less efficiently to Asperg///us stimulation. In 
contrast, macrophages responded normally upon challenge with Asperg///us despite deficient 
Dectin-1 receptor function.
Conclusions The human Dectin-1 Y238X polymorphism, when present in the heterozygous 
state, tends to enhance susceptibility to IA particularly in non-HSCT immunocompromised 
patients. The only moderate influence of the Dectin-1 polymorphism in humans may be at 
least partly attributable to a system of redundancy inherent to the host innate immune 
defense.
Keywords : C-type lectin, transplant, macrophages, redundancy, innate immunity
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Introduction
Invasive fungal infections (IFI) remain a major cause of morbidity and mortality in 
immunocompromised patients, of which invasive aspergillosis (IA) is emerging as the most 
common IFI [1, 2]. Susceptibility and host response to fungal infection is largely determined 
by the immune status of the host, its ability to recognize the pathogen and to respond 
appropriately [3]. The mechanism responsible for this recognition is regulated by host 
pathogen recognition receptors (PRRs) which include the family of Toll-like receptors (TLR) 
and C-type lectin receptors (CLR) [4]. Dectin-1 is a C-type lectin receptor present on human 
immune cells e.g. macrophages and monocytes. It recognizes the ß-1,3-glucan motif present 
on the cell walls of Cand/da and Asperg///us species, and mediates host immune response to 
these fungal pathogens [5].
Recently we described a functional single nucleotide polymorphism (SNP) in Dectin-1 
(Y238X, rs16910526) leading to an early stop codon which resulted in loss of the last nine 
amino acids of the carbohydrate-recognition domain of the Dectin-1 receptor [6]. 
Subsequently, this resulted in diminished expression of the Dectin-1 receptor on immune 
cells and its inability to bind ß-glucan, leading to defective production of proinflammatory 
cytokines. Clinically, this polymorphism was found to be associated with colonization with 
Cand/da spp. in hematopoietic stem cell transplantation (HSCT) recipients [7], as well as 
recurrent mucocutaneous fungal infection in a Dutch family [6].
Results from in-vitro and murine models have shown that Dectin-1 is pivotal in host defense 
against Asperg///us infection [8-10]. However, no data are available from human studies to 
validate these findings. Hence, we aimed to investigate the clinical relevance of the Dectin-1 
early stop codon polymorphism for the susceptibility and outcome to IA in a cohort of patients 
with underlying hematological disorders.
Patients, materials and methods 
Patients
Ninety-two patients of Dutch-Flemish ancestry with hematological diseases in which IA was 
diagnosed were enrolled in 3 academic hospitals : Leiden University Medical Center, 
Radboud University Nijmegen Medical Center, both in the Netherlands, and University 
Hospitals Leuven, Belgium between May 1996 to July 2009. Invasive aspergillosis had been
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diagnosed as either proven or probable IA as per current European Organization for 
Research and Treatment of Cancer/Mycology Study Group (EORTC/MSG) criteria [11]. One 
hundred and eight control patients with similar underlying disorders but who did not develop 
IA were enrolled as control cohort. Clinical characteristics of the patients and controls are 
summarized in Table 1. Of the 92 IA patients, 71 had the infection following HSCT. All HSCT 
IA patients and the control patients had undergone T cell-depleted allogenic HSCT for 
underlying hematological diseases. The remaining 21 non-HSCT patients developed IA 
following chemotherapy for hematological malignancies. None of the patients or controls 
received prior mould-active anti-fungal prophylaxis [12, 13]. DNA was obtained from patients 
following informed consent as required by the ethical committee of each respective institution. 
For all HSCT cases, DNA was obtained from both recipients and their respective donors prior 
to transplantation.
Genotyping for Dectin-1 Y238X polymorphism
The Y238X SNP (rs16910526) in exon 6 is the only known exonic polymorphism in the 
Dectin-1 gene [7]. Genotyping for the presence of the Y238X polymorphism was performed 
using the TaqMan SNP assay C_33748481_10 on the 7300 ABI Real-Time polymerase 
chain reaction system (Applied Biosystems).
Cytokine stimulation assays
Cytokine profiling was performed to ascertain the functional consequence of the Dectin-1 
Y238X polymorphism. The isolation of peripheral blood mononuclear cells (PBMC) and 
differentiation of monocyte-derived macrophages (MDM) from study subjects were performed 
as previously described [14]. The cells were stimulated with live and heat-killed conidia, as 
well as with heat-killed hyphae of a well-characterized Asperg///us fum/gatus clinical strain, 
V05-27 [15]. Where indicated, Cand/da a/b/cans blastoconidia belonging to strain ATCC 
MYA-3573 (UC820) [16] and particulate ß-glucan (courtesy of Dr David Williams, University 
of Tennessee) were used as control stimuli. The supernatants were collected after 24 h of 
incubation at 37oC and stored at -20oC until cytokine assay. Interleukin-6 (IL-6) and tumor 
necrosis factor alpha (TNF-a) concentrations were measured by commercial sandwich 
ELISA kits (Pelikine Compact, CLB, Amsterdam, Netherlands and R&D Systems 
respectively) according to manufacturers’ instructions.
Flow cytometry
Following isolation of PBMC, monocytes were purified by CD14+ MACS microbeads (Miltenyi 
Biotec, Utrecht, the Netherlands). MDM differentiation was performed as described above.
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Detection of Dectin-1 receptor surface expression was performed by incubating cells with 
5^g/mL murine anti-Dectin-1 conjugated with biotin, or mouse immunoglobulin (Ig) G2b 
isotype control, followed by streptavidin-allophycocyanin conjugated goat anti-mouse 
antibody (BD Pharmingen, Breda, the Netherlands). Surface mannose receptor (MR), TLR2 
and TLR4 expression was determined using anti-MR-FITC (R&D Systems, Abingdon, UK), 
anti-TLR2-FITC and anti-TLR4-PE (both from eBioscience, San Diego, CA) in addition to 
their respective isotype controls. Analysis was performed on a FACSCalibur flow cytometer 
(BD Biosciences, San Jose, CA).
Statistical analysis
Genotype frequencies were compared between groups by Fisher’s exact- and Pearson-chi- 
square tests. Odds ratio (OR) and 95% confidence interval were calculated for the presence 
(homozygous or heterozygous) or absence (homozygous wild type allele) of the Dectin-1 
Y238X polymorphism. Multivariate adjustment for neutropenia, age and development of 
graft-versus-host disease (GVHD) were made where appropriate. The influence of the 
variant Dectin-1 mutation on the course of disease i.e. day from HSCT or start of 
chemotherapy to the day of diagnosis was assessed by Kaplan-Meier analysis (logrank test). 
Likewise, associations with presence of the polymorphism and time from IA diagnosis to 
death were assessed. The cytokine data was presented as means + standard error of the 
means (SEM). Differences in cytokine production were tested by using Student’s t test. The 
level of significance was set at 0.05. The SPSS  version 17.0 statistical software package for 
Windows was used to perform the calculations.
Results 
Dectin-1 Y238X polymorphism in IA patients and controls
Presence of the Dectin-1 Y238X SNP was determined in the 92 IA patients and the 108 
controls. As following HSCT, primary immune cells of the recipient will eventually assume 
genotype of the donor after successful engraftment, donor genotype was also ascertained in 
all the post-HSCT IA cases as well as all the controls. The findings are summarized in Table
2. The genotype frequencies of the study cohort were in Hardy Weinberg equilibrium. Twenty 
of the 92 patients who had IA (21.7%) and 12 of 108 control patients (11.1%) had the Dectin-
1 Y238X SNP. All these individuals were heterozygous for the SNP with the exception of one 
homozygous individual in the IA group. Possession of the Y238X SNP was associated with 
apparent susceptibility to IA in this overall cohort (odds ratio [OR] 2.22, 95% confidence
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interval [CI] 1.02-4.84, p=0.05). Following multivariate adjustment for neutropenia and age, 
the OR was 2.18, 95% CI 0.98-4.8, p=0.06.
Variable Patients d iagnosed w ith  IA
Patients w ith o u t 
IA p-value
Tota l No. 92 108
Sex ra tio  m /f 60/32 71/31 1.00
A ge (median,IQR) 1 47 (40-57) 48 (40-56) 0.87
H em atological d isease n (%)
AML
CML
ALL
NHL
Aplastic anemia 
CLL
Multiple myeloma 
MDS
42 (46) 
11 (12) 
11 (12) 
9 (10) 
3 (3)
3 (3)
7 (8)
6 (6)
39 (36) 
18 (17) 
12 (11) 
14 (13) 
1 (1)
7 (7)
1 (1) 
16 (15)
A llogene ic  HSCT cases 71/92 108/108
Prolonged neutropenia 43/92 40/108 0 . 20
EORTC/MSG 2008 c lass ifica tion
Proven IA 
Probable IA
19
73
-
S ite o f IA n (%)
Pulmonary 88 (96) -
Extra-pulmonary 4 (4) -
IA denotes invasive aspergillosis; IQR : interquartile range, HSCT: hematopoietic stem cell 
transplantation, AML : acute myeloid leukemia, CML : chronic myeloid leukemia, ALL: acute 
lymphocytic leukemia, NHL : non-Hodgekin's lymphoma, CLL : chronic lymphocytic 
leukemia, MDS :myelodysplastic syndrome, Prolonged neutropenia was defined as absolute 
neutrophil count < 500 cells/mm3 for a period of more than 14 days prior diagnosis of IA. £: 
in the group of patients with IA more individuals were aged >60 years (OR 2.8 1.6-6.9 
p=0.03).P-values were calculated by student-t test for continuous- and Fishers exact test for 
binary data.__________________________________________________________________________
Table 1. Patient demographics and clinical characteristics.
Upon stratification of these 92 patients into HSCT-related and non-HSCT IA cases, we found 
that the Y238X polymorphism did not significantly influence susceptibility to IA in the 72 
patients belonging to the HSCT cohort (OR 1.79, 95% CI 0.77-4.19, p=0.19). However, for 
non-HSCT patients who had IA following chemotherapy, presence of the SNP was 
associated with increased occurrence of IA (OR 4.00, 95% CI 1.35-11.8, p=0.02). With 
multivariate adjustment for neutropenia and age, the OR was 4.50, 95% CI 1.40-14.5,
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Table 2.
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Study C ohort
Cases C ontro ls
Dectin-1 Dectin-1
Y238X Y238X
varian t varian t
present n/N present n/N
OR (95%CI) p-value
A ll IA patients vs non-IA  con tro l patients 20/92 12/108 2.22 (1.02-4.84) 0.05
HSCT IA rec ip ien ts vs con tro l recip ients 13/71 12/108 1.79 (0.77-4.19) 0.19
HSCT donors to  IA patients vs con tro l dono rsT 10/68 17/107 0.91 (0.39-2.0) 0.83
Non-HSCT IA patients vs con tro l patients 7/21 12/108 4.00 (1.35-11.8) 0.02
f  DNA belonging to HSCT donors of 3 IA cases and 1 control case were unavailable for genotyping
Table 2. Incidence of Dectin-1 Y238X variant in IA patients/donors and non-IA control patients/donors.
Influence of Dectin-1 polymorphism on clinical course of IA
In addition to its effect on the susceptibility to IA, we assessed whether the presence of the 
Dectin-1 variant gene might influence clinical course during IA. Kaplan-Meier analysis did 
not reveal a difference in time-to-development of IA from HSCT between recipients or their 
donors bearing either the wild-type (WT) or variant allele (Figs. 1a &b, p=0.94 and p=0.88 
respectively). Likewise, there was no difference in survival (time to death following diagnosis 
of IA) consequent to having the WT or variant Dectin-1 allele in both patients and donors 
(Figs. 2a & b, p-logrank =0.83 and 0.99 respectively).
Recipient/Patient genotype
Dectin-1 variant 
Y238X 
_ n  Absent 
_ n  Present
Time (Days) to D iagnosis o f IA from 
HSCT conditioning/chemotherapy
Time (Days) to Diagnosis o f IA from 
HSCT conditioning/chemotherapy
F igure 1. Kaplan-Meier plot on time (days) to diagnosis of IA following HSCT conditioning or chemotherapy in 
patients and HSCT donors who have either the Y238X polymorphism (Dectin-1 variant) or wild-type Dectin-1.
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Recipient/Patient genotype Donor genotype
Dectin-1 variant 
Y238X 
_ n  Absent 
_ n  Present
Dectin-1 variant 
Y238X 
_  Absent 
i— Present
Survival (Days) from Diagnosis o f IA Survival (Days) from  Diagnosis o f IA
F igure 2. Kaplan-Meier plot on first 180 days survival following diagnosis of IA in patients and HSCT donors who 
have either the Y238X polymorphism (Dectin-1 variant) or wild-type Dectin-1.
Functional consequences of the Dectin-1 Y238X polymorphism 
Cytokine stimulation
To fully characterize the phenotypic consequence of the Dectin-1 Y238X polymorphism, we 
isolated PBMC and differentiated MDM from two siblings whom we have characterized 
earlier as being homozygous for the variant Dectin-1allele [6] and from healthy control 
subjects who were WT for the Dectin-1 gene. We assessed the capacity of the immune cells 
to respond to the various stimuli. In PBMC, homozygosity for Dectin-1 Y238X resulted in 
marked reduction of proinflammatory TNF-a and IL-6 production in response to heat-killed A. 
fumigatus hyphae, C. albicans blastoconidia and live A. fumigatus condia as would have 
been anticipated given the key role that the Dectin-1 receptor is known to play in recognition 
of fungal cell wall ß-glucan (Figs. 3a & b) [7, 9]. In the MDM, however, there were no 
significant differences in proinflammatory cytokine responses between subjects who were 
homozygous or WT for Dectin-1. This was apparent for both live A. fumigatus conidia, as well 
as heat-killed hyphae (Figs. 3c & d). As control, stimulation using ß-glucan still failed to 
generate TNF-a response in the Dectin -/- MDM in contrast to Dectin+/+ MDM. This finding 
demonstrated that the Dectin-1 signaling pathway remained hyporesponsive in the Y238X 
homozygous MDM, and the ability of these cells to respond to Aspergillus had to be 
mediated via other alternative signaling pathways.
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(a) PBMC
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0
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I■
Candida
£  2000 
□ Dectin - /-  ht 1 0 0 0 .
I Dectin + /+
□  Dectin - /- 
■  Dectin + /+
100
□  Dectin -/- 
■  Dectin + /+
Asp Conidia Asp Hyphae
(d) MDM 
800 
700 
600
□  Dectin -/- 
■  Dectin + /+
Asp Conidia Asp Hyphae Candida Beta-Glucan Asp Conidia Asp Hyphae
F igure 3. Functional assays to assess consequence of the Dectin-1 Y238X polymorphism in response to live 
Aspergillus fumigatus conidia 1x107/ml (Asp Conidia), heat-killed A. fumigatus hyphae 1x107/ml (Asp hyphae), 
Candida albicans blastoconidia 1x106/ml (Candida) and beta-glucan 20|jg/ml. Tumor necrosis factor-alpha (TNF-a) 
and interleukin-6 (IL-6) responses of peripheral blood mononuclear cells (PBMC, Fig 3a &b) and monocyte- 
derived macrophages (MDM, Figs. 3c & d) from 2 sibling homozygous for the Y238X polymorphism (Dectin -/-) [6] 
and 5 Dectin-1 wild-type controls (Dectin +/+) were assessed. Data was from 3 sets of experiments and 
presented as mean +standard error of the mean (SEM).
* denotes statistical significance p < 0.05 as determined by Student's t test.
* *
7000
2000
*
1000
*
0 0
200
100
0
Flow cytometry
We had earlier shown that monocytes from individuals homozygous for Y238X polymorphism 
had diminished Dectin-1 receptor expression on the cell surface [7]. We further demonstrate 
here that MDM from these individuals had deficient expression of the Dectin-1 receptor (Figs. 
4a & c) which is corroborated by the inability to respond to ß-glucan as shown above. 
Besides Dectin-1, it is known that other PRRs, like the mannose receptor (MR), TLR2 and 
TLR4, also participate in recognition of fungal ligands [5]. Of note, the MR is a distinct CLR 
commonly found mainly on macrophages, while TLR2 and TLR4 are ubiquitous on most 
immune cells including monocytes and macrophages. It is plausible that the host tissue 
macrophages recognize Aspergillus through these alternative PRRs, especially the MR
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pathway. This may circumvent any deficiency in the Dectin-1 signaling pathway, and account 
for the normal cytokine production in Dectin-1 deficient MDM. To substantiate this, we have 
demonstrated that Dectin-1 deficient MDM had similar levels of expression of MR as normal 
cells (Figs. 4b & d), and likewise, TLR2 and TLR4 expression was normal (data not shown). 
This provides the proof of concept that a system of redundancy exists in the capacity of the 
macrophage to recognize pathogens, in particular A. fumigatus.
Dectin 238X Monocytes Dectin Y238 Monocytes Dectin238X MDM Dectin Y238 MDM
(c)
(d)
o
a<uo<uE w
<D</) £
O  LUcCro
10 “  1 0 '  10 z 10 3 10
F igure 4. Representative flow cytometry analysis on surface staining of human Dectin-1 receptor and mannose 
receptor on Dectin -/- (238X) and Dectin +/+ (Y238) CD14+ monocytes (Figs. 4a & b) and m Dm  (Figs. 4c & d). 
Thin lines represent the respective isotype controls.
Discussion
Though much has been reported on the role that Dectin-1 plays in host recognition of 
Aspergillus, this is based largely on findings from experimental models. In this study, 
however, we found that a defective function of Dectin-1 due to a premature stop codon 
polymorphism may enhance susceptibility to IA in specific patient cohorts without significantly 
altering clinical outcome of the disease. This moderate effect may be due to an inherent 
redundancy in the PRRs responsible for the recognition of invading pathogens.
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In recent years, Dectin-1 has been recognized as being a pivotal PRR for the control of 
fungal infections [17] and specifically for anti-Aspergillus host defense [10]. In-vitro studies 
have shown the involvement of Dectin-1 in both TLR-dependent and TLR-independent anti­
fungal responses [14, 18]. The clinical significance of Dectin-1 in mucosal candidiasis was 
highlighted recently in a study that described how defective Dectin-1 expression and function 
resulted in recurrent vulvovaginal candidiasis in a family of siblings who were homozygous 
for the Y238X polymorphism [6], while another study reported an increased incidence of oral 
and gastrointestinal Candida colonization in HSCT recipients heterozygous for the same 
variant gene [7].
Despite the in-vitro studies pointing out the importance of Dectin-1 as receptor for fungal ß- 
glucans, the perceived importance of Dectin-1 for invasive mycosis in mice models had been 
debated. Contrary to findings of Taylor et al that Dectin-1 deficient mice showed increased 
susceptibility to disseminated candidiasis, another study by Saijo et al did not yield similar 
corresponding results using an independently developed Dectin-1 -/- mice strain [19, 20]. A 
later study showed that Dectin-1 had an important role in a murine model of invasive 
aspergillosis [10]. Nevertheless, it is interesting to note that a family with siblings who had a 
complete deficiency of the Dectin-1 function did not report susceptibility to systemic fungal 
infections. Similarly, the increased risk of mucosal colonization did not invariably lead to an 
increased incidence of invasive candidiasis in HSCT recipients [7], as one would have 
anticipated [21]. These findings suggest that although Dectin-1 has an unchallenged role as 
ß-glucan receptor, in the in-vivo situation, alternative recognition pathways can initiate 
effective anti-fungal responses.
Patient studies remain crucial for the validation of the host defense mechanisms identified in 
in-vitro and experimental studies. To be at-risk for development of IA, a profoundly 
immunocompromised status consequent to immune-ablative chemotherapy, HSCT 
conditioning regimens or chronic corticosteroid treatment is obligate. We found that presence 
of the Y238X polymorphism in the patient was associated with trend towards susceptibility to 
IA (OR 2.22, 95% CI 1.02-4.84, p=0.05). This moderate susceptibility, however, was not 
accentuated following multivariate adjustment (OR was 2.18, 95% CI 0.98-4.80, p=0.06). On 
stratification, this polymorphism was non-consequential in the HSCT cases. Rather, the 
propensity towards susceptibility was attributable to the non-HSCT patients who acquired IA 
post chemotherapy (OR was 4.00, 95% CI 1.35-11.80, p=0.02 after multivariate adjustment). 
However, given the smaller non-HSCT IA patient numbers (n=21), it will be prudent to
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exercise caution against over-interpretation of this finding while awaiting validation in a larger 
patient cohort.
In this study, the control cohort consisted of non-IA patients with similar hematological 
diseases who proceeded beyond conventional chemotherapy to further undergone HSCT as 
definitive treatment. This was because the most of our IA case patients (77%) were primarily 
post-HSCT and non-HSCT IA patients constituted only a minority as alluded above. To be 
satisfied that this control patient cohort was appropriate for study against both the HSCT and 
non-HSCT IA patients, we had determined that the allelic frequency of Y238X in these 
control patients was 5.6%. Given the comparable allelic frequency of 6.9% in a similar 
healthy population [6], the Y238X polymorphism is not likely to be linked to acquisition and 
progression of hematological disease states. Another consideration is the a-priori risk of IA 
between HSCT and non-HSCT patients. Although one study had suggested difference in IA 
susceptibility between the two treatment groups [22], others had reported similar risks for IA 
development, supporting our decision to use the non-IA HSCT patients as controls [23, 24].
Our functional assays using cells isolated from individuals homozygous for the Dectin-1 
Y238X polymorphism also shed light on why susceptibility to Aspergillus infection may be 
limited and clinical course of disease relatively unaltered despite reduced Dectin-1 receptor 
function. In contrast to the PBMC, Dectin-1 defective MDM had the capability to respond with 
normal production of proinflammatory cytokines upon challenge with A. fumigatus. This 
observation on MDM response is important because in-vivo, it is invariably the pulmonary 
macrophages which first encounter and react to the invading fungi. The capability of the 
macrophages to retain their response even in the absence of Dectin-1 function probably lies 
in their capacity to engage alternative PRRs: MR, TLR2 and TLR4. These receptors are 
known to be involved in immune recognition of Aspergillus and antifungal host defense [25­
28]. This ability to retain the capacity to respond to the pathogen in the absence of Dectin-1 
underscores the redundancy that is inherent to the human antifungal host defense. On the 
other hand, the modest susceptibility to aspergillosis in patients bearing the Y238X 
polymorphism, coupled to the defective monocyte function, suggest an adjuvant yet essential 
role of infiltrating monocytes for host defense. In contrast to monocytes and macrophages, 
the main ß-glucan receptor on neutrophils is complement receptor 3 [29] and neutrophil 
function is normal in individuals with homozygous Dectin-1 Y238X mutation [6].
Other polymorphisms in genes coding for components of the innate immunity have been 
recently reported to increase susceptibility to Aspergillus infections: TLR1, TLR4, TLR6, IL-
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10 promoter [30-35]. In all of the above studies, like ours, the polymorphism of interest was 
studied in isolation and not in association with each other. It is tempting to consider that 
perhaps, the concomitant presence of two or more of these polymorphisms in a patient may 
further enhance the risk profile to IA.
In conclusion, in the present study we report that the Dectin-1 Y238X polymorphism alone 
was associated with a suggestive moderate susceptibility to IA only in non-HSCT 
immunocompromised patients, but not in patients undergoing HSCT. Additional studies are 
needed to validate these findings, yet these data provide novel insight in human host 
defense during invasive aspergillosis.
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Abstract
Background Monitoring of treatment response in invasive aspergillosis (IA) is challenging, 
as an immunocompromised host may not exhibit reliable symptoms and clinical signs. As 
cytokines play a pivotal role in mediating host immune response to infection, the profiling of 
biomarkers may be an appropriate surrogate for disease status.
Methods From a cohort of 119 IA patients recruited in a multicenter clinical trial, we studied 
serum interleukin (IL)-6, IL-8, IL-10, interferon-gamma and C-reactive protein (CRP) trends 
over the first 4 weeks of therapy and correlated these to clinical outcome parameters.
Results Circulating IL-6 and CRP levels were high at initiation of therapy and generally 
showed a downward trend with anti-fungal treatment. However, subjects with adverse 
outcomes exhibited a distinct lack of decline in IL-6 and CRP levels at week 1 as compared 
to the responders (p=0.02 for both IL-6 and CRP). Non-responders also had significantly 
elevated IL-8 levels (p=0.001).
Conclusions High initial IL-8 and persistently elevated IL-6, IL-8 and CRP levels following 
initiation of treatment may be early predictors of adverse outcome in IA. Cytokine and CRP 
profiles could be used for early identification of patients with poor response to anti-fungal 
treatment who may benefit from more aggressive anti-microbial regimens.
Keywords : interleukin; interferon-gamma; biomarkers; monitoring; prognosis
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Introduction
Invasive aspergillosis continues to be a leading cause of mortality and morbidity among 
patients treated for hematological malignancies [1, 2]. The adverse outcomes associated 
with acquisition of the disease may in part be attributable to the compromised immune 
system of patients at-risk. Securing a firm diagnosis of invasive aspergillosis remains difficult. 
Management is complicated by the absence of appropriate tools to assess progress and 
treatment response. Firstly, monitoring of symptoms and clinical signs are not reliable 
indicators of improvement in the patient on therapy, as they can be influenced by the 
patient’s white cell counts and concurrent medications. Secondly, it is recognized that 
radiologic follow-up may not be an accurate or timely reflection of progress, as appearance 
of pulmonary lesions on serial computed tomography scans may lag behind response in 
invasive pulmonary aspergillosis [3]. Thirdly, a procedure-based microbiologic test-of-cure or 
-response is not feasible as these patients are high-risk candidates for peri-operative 
complications following invasive procedures.
Current understanding on the pathogenesis of invasive aspergillosis has shown that alveolar 
macrophages and monocytes form the first line of host defense after inhalation of Aspergillus 
conidia from the environment [4]. Upon recognition of the pathogen, the host innate immune 
defense is activated, resulting in phagocytic ingestion of conidia and release of microbicidal 
compounds [5, 6]. In the absence of adequate immune containment, conidial germination 
with development of hyphae heralds invasive disease. Neutrophils, which form the second 
line of defense, attack the hyphae through release of oxidants and degranulation. These are 
lacking in the neutropenic host. Meanwhile, antigen-presenting functions as performed by 
mononuclear phagocytes and dendritic cells facilitate the development of T-helper cell (Th)- 
based adaptive immune response. [5] During this process of immune activation and 
response, cytokines play a pivotal role in mediating the host inflammatory response. 
Interleukin-6 (IL-6) is a pleiotropic cytokine produced by macrophages and lymphocytes [7]. It 
facilitates lymphocyte differentiation, proliferation of hematopoietic progenitor cells and is an 
important mediator of the acute phase response, of which C-reactive protein (CRP) is a 
major product. Interleukin-8 (IL-8), released by monocytes, macrophages and endothelial 
cells, recruits neutrophils and induces chemotaxis to the site of infection [8]. T-cell-derived 
cytokines also play an important role in the modulation of host defense. Interferon-gamma 
(IFN-y) is the prototypic type 1 T-helper cell (Th1) proinflammatory cytokine which activates 
cell-mediated immune responses, while interleukin-10 (IL-10) is an anti-inflammatory product
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released mainly by type 2 T-helper lymphocytes (Th2) and T-regulatory (Treg) lymphocytes 
that keeps in check the inflammatory cascades [4, 8].
We hypothesize that cytokine concentrations in the blood during invasive aspergillosis may 
form appropriate surrogate markers of disease progress, and may also be predictive of 
treatment response. The availability of such a non-invasive means of monitoring would be of 
immense practical utility in the clinical setting. Herein, we report findings from a study 
involving a cohort of 119 IA patients enrolled in a multicentre clinical trial in which we 
assessed whether circulating cytokine concentrations correlate with outcome of infection.
Patients and methods 
Study patients and design
Study patients were from the Global Comparative Aspergillosis Study (protocol 150-307), a 
multicenter randomized trial that compared the efficacy of voriconazole versus amphotericin 
B for primary treatment of invasive aspergillosis [9]. Selection of eligible patients for the trial, 
as well as the case definitions for definite or probable invasive aspergillosis were as 
previously detailed [9]. These were in accordance to the protocols as then approved by the 
European Organization for Research and Treatment of Cancer (EORTC).
Briefly, patients were randomized to receive either voriconazole or amphotericin B as primary 
therapy. In patients with intolerance or no response to initial therapy, the initial randomized 
drug could be switched to other licensed antifungal therapy (OLAT). The planned duration of 
therapy was 12 weeks, at which time outcome measures, including survival, were assessed 
by an independent and blinded data review committee (DRC) based on reviews of the 
clinical, mycological and radiological data [9, 10]. Response to therapy was determined by 
the DRC at two time-points: the primary endpoint at week 12 (W12) and at end-of-(initial)- 
randomized-therapy (EORT), which was a pre-specified secondary endpoint reached when 
the patient stopped the randomized therapy (v.i.z. either voriconazole or amphotericin B) and 
was switched to an OLAT. Satisfactory response at week 12 (W12 success) or at end- 
randomized-therapy (EORT satisfactory) was defined as complete or partial response 
following treatment; while a poor response at week 12 (W12 failure) or at end-randomized- 
therapy (EORT unsatisfactory) was defined as treatment failure or unchanged disease state 
at the pre-set endpoints in accordance with the assessment criteria of the blinded DRC [9].
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Biomarker levels were measured in the serum of trial patients obtained serially at the 
following time points: prior to initiation of therapy (as baseline) and at weeks 1, 2, 4, 8 and 12 
(end-point) after commencement of anti-fungal treatment. All specimens were identified only 
by codes during assay for the respective biomarker levels to blind investigators to the 
corresponding clinical data until the stage of data analysis. The serum specimens had been 
stored at -20oC prior to assay; multiple freeze-thaw cycles were avoided. IL-6, IL-8, IL-10 and 
IFN-y concentrations were measured using commercial sandwich enzyme-linked 
immunosorbent assay (ELISA) kits (Pelikine Compact, CLB, Amsterdam, the Netherlands) 
according to the instructions of the manufacturer. The inter-assay coefficient of variation was 
14%. The lower detection limits of the assays were 3.1 pg/ml for IL-6, 16 pg/ml for IL-8, 4.7 
pg/ml for IL-10 and 3.1 pg/ml for IFN-y respectively. CRP was measured by ELISA according 
to the instructions from the manufacturer (Dako, Glastrup, Denmark) and the lower detection 
limit was 20 mg/L.
Statistical analysis
Correlation between cytokine/biomarker trends over time and outcome (or primary therapy) 
were graphically presented by plotting the mean per time point with error bars denoting the 
standard error of the mean (SEM). As patients had repeated measurements at designated 
intervals over time, the generalized estimating equations approach (GEE) was used to 
analyze differences in time trends. More specifically, differences in change from baseline 
were tested: a significant difference at the specified time interval after initiation of anti-fungal 
treatment (e.g. at week 2) implied that the change in serum biomarker concentration from 
baseline to week 2 was significant in one group compared to that of the other group. 
Correlation between biomarker levels (at baseline and specified time points) and outcome 
were also assessed. Receiver operating characteristics (ROC) analysis was used to 
determine the sensitivity and specificity of prediction rules based on baseline 
cytokine/biomarker levels or based on the change from baseline to week 1. Statistically 
significant results were reported whenever p-values were <0.05.
Results
Five hundred and thirty-nine serial serum specimens from 119 patients enrolled in the clinical 
trial were available for analysis. Missing specimens or specimens with inadequate serum 
volumes for assay constituted 1.6 %  of all specimens to be measured and these were treated
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as missing values during data analysis. Table 1 summarizes the demographic characteristics 
of this study cohort and the treatment-related outcomes of interest.
Parameters n % n %
Sex Male 81 68.1 Female 38 31.9
Certainty of diagnosis Definite 31 26.1 Probable 88 73.9
Underlying disease* Leukemia & Lymphoma 88 73.9 Post-HSCT 24 20.2
Infection site Pulmonary 107 89.9 Extra-pulmonary 12 10.1
Primary randomized drug Amphotericin B 56 47.1 Voriconazole 63 52.9
Switch to OLAT Yes 78 65.5 No 41 34.5
Week 12 response Success 58 48.7 Failure 61 51.3
EORT response Satisfactory 49 41.2 Unsatisfactory 70 58.8
Day 84 survival Survivors 84 70.6 Non-survivors** 35 29.4
Table 1. Demographic characteristics of study cohort and the treatment-related outcomes of interest. The mean 
age of the patients was 49.9+14.9 years old. HSCT : hematopoietic stem cell transplantation. OLAT : other 
licensed anti-fungal therapy. Week 12 Response : Clinical response at Week 12 as assessed by data review 
committee (DRC). EORT Response : End-of-randomized-(primary)-therapy clinical response as determined by 
DRC. D84 survival : survival after 84 days (12 weeks). *The remaining 7 patients had human immunodeficiency 
virus (HIV), solid organ transplant or corticosteroid treatment. ** The majority of the deaths were determined by 
the DRC as being “caused by Aspergillosis". Two cases were classified as “unrelated to Aspergillosis" and 
another 6 cases classified as “unrelated to Aspergillosis but evidence o f active Aspergillus infection was present ”. 
Attributable cause of death in 5 cases could not be determined.
Serum IFN-y levels were low and barely detectable in the first 300 specimens measured. The 
median IFN-y level was 3.1 pg/ml (range 3.1 - 12.0 pg/ml). This was verified with use of 
another assay (Luminex, BioRad Inc). Given the low yield of almost undetectable IFN-y levels 
in the serum of these patients, IFN-y measurements were discontinued after 300 specimens.
Serial IL-6, IL-8 and IL-10 levels of patients were assayed at the above designated intervals 
as long as the patients remained enrolled in the study. On reviewing the results, it was 
decided that only cytokine readings obtained between baseline and 4 weeks after therapy 
would be analyzed. Beyond this time point, there were concerns that the cytokine trends
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might not be representative due to the diminishing patient (denominator) numbers from 
deaths and withdrawals over time, resulting in wide variances of some results.
Cytokine trends and clinical response at 12 weeks
Generally, circulating cytokine levels of the patients were elevated at baseline and displayed 
a declining trend over time on therapy.
Serum IL-6 levels revealed a distinct difference between patients who did not show clinical 
response to treatment after 12 weeks (W12 failure) and those who did (W12 success) (Fig. 
1). Non-responders had transiently elevated IL-6 levels one week after initiation of anti-fungal 
therapy, in contrast to responders who showed progressive decline of this inflammatory 
cytokine, i.e. there was a delayed decrease in IL-6 levels in the non-responders (p=0.02). IL- 
8 levels were significantly higher in the non-responders through the first 2 weeks of therapy 
for IA (p=0.002 at both weeks 1 and 2). The serum IL-10 concentrations decreased more 
precipitously from baseline to weeks 1 and 2 in the non-responder group of patients as 
compared to the responders (p=0.03 and p=0.045 respectively).
W12 Sucess 
W12 Failure
Figure 1. Interleukin(IL)-6, IL-8 and IL- 
10 trends during the first 4 weeks 
between the responders and non­
responders to treatment as determined 
at week 12 by data review committee 
(DRC). * p < 0.05 : change in cytokine 
concentration from baseline to 
specified time-point between 
responders and non-responders, as 
analyzed by generalized estimating 
equations. ** p < 0.05 : difference in 
cytokine concentration between 
responders and non-responders at 
specified time point. W12 Success : 
clinical response to treatment after 12 
weeks, W12 Failure : poor response to 
treatment after 12 weeks.
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Cytokine trends and clinical response at end-of-(initial)-randomized-therapy (EORT)
At the EORT end-point, serum IL-6 trends were similar to those found for week 12 response 
(Fig. 2). Patients deemed as having unsatisfactory response at EORT showed a delayed 
decline in circulating IL-6 levels as compared to the responders (p=0.045). The variations of 
IL-8 levels were wide, and the differences between the patients with EORT-satisfactory or - 
unsatisfactory response to treatment were not distinct. Likewise, there was no significant 
difference in IL-10 trends between the EORT-responders and -non-responders.
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F igure 2. Interleukin (IL)-6, IL-8 and IL- 
10 trends during the first 4 weeks 
between patients who had satisfactory 
or unsatisfactory end-of-randomized 
therapy response (EORT satis or 
EORT unsatis respectively) to initial 
primary treatment as determined by 
data review committee (DRC). * p < 
0.05 : change in cytokine concentration 
from baseline to specified time-point 
between responders and non­
responders, as analyzed by 
generalized estimating equations.
Baseline Week 1 Week 2 Week 4
Cytokine trends and mortality at day 84
The association between cytokine trends and overall mortality at 84 days (12 weeks) is 
presented in Fig. 3. A prompt decline in IL-6 level after 1 week on anti-fungal therapy was 
linked to survival at the study end-point (D84 survivors). Patients who did not survive until 
day 84 displayed a trend of persistently elevated IL-6 levels at week 1. Low IL-8 levels at
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baseline and week 1 were associated with survival to day 84 (p=0.001 and p=0.01 
respectively). The observed differences in cytokine profiles between survivors and non­
survivors paralleled the trends observed for clinical response at week 12.
(a)
F igure 3. IL-6, IL-8 and IL-10 
trends during the first 4 weeks 
between survivors and non­
survivors at 84 days post 
initiation of treatment for IA. ** 
p < 0.05 : difference in 
cytokine concentration
between survivors and non­
survivors at specified time 
point. There was no statistical 
difference by generalized 
estimating equations
approach analyzing the 
change in cytokine 
concentrations from baseline 
to any sampling time point.
Cytokine trends and primary anti-fungal therapy
As the primary aim of the trial was to compare efficacy of voriconazole versus amphotericin B 
as initial therapy for invasive aspergillosis, we were also interested in the effects of the two 
drugs on the cytokine profile of IA patients. Because the design of the original study had 
permitted a switch from the initial trial drug to an OLAT in the event of intolerance or poor 
response, patient data were only used up to the point of switching/discontinuation in the 
analysis of cytokine trends. As illustrated in Fig. 4, IL-6, IL-8 and IL-10 profiles through the 
first 4 weeks of therapy were not significantly different between patients receiving either 
voriconazole or amphotericin B.
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Figure 4. IL-6, IL-8 and IL-10 
trends of patients who were 
randomized to either amphotericin 
B or voriconazole and who had 
remained on the primary trial drug 
at the specified time points.
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CRP trends in relation to clinical outcomes and primary therapy
CRP is a classical marker of inflammation, and its induction is initiated by IL-6. Given the 
trends observed with IL-6, we proceeded to ascertain CRP levels in our specimens. A steady 
decline in CRP profile was predictive of both clinical response and survival at week 12, as 
well as a satisfactory EORT response (Fig. 5). Notably, elevated or minimally changed CRP 
level at weeks 1,2 and 4 after start of therapy were all significantly associated with D84 
mortality or poor response as EORT. Patients who had received voriconazole as primary 
therapy showed a trend towards more prompt reduction of CRP levels as compared to those 
who had amphotericin B (Fig. 5d).
Relationship between biomarker levels at baseline and outcome parameters
Baseline IL-8 and IL-10 measurements correlated with W12 clinical response and mortality
(Fig. 6a). High baseline IL-8 concentration was associated with poor clinical response
(p=0.012) and mortality (p=0.013). On the other hand, a high initial IL-10 concentration was
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F igure 5. C-reactive protein (CRP) trends during first 4 weeks between (a) responders and non-responders at 
week 12 (b) patients who had satisfactory or unsatisfactory EORT response (c) survivors and non-survivors (d) 
patients who received amphotericin B or voriconazole as primary therapy. * p < 0.05 at specified time-point 
relative to respective baseline level between the two respective comparative cohorts.
linked with survival (p=0.01). In contrast, baseline CRP measurement did not predict either 
response or survival. The above usefulness of IL-8 as a point-of-care prognostic marker was 
further evaluated. As demonstrated by the ROC diagram (Fig. 6b), IL-8 had a moderate 
capacity as a prognostic marker for eventual outcomes. A baseline IL-8 cut-off above 135 
pg/ml gives a sensitivity of 85% and specificity of 55% for poor clinical response. In contrast, 
outcome measures could not be correlated with CRP read-out at baseline as further 
demonstrated by the ROC diagram.
Threshold of change between baseline and week 1 measurements associated with 
adverse outcomes
A persistently elevated or minimally changed IL-6 and CRP concentration between baseline 
and week 1 was associated with adverse outcomes as described above. ROC analyses 
assessing percentage decrease between baseline and week 1 for IL-6 and CRP as a test to 
predict W12 clinical response or D84 mortality were performed (Fig. 6c). Changes in CRP 
concentration were more strongly correlated with the clinical outcomes than that of IL-6. 
Failure of treatment at 12 weeks may be anticipated if the decrease of serum CRP
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(a) Analysis o f Baseline Cytokine/CRP Levels with Outcome Parameters
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Figure 6. (a) Association of 
baseline interleukin(IL)-8, IL- 
10 and C-reactive protein 
(CRP) concentrations with 
clinical outcomes : clinical 
response at week 12 (W12 
response) and survival at 84 
days (D84 survival) (b) ROC 
diagrams comparing baseline 
IL-8 against CRP 
concentrations in relation to 
predicting poor clinical 
response at 12 weeks (W12 
response) and mortality by 84 
days (D84 mortality) (c) Ro c  
diagrams for percentage 
decrease of serum IL-6 and 
CRP from baseline to week 1 
in relation to poor clinical 
response at week 12 (W12 
response) and mortality by 84 
days (D84 mortality). ns : not 
significant.
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concentration from baseline to week 1 is less than 48% [sensitivity 83%, specificity 50%]. 
There is also increased likelihood of mortality if the reduction in CRP is less than 20% 
following 1 week of anti-fungal therapy [sensitivity 78%, specificity 70%]. As has been 
demonstrated, the magnitude of CRP decrease between baseline and week 1 post antifungal 
treatment is a sensitive, simple and economical test predictive of clinical outcome in invasive 
aspergillosis over existing diagnostic means.
Discussion
The monitoring of response to therapy remains a major challenge in the management of 
invasive aspergillosis (IA). We have demonstrated the usefulness of biomarker monitoring as 
a non-invasive and convenient tool, not only for the follow-up of treatment response, but 
even more importantly, as a predictive marker of adverse outcomes. The persistence of an 
elevated IL-6 and CRP after 1 week of therapy was linked to an increased likelihood of 
treatment failure and death. A high baseline circulating IL-8 concentration level was also a 
predictor of poor prognosis in terms of response to treatment.
It has been proposed that measurements of IL-6 and IL-8 levels could be proposed to be 
used to identify low-risk febrile neutropenic patients compared with a high likelihood of 
acquiring severe bacterial sepsis necessitating aggressive antimicrobial therapy [11-14]. 
Currently CRP is the standard bedside inflammatory marker for the diagnosis of infection 
[15]. However, the potential of these biomarkers for the monitoring of response to therapy in 
IA has not been previously studied. Difficulties with the definitive diagnosis of the disease as 
well as a lack of consensus on outcome definitions of IA had hampered case identification 
until recently [9, 16-18]. We have demonstrated, for the first time, the prognostic value of 
these markers for assessing response to therapy in a well-characterized cohort of patients 
with IA.
Our study had shown that circulating cytokine and CRP levels were high in patients following 
acquisition of IA and subsequently decrease during treatment. Notably, we show that trends 
in IL-6 and CRP concentrations during the first week after start of treatment correlates with 
the outcome of infection. Patients who had a good clinical response showed a prompt and 
sustained decline in serum IL-6 and CRP levels. This is in contrast to the non-responders, 
whose IL-6 and CRP levels remained elevated at week 1 despite receiving treatment. In 
addition patients with adverse therapeutic outcomes (W12 failure and D84 non-survivors)
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had elevated IL-8 concentrations throughout the initial weeks of treatment. These distinct 
cytokine trends can be accounted for based on our current understanding on the 
pathophysiology of host immune response during sepsis. It is thought that the outcome to 
sepsis is determined, to a significant extent, by the intensity of the host inflammatory 
response which entails a coordinated balance between pro-inflammatory and anti­
inflammatory mediators. An exaggerated and uncontrolled pro-inflammatory response 
induces undue damage at the cellular and organ level [19, 20]. Recently it has also been 
proposed that prolonged and unchecked pro-inflammatory responses may, paradoxically, 
facilitate the pathogenesis of A. fumigatus [21]. This may also explain why a higher anti­
inflammatory IL-10 level, especially after week 1, may possibly be linked to a better clinical 
outcome as seen in our study. On the other hand, high cytokine concentration may also 
mirror the incapacity of the host to effectively eliminate the fungus, resulting in a prolonged 
stimulation and release of pro-inflammatory cytokines.
Our results are also consistent with two earlier studies in sepsis and hematopoietic stem cell 
transplantation (HSCT) patients. One study involving septic ICU patients had found that a 
limited CRP drop after 48 h following intervention was associated with treatment failure [22]. 
The second study observed that a high serum IL-6 at week +1 after HSCT may be an early 
predictor of transplant-related complications in a cohort of 52 patients [23]. These findings 
highlight how the study of biomarker kinetics may yield potential benefit in inflammation- 
driven disease conditions beyond the setting of IA.
Only one small previous study had investigated the cytokine profiles of patients with invasive 
aspergillosis [24]. Roilides and colleagues reported a possible correlation between elevated 
serum IL-10 and unfavorable outcome in 7 non-neutropenic IA patients. In their report, the 2 
patients with poor outcomes had a distinct progressive rise in IL-10 preceding death. By 
contrast our study revealed that a precipitous drop in IL-10 early by week 1 led to W12 
treatment failure, and a higher IL-10 at baseline was associated with D84 survival. The 
reason behind the differences in IL-10 trends between our study and that of Roilides et al are 
unclear. However, we employed a much larger cohort of patients, many of whom were, or 
had recently been neutropenic. Our larger patient population also permitted statistical 
analysis to avoid chance observation.
Although IFN-y is a cytokine that is clearly involved in the host defense against aspergillosis 
[25-27], circulating levels in our study were very low. We have also observed low IFN-y in 
bronchoalveolar lavage (BAL) in a separate cohort of patients with pulmonary invasive
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aspergillosis [unpublished results]. Low levels of IFN-y in this patient cohort may be due to 
the numerous immune suppressive treatments that these patients undergo [25, 28].
The criteria for definite and probable invasive aspergillosis in our study cohort had been the 
consensus case definitions as determined by the EORTC then at the time of the conduct of 
this study [9]. Since then, the case definitions for IA by the EORTC/MSG have seen 
modifications in 2002 and 2008 with the diagnostic threshold generally being lowered 
allowing more patients to qualify as ‘probable IA’ than would have been so during the time of 
this study [16, 17]. We feel that the higher degree of certainty of disease (as was seen with 
this study) is in tune with our aim to determine the usefulness of biomarkers as an indicator 
of disease progress in IA. Another strength of the study is that besides the case definitions, 
the end-points and criteria for determination of clinical response were well established and 
objectively determined by a blinded panel of experts. Caution however should be exercised 
before extrapolating the findings of this study to all IA patients irregardless of underlying 
predisposing disease conditions, as in this study cohort, the majority (80%) were patients 
who had undergone chemotherapy for hematological malignancies. HSCT patients 
constituted the remaining 20% and this limited attempts at further meaningful analysis of the 
HSCT sub-cohort. This study remains a retrospective analysis involving patients in a 
landmark clinical trial which had not been designed with the purpose of correlating the 
performance of circulating biomarkers with outcome parameters. Nonetheless, it is unlikely 
that a prospective trial with such intent alone will be conducted in the foreseeable future, and 
therefore the robust original trial design and sizable patient cohort gives much weight to the 
results of this study.
In conclusion, we have demonstrated that inflammatory markers such as cytokines and CRP 
may be used to monitor response and predict clinical outcome to invasive aspergillosis at an 
early stage of the disease. Measurement of these biomarkers (such as CRP and IL-8) is 
economical and can be easily performed. These assays will be value to physicians who are 
challenged with the difficult management of IA patients in hematology-oncology services.
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Abstract
Background Monitoring and anticipation of response to treatment of invasive aspergillosis 
is difficult in the immunocompromised host. As galactomannan (GM) antigen levels had been 
reported to mirror clinical response, we studied whether determination of serial serum GM 
trends early in the course of disease may be useful in predicting eventual clinical outcome. 
Methods From a cohort of 170 patients recruited into the multicentre Global Aspergillosis 
Study, serial serum GM index (GMI) were measured at baseline prior commencement of 
anti-fungal therapy, and at weeks 1,2 and 4 following treatment. The two outcome measures 
assessed were clinical response and survival at week 12 (W12). The GMI trends were 
analyzed using generalized estimating equations (GEE) approach with multivariate 
adjustment. Receiver operating characteristics (ROC) analysis was performed to derive 
prediction rules.
Results Out of the 170 patients, 63 (37.1%) had baseline GMI > 0.5. In these patients, GMI 
at week 1 was significantly lower in patients who responded to therapy at Week 12 as 
compatred to the non-responders (GMI 0.66+0.08 versus 1.29+0.27 respectively, p=0.037). 
ROC analysis revealed that GMI reduction < 10% between baseline and week 1 
(AGMIbaseline^ W1) can be a predictor of poor clinical response. A GMI drop between week 1 
and week 4 (AGMIW1^ W4) was associated with eventual survival (p=0.017). For the 107 
patients (62.9%) diagnosed with IA but with baseline GMI < 0.5, early rise in AGMIbaseline^ W 2 
was predictive of poor clinical response and mortality.
Conclusions Clinical outcomes may be anticipated by charting early GMI trends during first
2 weeks of anti-fungal therapy. These findings have significant implications for the 
management of patients with invasive aspergillosis.
Keywords : Aspergillus, biological marker, monitoring, neutropenia
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Background
Invasive aspergillosis (IA) remains the most common mould infection causing significant 
mortality and morbidity in immunocompromised patients [1, 2]. Securing a firm diagnosis of 
the disease and monitoring of treatment response is difficult, as the patient may not exhibit 
reliable symptoms and signs in the presence of neutropenia and immunomodulating drugs, 
such as corticosteroids. Over the years diagnostic capability with regards to detection of IA 
has improved through the use of Aspergillus-specific galactomannan antigen. 
Galactomannan (GM) from the Aspergillus cell wall is released during invasive disease and 
the level of circulating GM is indicative of the intrinsic fungal burden in the host [3]. GM can 
be detected by the Platelia Aspergillus enzyme immunoassay (PA-EIA; Bio-rad 
Laboratories), and results are reported as the galactomannan index (GMI) [4, 5]. GMI 
measurements have been studied extensively, gaining general acceptance as a non-invasive 
diagnostic tool for IA in at-risk patients [6], and has recently been included as a mycological 
criteria for case definition of probable IA by the European Organization for Research and 
Treatment of Cancer/Mycology Study Group (EORTC/MSG) consensus group [7-9].
Furthermore, in addition to serving as a diagnostic tool, serial GMI determination may be 
useful for following treatment response [10], or used as a surrogate endpoint for outcome of 
invasive aspergillosis [11-13]. However, the potential use of GMI trends to predict eventual 
clinical outcomes early in the course of IA has not been well established, although it may 
have significant implications for patient management.
We herein report findings from a study involving a cohort of 170 IA patients enrolled in a 
multicentre anti-fungal drug trial in which we retrospectively assessed if serial serum GM 
trends early in the course of treatment correlate with outcome of IA.
Methods 
Study patients and design
Patients were enrolled in the Global Comparative Aspergillosis Study (protocols 150-307 and 
150-602), a multicenter randomized trial that compared the efficacy of voriconazole versus 
amphotericin B for primary treatment of invasive aspergillosis [14]. Selection of eligible 
patients for the trial, as well as the case definitions for definite or probable invasive
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aspergillosis were as previously detailed [14]. These had been in accordance to the protocols 
as then approved by the EORTC.
Outcome measures were assessed by an independent and blinded data review committee 
(DRC) based on reviews of clinical, mycological and radiological data [14, 15]. Satisfactory 
clinical response was defined as complete or partial response at week 12 after 
commencement of anti-fungal therapy; while poor response was defined as treatment failure 
or unchanged disease state at the above pre-set endpoint in accordance with the pre­
established assessment criteria of the blinded DRC. The other definitive outcome measure 
was survival at 12 weeks after start of anti-fungal treatment.
Blood samples were obtained serially from trial patients at baseline prior to initiation of anti­
fungal therapy and at intervals of weeks 1,2 and 4 following commencement of treatment. 
Serum GM was measured at a central laboratory (Health Protection Agency Mycology 
Reference Laboratory, Bristol, U.K.)and reported according to the manufacturer’s instructions 
(Platelia Aspergillus EIA, Bio-Rad Laboratories, Marnes-la-Cocquette, France). Results were 
recorded as the galactomannan index (GMI) which was relative to the optical density of the 
mean cut-off of the control sample obtained in the same run. All reagents were obtained from 
Bio-Rad Laboratories.
Statistical analysis
Correlation between GMI at a fixed point in time or change in GMI between 2 specified time 
points (AGMI) and the respective outcome measure (clinical response and survival at week 
12) were graphically presented by plotting the mean per time point with the standard error of 
the mean (SEM). The generalized estimation equations (GEE) approach was used to 
analyze difference in AGMI between groups within a clinical outcome. Multivariable logistic 
regression analysis was incorporated, controlling for age, sex, underlying hematological 
condition (leukemia/lymphoma post-chemotherapy versus hematopoietic stem cell 
transplant), neutropenia and receipt of primary trial drug (amphotericin B versus 
voriconazole). Neutropenia was defined as neutrophil count of less than 500 per cubic 
millimeter in the previous 2 weeks prior recruitment into the trial. Results from the trend 
analysis using G EE were used to indicate which GMI study parameters might potentially be 
of use as predictive tool. For this intent, receiver operating characteristics (ROC) analysis 
was used to determine the sensitivity and specificity of prediction rules (as indicated ) based 
on the selected GMI study parameter, which may either be absolute GMI values at the
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specified time point or based on the change of GMI between 2 specified time points i.e. 
AGMI. The threshold for statistical significance was set at p < 0.05.
Results
From 170 patients with definite and probable IA, serum galactomannan measurements were 
performed on 605 distinct serial specimens obtained at the respective study intervals : 
baseline, weeks 1,2 and 4 after commencement of anti-fungal therapy. Missing specimens 
constituted 2.7% of the total specimens. Sixty-three of the 170 patients in the trial (37.1%) 
had a baseline GMI measurement of > 0.5. The patient demographics stratified according to 
baseline GMI > or < 0.5 upon entry into the trial [16] are as presented in Table 1.
C h a ra c te r is tic s  P a tien ts  (n = 170) p va lues
Baseline GMI > 0.5 Baseline GMI < 0.5
______________________________ n = 63 (%)___________ n = 107 (%)______________
Sex
Male 45 (71.4) 75 (70.1)
0.85
Fem ale 18 (28.6) 32 (29.9)
Certainty o f Disease 
D e fin ite  IA 
P robab le  IA
P u lm onary  IA 54 (85.7) 97 (90.7) 0.32
N eu tropen ia  40 (63.5) 57 (53.3) 0.19
Underlying diseases
Leukaem ia /Lym phom a  
HSCT 
Antifungal
V o rico n azo le  
A m p h o te r ic in  B 
Week 12
R esponders  
N o n -responde rs  
Week 12
S u rv iv o rs  
N o n -su rv ivo rs
Table 1. Demographic characteristics of study cohort and the treatment-related outcomes of interest. HSCT : 
hematopoietic stem cell transplantation. W eek 12 Response : Clinical response at Week 12 as assessed by data 
review committee (DRC).
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45 (77.6) 73 (73.7)
0.59
13 (22.4) 26 (26.3)
38 (60.3)
25 (39.7)
27 (42.9)
36 (57.1)
42 (66.7)
21 (33.3)
57 (53.3)
0.37
50 (46.7)
56 (52.3) 
51 (47.7)
0.23
78 (72.9) 
29 (27.1)
21 (33.3) 
42 (66.7)
31 (29.0) 
76 (71.0)
0.55
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GMI and clinical outcomes in patients with baseline GMI > 0.5
Of the 63 IA patients, who had GMI > 0.5 upon entry into the clinical trial, 27 (42.9%) had 
satisfactory response following 12 weeks of anti-fungal treatment. The remaining 36 (57.1%) 
were assessed to have poor response to therapy as determined by the DRC.
Week 12 clinical response
GMI generally showed a downward trend with anti-fungal treatment (Fig. 1). Non-responders 
at week 12 (W12 Non-responders) tended to have higher baseline GMI (mean 1.49+0.25) 
than responders (mean GMI 1.16+0.22), but this difference was not significant (p=0.211). 
However, responders (W12 Responders) had a reduced week 1 GMI value compared to 
patients who eventually failed treatment (GMI 0.66+0.08 versus 1.29+0.27 respectively, 
p=0.0016; Fig. 1a). This difference remained statistically significant after adjustment for the 
co-variates: age, sex, neutropenia, underlying disease and class of anti-fungal drug 
(p=0.037). As noted from the GMI profile, patients who had W12 satisfactory response 
tended to show a more discernible AGMI drop from baseline to week 1 (AGMIbaseline^ W1) as 
compared to the non-responders (Fig. 1a, p=0.187); after multivariate adjustment, p-value 
was 0.165.
With the above findings, ROC analysis was performed to assess if a prediction rule could be 
derived to anticipate W12 response. It turned out that using absolute GMI readout at week 1 
was a suboptimal model : attaining GMI > 0.66 at week 1 had 57% sensitivity and 64% 
specificity for poor W12 clinical response (area under curve, AUC 0.606, p=0.224) despite 
this difference being statistically significant on GMI profile analysis as above. On the other 
hand, ROC analysis revealed that AGMIbaseline^ W1 can be a good predictor of W12 response 
despite profile analysis indicating a trend : < 10% drop in AGMIbaseline^ W1 was 52% sensitive 
and 82% specific for W12 poor response (AUC 0.721, p=0.011)
Week 12 survival
Twenty-one of these 63 patients (33.3%) with baseline GMI > 0.5 survived until the 
designated study end-point while mortality was recorded in other 42 patients (66.7%). A 
marked drop in GMI between week 1 and week 4 (AGMIW1^ W4) was associated with W12 
survival (p=0.038). After multivariate adjustment for age, sex, neutropenia, underlying 
disease and anti-fungal medication, the p value remained significant at 0.017. However 
earlier GMI trends were non-discriminative between eventual survivors and non-survivors 
(Fig. 1b).
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0.543
(b)
2 
1.8 
1.6 
1.4 
1.2 
1
ID 0 .8  
0 .6  
0 .4  
0.2 
0
xai~a
c
0.907
0.630
0.038
W12 Non-survivors 
W12 Survivors
--------------------- 1------------------------1------------------------1------------------------1
Baseline W e e k  1 W e e k  2 W e e k  4
F igure 1. Galactomannan index (GMI) of patients with positive GMI >  0.5 at baseline plotted against pre-defined 
clinical outcome parameters at week 12 : treatment response (a) or survival (b). The value enclosed by horizontal 
brackets represents univariate p value for the difference in AGMI of both groups between the indicated study 
interval. #1 is the p value for the difference in absolute GMI value between W12 responders and non-responders. 
#1 p value was 0.0016 by univariate analysis, after multivariate correction #1 p value was 0.037. Statistical 
analysis was performed by the generalized estimating equation (GEE) approach.
Using ROC analysis to derive a prediction rule, AGMIW1^ W4 of <33% decrease had 83%
sensitivity and 53% specificity for mortality by 12 weeks (AUC 0.775, p=0.034).
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In summary, in IA patients with baseline GMI > 0.5, the above results indicate AGMIbaseline^ W1 
should see > 10% drop, preferably to a GMI value < 0.66 for likelihood of satisfactory W12 
response. Likewise, AGMIW1^ W4 drop of > 33% was desirable for survival.
GMI and clinical outcomes in patients with baseline GMI < 0.5
Of the patients who were diagnosed with either definite or probable IA as per trial inclusion 
criteria, 107 of them (62.9%) had a baseline GMI < 0.5. Fifty-six of these 107 patients 
(52.3%) were deemed to have had satisfactory response to anti-fungal treatment as 
determined by the DRC at week 12 (Table 1). Survival rate was 72.9% (78 of 107 patients) in 
this cohort.
Week 12 clinical response
Correlating GMI and W12 response revealed that baseline and week 1 GMI values were 
similar with regards to clinical outcomes (Fig. 2a). In contrast, GMI trends showed results 
that correlated significantly with outcome. Non-responding patients displayed a significantly 
increased AGMIbaseline^ W 2 (p value remains at 0.001 after multivariate adjustment) as 
compared to responders. Similarly, an increased GMI trend between W12 responders and 
non-responders was also observed for AGMIW1^ W2 (p value 0.032; with multivariate 
adjustment, p=0.021). But statistical significance was lost for AGMIbaseline^ W4 with multivariate 
analysis (p value from 0.046 to 0.085). Using ROC analysis, AGMIbaseline^ W 2 increase > 40% 
yielded 58% sensitivity and 78% specificity for poor W12 clinical response in this cohort of 
patients (AUC 0.68, p=0.013).
Week 12 survival
Early GMI trends between W12 survivors and non-survivors mirrored that of treatment 
response (Fig. 2b) : non-declining, or increasing AGMI at weeks 2 and 4 were predictive of 
mortality. After multivariate adjustments were made, the difference trends between survivors 
and non-survivors all remained significant (p value for AGMIbaseline^ W 2 still < 0.001, 
AGMI baseline^ W4 p=0.034 to 0.033, AGMIw1^W2 p=0. 004 to 0.008). Applying ROC analysis for 
AGMIbaseline^ W2 , an increase of > 40% was 60% sensitive and 76% specific for mortality by 
W12 (AUC 0.70, p=0.008).
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In summary, for IA patient who started off with baseline GMI < 0.5, a rising AGMI despite 
treatment was likely detrimental: AGMIbaseline^ W 2 showing an increase of > 40% could be 
predictive of both poor response to treatment and mortality at week 12.
(a) 0.046
X01■ac
0.9 
0.8 
0.7 
0.6 
0.5 
0.4 
0.3 
0.2 
0.1 
0
<0.001
0.032 J
0.211
W12 Non-responders 
W12 Recponders
---------------------------1-------------------------------1-------------------------------1------------------------------ 1
Baseline W e e k  1 W e e k  2 W e e k  4
0.035
(b)
x
<u
■a
1
0.9 
0.8 
0.7 
0.6 
£  0.5 
IS 0.4 
0.3 
0.2 
0.1 
0
<0.001
0.004 J
0.227
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Baseline W e e k  1 W e e k  2 W e e k  4
F igure 2. Galactomannan index (GMI) of patients with baseline GMI < 0.5 at baseline plotted against pre-defined 
clinical outcome parameters at week 12 : treatment response (a) or survival (b). The value enclosed by horizontal 
brackets represents univariate p value for the difference in AGMI of both groups between the indicated study 
interval. Statistical analysis was performed by the generalized estimating equation (GEE) approach.
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Discussion
In the present study, using the well-characterized cohort of IA patients from the Global 
Aspergillosis Study [14], we have demonstrated that serum galactomannan index (GMI) can 
be utilized as an early marker to prognosticate clinical outcome following treatment. For IA 
patients with baseline GMI > 0.5, a drop of GMI to less than 0.7 following 1 week of treatment 
is desirable for an anticipated satisfactory clinical response and a progressive GMI decline all 
through the first 4 weeks of therapy is reassuring. In patients fulfilling diagnostic criteria for IA 
but with baseline GMI < 0.5, the GMI should stay low through first 4 weeks of treatment 
should satisfactory clinical response be anticipated. An increasing GMI trend after week 1 is 
predictive of poor treatment response and mortality.
Clinical response to anti-fungal treatment in hematological patients with IA may be obscured 
in face of neutropenia, concurrent immune-modulatory drugs and the compromised immune 
system of the host. Until recently, assessment of response has been difficult in the absence 
of a reliable surrogate marker of the disease state [17]. With the introduction of the Platelia 
Aspergillus GM EIA, much interest has been generated on the usefulness of the GM assay 
as a diagnostic tool for IA in various clinical settings [6, 18-20]. However, less has been 
recognized on the potential role of GM as a marker of disease status. This aspect was first 
explored by Boutboul et al who reported that an increasing GMI was associated with disease 
progression [10]. It is only recently that two independent groups reported findings that serum 
Aspergillus GMI strongly correlated with outcome of invasive aspergillosis and could likely 
serve as surrogate marker to assess outcome of disease. Using survival as a definitive 
outcome, Anaissie et al noted that normalization of serum GMI (to OD < 0.5) after treatment 
was associated with survival [21]. Similarly, Maertens el al had shown that normalization of 
GMI (<0.5) 6 weeks after start of anti-fungal therapy strongly correlated with response 
outcome and survival [12]. Subsequent to their finding, Anaissie et al performed a literature 
review of prior published studies and found that serial GMI trends through the course of 
illness showed strong correlation with clinical outcome [13].
Our findings here differ from earlier observations made by the above latter two authors on 
three aspects. Firstly, the design of the earlier studies stemmed from the original intent of 
using GMI as a surrogate end-point to assess outcome of therapy [11][. As such serial GMI 
measurements of IA patients were followed up until within 1 week of eventual outcome 
evaluation (either discharge or death) by Anaissie et al, or in the case of Maertens et al, the 
earliest assessment point was at 6 weeks post start of anti-fungal therapy. In our case, we
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were interested in using early GMI trends as a potential tool to predict clinical outcome. We 
were able to demonstrate that GMI trend as early as 1 week after start of appropriate anti­
fungal therapy was informative and could predict eventual clinical outcome 12 weeks later. 
Secondly, analyses of the earlier studies had been performed using GMI as a dichotomous 
variable i.e. either positive > 0.5 or negative < 0.5. In our study design, we had used GMI as 
a continuous variable and were able to ( i ) correlate increasing GMI with poor 
outcome/survival ( ii ) quantitatively assign an early GMI reduction cut-off value as being 
associated with eventual satisfactory clinical response at 12 weeks. Thirdly, though GM 
assay has to date, been acknowledged as a reliable means to assist diagnosis of IA [6, 20], 
we recognize that at the bedside, not all patients with a high suspicion for IA on clinical 
grounds will fulfill all the EORTC diagnostic criteria [7] and invariably have GMI > 0.5. Such 
patients, with GMI < 0.5, nonetheless, will still be initiated on anti-Aspergillus therapy by their 
attending hematologists. With our well-characterized cohort of IA patients, we were able to 
stratify the patients into those with baseline GMI < or > 0.5. By following their respective GMI 
profiles, we were able to demonstrate that the GMI trends between patients with starting GMI 
< or > 0.5 do differ through the clinical course.
At this point, we acknowledge the recently-presented findings of another group [22] which 
reported that GMI trend between baseline to week 1 was predictive of mortality at 6 weeks in 
74 GM-positive IA patients. Our study had revealed an analogous finding that a drop in GMI 
should be anticipated after 1 week of anti-fungal therapy should satisfactory response be 
anticipated in patients whose baseline GMI was > 0.5. Furthermore we were able to derive 
early AGMI cut-off thresholds predictive of subsequent poor clinical response and mortality. 
For clinicians, this enables timely identification of patients who may potentially fail first-line 
anti-fungal treatment so as to facilitate intervention with more aggressive second line or 
combination anti-fungal therapy.
The criteria for definite and probable invasive aspergillosis in our study cohort had been the 
consensus case definitions as determined by the EORTC then at the time of the conduct of 
this study. Since then, case definitions for IA have seen modifications by the EORTC/MSG in 
2002 and 2008 with the diagnostic threshold generally being lowered allowing more patients 
to qualify as ‘possible IA’ than would have been so during the enrollment of this study. As 
such, the high certainty of disease as diagnosed in this study cohort was highly unlikely to be 
of doubt. Furthermore, the plurality of the scope of this trial, as well as the well-established 
end-points and objective criteria for determination of clinical response by a blinded panel of 
experts support the findings of this study. We are also aware that the proportion of patients
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with definite/probable IA, but with baseline GMI of > 0.5 in this study, was lower than would 
have been anticipated which could influence power of the analysis. However similar 
observations have also been reported in other IA patient cohorts [23]. Whilst this could be 
reasonably accounted for by the design and recruitment/inclusion criteria of the original trial 
[14], this unique setting had also permitted us to profile the GMI trends of the 2 cohorts 
(starting GMI < or > 0.5) appropriately and to arrive at our conclusions as presented above.
In conclusion, we have shown that early GMI trends can be used to predict eventual clinical 
response and mortality in patients with IA. Early identification of patients who may potentially 
fail therapy is pivotal to facilitate prompt intervention in order to optimize outcome in invasive 
aspergillosis.
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Invasive aspergillosis remains practically a disease of the immunocompromised. This 
indisputable fact underlines the fundamental tenet that the host immune status is paramount 
in determining susceptibility and outcome of infection. The past decade has seen remarkable 
progress through the development of novel classes of anti-fungal drugs active against 
Aspergillus and other mould infections. It remains evident, however, that despite new drugs 
and strategies of combination therapy in an attempt to improve response rates, the available 
drugs can only achieve a limited level of efficacy in a host that is unable to mount an 
adequate immune response. Consequently, invasive aspergillosis still remains a disease with 
high mortality and morbidity. This underscores the need to shift our thinking about disease 
management beyond traditional anti-microbials and to approach adjunct management with 
the intent of augmenting and modulating the host immunity.
Before tailor-made immunotherapeutic strategies can be adopted for clinical application, the 
innate immune interaction between the host and pathogen must be deciphered. This is 
achieved through studying the pathogen recognition receptors (PRRs), signaling pathways 
and host immune responses to Aspergillus species or its components in in-vitro and in-vivo 
systems. In turn, this knowledge may be thereafter translated to the immunocompromised 
patient at-risk to aid in management of the disease.
Besides learning how the host immune system is being activated upon encountering a fungal 
pathogen, it is known that the fungus can develop strategies to evade recognition and 
overcome host anti-fungal defenses. This was reviewed in Chapter 2 of the thesis. The 
immune evasion strategies can be broadly categorized into (i) shielding of stimulatory 
PAMPs, (ii) modulation of inflammatory signals, (iii) shedding of decoy components, (iv) 
intracellular persistence of fungi and (v) complement evasion. The elucidation of these 
mechanisms extends beyond the realm of microbiologic interests, as this understanding may 
guide future approach to new avenues for intervention in invasive fungal disease. Table 1 
provides a list of the potential therapeutic applicability of this knowledge.
Because little is known about the immunomodulatory capability of Aspergillus morphotypes, 
the modulation of Toll-like receptor (TLR)-based signaling pathways by the fungi was 
investigated. In Chapter 3, we described a novel immunomodulatory mechanism 
perpetuated by A. fumigatus conidia which resulted in the attenuation of TLR2- and TLR4- 
mediated proinflammatory responses, such as interleukin (IL)-1ß and lL-6 production. We
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demonstrated that down-regulation of TLR2-signaling was attributable to the internalization of 
A. fumigatus conidia together with the TLR2-receptor into the phagosome during the course 
of infection. On the other hand, A. fumigatus hyphae showed a selective propensity to inhibit 
TLR4-mediated signaling resulting in diminished IL-6 and tumor necrosis factor-alpha (TNF- 
a) response, and this effect was found to be partially mediated by the mannose receptor 
(MR). Elucidation of the intimate molecular mechanisms responsible for this effect warrant 
further in-depth experiments. Consequently, activation of TLR2 in the absence of TLR4 
signals by A. fumigatus hyphae may favour a pro-Th2-type anti-inflammatory response. 
Taken together, the above-described effect shifts the host cytokine profile away from a pro- 
inflammatory-type response and this confers a survival advantage to the fungi.
Following up on this interesting observation, we investigated which Aspergillus cell wall 
components could have contributed to the above-described immunomodulatory effects. 
Although cell wall ß-glucan is the best studied PAMP of Aspergillus, the immunological 
properties of the other Aspergillus cell wall components such as a-glucan, galactomannan 
and chitin are less studied. In Chapter 4, we found a novel immunomodulatory role of a- 
glucan which, like galactomannan, had the capacity to attenuate both TLR2- and TLR4- 
mediated pathways in host immune cells. In contrast, the effects of ß-glucan were specific 
through the modulation of TLR4 signaling. Beta-glucan is a well-established ligand for 
Dectin-1 [1]. In our hands however, the ß-glucan-induced TLR4-suppressive effect was 
independent of the Dectin-1 receptor as the use of glucan phosphate, a Dectin-1 antagonist, 
did not reverse the inhibitory effects via TLR4. This observation was consistent with our 
earlier findings in Chapter 3, in which laminarin (another inhibitor of Dectin-1) also did not 
influence the modulatory effects of intact A. fumigatus conidia. These data confirm that TLR2 
and TLR4 mediated cytokine induction can take place independent of beta-glucan signalling 
through dectin-1. While research is still ongoing to establish the recognition receptors for 
galactomannan and a-glucan, the above findings suggest that the modus operandi of ß- 
glucan in immune modulation is probably more complex than just engaging the Dectin-1 
signaling pathway. Other candidate ß-glucan receptors include complement receptor 3 (CR3) 
[2] or a yet-to-be-identified novel receptor. In the author’s opinion, it is also very likely that 
Aspergillus cell wall a-glucan and galactomannan are candidate PAMPs which participate in 
immune recognition. Future studies into PRR-Aspergillus PAMP interactions are warranted.
Besides providing an insight into pathogenesis, the challenge of harnessing this knowledge 
lies in finding the potential means to curtail any of the above-described mechanisms adopted 
by the pathogen to retard appropriate host immune response. In particular, the fungal cell
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wall polysaccharides described above present an attractive target for therapy. Much effort 
has been channeled into targeting ß-glucan and this has culminated in development of a new 
class of ß(1,3)glucan synthase inhibitors, the ecchinocandins, which is currently on the 
market [3]. Not surprisingly, it has been shown that besides disrupting the fungal cell wall, 
ecchinocandins can in turn augment the host immune profile in response to the pathogen 
through the unmasking of ß-glucan in the hyphal growth forms, which would have otherwise 
remained concealed [4, 5]. The challenge remains to develop new strategies to target cell 
wall ß-glucan, a-glucan and galactomannan. Strategies aimed at disrupting these cell wall 
polysaccharides not only serve to affect the fungal cell wall integrity directly, but also have 
the potential to optimize the host immunologic response during treatment. Further research 
and understanding the immunologic characteristics of the various cell wall components may 
potentially provide the basis for vaccine development against invasive fungal diseases [6].
In Chapter 5, we have shown for the first time that melanin on the surface of intact 
Aspergillus conidia has a shielding function and modulates host proinflammatory response. 
Melanin masked PAMPs (such as ß-glucans) on the fungal cell wall from being recognized 
by host PRRs and prevented these PAMPS from eliciting an inflammatory response. This 
postulation was further strengthened by our demonstration that purified melanin was a very 
poor inducer of cytokine production, a prerequisite characteristic for the assumption of its 
‘masking’ role. Recently, our findings were corroborated by another group which showed that 
hydrophobic proteins on Aspergillus conidial surface serve to immunologically silence the 
mould [7]. Given the ubiquity of fungal spores in the environment, it is conceivable that the 
host defense should only be activated in case of an invasive threat. An unnecessary but 
overwhelming pro- inflammatory response in the absence of a genuine threat could be 
disruptive. The fact that the immune system is not triggered by immune recognition of 
melanin may represent one mechanism by which the host avoids unnecessary airway and 
pulmonary tissue damage. From the perspective of the pathogen however, this is yet another 
immune evasive strategy. The conferred ability to dampen its immune signature beneath the 
façade of the melanin layer enables dormant conidia to escape host immune detection and 
remain viable within non-phagocytic cells or sanctuary sites in the host until a favorable 
moment for germination and eventually tissue invasion [8, 9].
Consequent to activation of the innate immune system which triggers the inflammatory 
signaling cascade, the acquired immune system gradually assumes its role through 
proliferation and differentiation of effector CD4 T-cells specific against A. fumigatus. On the 
one hand, host defense to A. fumigatus has been described to be strongly enhanced by
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interferon-gamma (IFN-y) release by T helper type 1 (Th1) CD4 T cells. On the other hand, 
interleukin-17-producing CD4 T cells (Th17), being the most recently- described T-helper cell 
lineage, have been reported to be a pivotal mediator of host antimicrobial response through 
coordination of neutrophil recruitment and bactericidal potency at site of infection. In Chapter
6, we studied the relative importance of both human Th1 and Th17 responses against 
Aspergillus in human immune cells. We learned that anti-Aspergillus response relied more on 
Th1 than on Th17 cellular immunity, by showing that A. fumigatus induced significant levels 
of IFN-y but was a weak inducer of IL-17. This was contrary to findings reported by others 
based on mouse models [10, 11]. Furthermore, the relative incapacity to stimulate Th17 
responses appeared to be intrinsic, rather than the result of indirect down-regulatory effects 
through Th1 induction. Clinically, the limited involvement of IL-17 in anti-Aspergillus host 
response is supported by observations that patients with Hyper IgE syndrome (HIE) and 
chronic mucotaneous candidiasis (CMC), who are known to have defective Th17 response 
[12, 13], do not suffer from invasive forms of Aspergillus infections.
One of the requisites of translational research calls for findings obtained from in-vitro/in-vivo 
models to be validated in the relevant human clinical situations. One such example is the 
question on the clinical significance of Th17 in the human host. In Chapter 6 we showed that 
levels of IL-17 in bronchoalveolar lavages of patients with invasive aspergillosis were very 
low, and these clinical data corroborated the in-vitro results of at best a limited role for IL-17 
in invasive aspergillosis. Likewise, Dectin-1 has generally been recognized as the pivotal 
PRR for recognition of fungal pathogens (via ß-glucan) based on compelling results derived 
from in-vitro and mice models [14, 15]. In Chapter 7 the clinical significance of the Dectin-1 
Y238X polymorphism in a cohort of IA patients was investigated. The results of Dectin-1 
Y238X genotyping -the only known functional Dectin-1 SNP resulting in diminished Dectin-1 
receptor expression, indicated that possession of this SNP conferred limited susceptibility to 
invasive aspergillosis in immunocompromised patients at risk for the infection.
Functional studies of PBMC and monocyte derived macrophages (MDM) obtained from 
individuals with complete deficiency of Dectin-1 receptor expression showed differences in 
response to Aspergillus that depended on the cell-type studied. Whereas Dectin-1-deficient 
PBMC showed a diminished host proinflammatory cytokine in response against the fungal 
pathogen as anticipated, Dectin-1-deficient tissue macrophages that form the first line of 
defense against Aspergillus (as represented by MDMs in-vitro), retained the capacity for an 
effective response. These results suggest that although Dectin-1 might play pivotal role in 
some in-vitro systems and mice models [15], a system of redundancy exists in the host
162
Summary and discussion
innate immune defense in humans: in the absence of Dectin-1, alternative signaling by other 
PRRs pathogen recognition receptors like TLR4 and MR may compensate for the deficient 
functioning of the Dectin-1 signaling arm.
What is considered an ‘adequate’ cytokine response during invasive aspergillosis in 
humans? Are higher levels of proinflammatory cytokines desirable during the course of 
invasive aspergillosis or otherwise? We need a deeper insight into these fundamental 
questions should we aim to eventually translate what has been learned from the bench to the 
bedside, so that cytokine assays and other biomarkers may one day be utilized in the clinical 
management of patients. It is hoped that the observations in Chapters 8 and 9 may bring us 
closer to this understanding. In Chapter 8, following up a well-characterized cohort of IA 
patients, we found that circulating proinflammatory cytokine levels were high during disease 
and generally a downward trend with anti-fungal therapy. Interestingly, subjects with adverse 
outcomes showed a distinct lack of decline of IL-6 and CRP at 1 week post-treatment as 
compared to the responders. Non-responders also had persistently elevated IL-8 levels. 
These novel findings highlight the usefulness of biomarker monitoring as a convenient and 
non-invasive tool for early identification of patients with poor response to anti-fungal 
treatment who may potentially benefit from more aggressive anti-microbial regimens.
Through our understanding of Aspergillus cell wall biology, it is known that galactomannan 
(GM) is a cell wall polysaccharide distinct to Aspergillus and its quantification may be a 
reflection of the inherent fungal load during disease. Hence in Chapter 9, we investigated if 
serial GM trends may be used as a biomarker for disease status and prognosis of outcome. 
Indeed, we showed that a distinct decline in GM trends at weeks 1 and 4 post treatment were 
prognostic for good clinical outcomes. The findings as described above demonstrate how 
knowledge of cytokine biology and biomarkers may be harnessed to optimize clinical 
management, in order to follow treatment response and identify potential poor responders 
who may benefit from early institution of aggressive anti-microbial regimens. Given our 
findings, it will be prudent to seek similar opportunities in future anti-fungal clinical trials to 
prospectively monitor circulating cytokine and galactomannan levels of IA patients at closer 
intervals. More recently it has been proposed that ‘immune reconstitution syndrome’ (IRIS) 
may be the cause of apparent disease progression in some IA patients which is not 
consequent to failure of therapy [16]. It will be tantalizing to attempt correlating the clinical 
and radiological progress of our IA patients with the cytokine (as surrogate for immune 
response) and galactomannan (as surrogate for fungal load) levels as proof of concept for 
the occurrence of IRIS in IA.
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The findings presented in Chapter 8 also shed light on our understanding of ‘appropriate 
host immune response’ during the course of illness in patients with invasive aspergillosis. 
First and foremost, it remains to be stated that patients who are at risk and those who 
acquire the disease are invariably immunocompromised. They may have had prolonged 
neutropenia and their ability to mount appropriate Th1/IFN-y or TNF-a responses may be 
impaired iatrogenically as a result of treatment regimens [17]. Upon encountering inhaled 
conidia in the susceptible host, resident pulmonary macrophages attempt to contain conidial 
germination through phagocytosis and a proinflammatory response. A proinflammatory milieu 
consisting of heightened IL-6, IL-8 and TNF-a amongst others, constitutes the host response 
against invading Aspergillus and this is accompanied by recruitment of inflammatory 
macrophages from the circulation and (any residual) neutrophils. Whilst the macrophages 
contain conidial germination, neutrophils are active against the developing hyphae through 
induction of respiratory burst and degranulation. However, as demonstrated, the pathogen 
possesses the capability to dampen host pro-inflammatory response, and hyphal germination 
cannot be effectively dealt with by the immunocompromised host.
Inflammation, however, is a double-edged sword. The inflammatory response that is initiated 
by the innate immunity is to be followed by adaptive immune system which not only 
orchestrates specific counter-measures against the pathogen, but also regulates the 
inflammatory signals originating from the initial innate response. Dysregulated or 
overwhelming inflammation leads to undue tissue damage and this is classically seen in 
autoimmune diseases. Recently, it has been proposed that dysregulated inflammation may 
be a component of the pathophysiology of invasive aspergillosis [16, 18]. As a result, this 
inability to adequately control the inflammatory process leads to worsening disease, tissue 
damage and consequently, morbidity. Indeed, our clinical study lent support to this 
hypothesis. Though the generation of a proinflammatory milieu is a necessity in order to 
mount an initial early response against the fungi, an unnecessarily prolonged inflammatory 
process, as characterized by raised IL-8 and persistence of elevated IL-6 beyond the first 
week of illness, was associated with likelihood of treatment failure and mortality. Hence, it is 
conceivable that an appropriate host immune response in invasive aspergillosis is a dynamic 
system as it is intrinsically dependent on the temporal course of the disease, which 
necessitates strict control by regulatory immune mediators. It is only with such understanding 
of the immune kinetics that the appropriate immunotherapy may be rightly administered at 
the right time during the course of illness to optimize outcome in IA.
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It is without doubt that our understanding of host immunologic response during invasive 
aspergillosis still remains an oversimplification of reality. The findings in this thesis and its 
clinical contribution are a few additional pieces fitting into a big jigsaw, as we seek to learn 
more about the disease and to manage it. The complexity of the human immune system will 
be enhanced by the further discovery of more receptors, ligands, signaling pathways and 
mediator molecules. Lest however, as exciting as it might be to explore unchartered 
territories in as we grapple to learn even more about the intrinsic workings of cellular 
immunity, we must never lose sight of our ultimate goal: which is to translate the knowledge 
gained at the bench back to the patient, and it is hoped that studies in this thesis have 
contributed to this process.
‘To study the phenomenon of disease without books (as with research) 
is to sail an unchartered sea, while to study books (and conduct research) 
without patients (in mind) is not to go to sea at all.’
Paraphrased from Sir William Osler 1849~1919
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Shielding stimulatory PAMPs
Example Possible therapeutic strategy
Shielding of ß-glucan in C.albicans 
hyphae
a-1,3 glucan outer layer masks 
immunostimulatory ß-glucan in 
H.capsulatum
Extracapsular glucuronoxylomannan of 
C.neoformans masks surface PAMPs
Disruption of fungal cell wall by use 
of ß-1,3-glucan synthase inhibitors
a-1,3-glucan synthase inhibitor 
Inhibitor of capsule synthesis
Modulation of inflammatory signal
Example Possible therapeutic strategy
Preferential activation of TLR2 over TLR4 
by hyphal forms of C.albicans and 
A.fumigatus
Inhibitor of morphological change
Shedding of decoy
Example Possible therapeutic strategy
Shedding of gpA as decoy by P.jiroveci to 
block MR
Antibodies against gpA
Intracellular persistence
Example Possible therapeutic strategy
Post-phagocytosis persistence of 
C.albicans and immune escape
Use of TLR ligands or immune 
mediators (e.g. IFN-y) to increase 
lysis efficiency of phagosomes
Complement evasion
Example Possible therapeutic strategy
C.albicans binding of Factor H and C4BP Development of opsonizing 
antibodies and opsonins against 
specific pathogens
Table 1 Mechanisms of immune escape by fungal pathogens and potential strategies for therapy (adapted from 
Chai et al and Rappleye & Goldman [19, 20])
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Invasieve schimmel infecties vormen een ernstige bedreiging voor 
immuungecompromitteerde patiënten. Aspergillus fumigatus is een veelvoorkomende 
schimmel in het milieu en tevens de meest voorkomende verwekker van invasieve schimmel 
infecties in bovengenoemde patiëntengroep. Het ziektebeeld dat A. fumigatus veroorzaakt is 
afhankelijk van de onderliggende afweerstoornis, maar manifesteert zich doorgaans in de 
longen. De sterftekans is ondanks de behandeling met antifungale middelen hoog, indien 
niet tegelijkertijd de afweer van de patiënt wordt verbeterd. Dit impliceert dat naast de 
ontwikkeling van nieuwe antifungale middelen interventies wenselijk zijn die de 
onderliggende afweerstoornis gericht kunnen moduleren of verbeteren. Hiermee zou een 
belangrijke stap in de behandeling van invasieve aspergillose kunnen worden gezet: 
“immunotherapie op maat”. Voordat op maat gemaakte immunotherapeutische strategieën 
grootscheeps klinisch kunnen worden toegepast, dient onder meer de interactie tussen 
schimmel en afweersysteem van de gastheer in kaart te worden gebracht. Het onderzoek dat 
ten grondslag lag van dit proefschrift had tot doel deze interacties te karakteriseren en, voor 
zover mogelijk, naar de klinische praktijk te vertalen.
De kleinste vorm van de schimmel, de sporen, wordt eenvoudig via de lucht gedragen en 
belandt na inademing diep in de longen. Als de sporen (conidia) daar tot schimmeldraden 
(hyfen) ontkiemen ontstaat invasieve pulmonale aspergillose. Om invasie te voorkomen is 
het noodzakelijk dat de binnendringende schimmel door het afweersysteem van de gastheer 
als lichaamsvreemd wordt herkend. Schimmels dragen aan het oppervlak zogenaamde 
‘pathogeengeassocieerde moleculaire patronen’ (PAMPs). Een voorbeeld van een PAMP is 
galactomannan dat onderdeel is van de celwand en wordt gebruikt in de diagnostiek van 
invasieve aspergillose. PAMPs worden herkend door patroonherkennende receptoren 
(PRRs) op cellen van het afweersysteem. Herkenning leidt vervolgens tot signaaltransductie 
in de cel en tot productie van signaaleiwitten (cytokinen) die het afweersysteem kunnen 
versterken of dempen.
De herkenning van een schimmel door het afweersyteem is een dynamisch proces dat in 
zekere zin kan worden gezien als een “kat- en muisspel”. Een schimmel kan op diverse 
manieren het afweersysteem op het verkeerde been zetten. De wijzen waarop schimmels in 
staat zijn herkenning en de afweerreactie in eigen voordeel te beïnvloeden zijn in Hoofdstuk
2 beschreven. Deze afweersysteem ontwijkende strategieën kunnen grofweg in de volgende 
categorieën worden ingedeeld: (i) afscherming van PAMPs, (ii) modulatie van de
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afweerreactie, (iii) uitzetten van valstrikken/ misleidende signalen, (iv) intracellulair verblijf en 
(v) evasie van het complementsysteem. De opheldering van dit soort mechanismen kan 
richting geven aan toekomstige ontwikkeling van nieuwe antifungale strategieën. Enkele uit 
deze mechanismen voortvloeiende potentiële therapeutische toepassingen zijn in tabel 1 
weergegeven.
De morfologie van A. fumigatus is wisselend. Er is weinig bekend over de 
immunomodulerende effecten van de verschillende groeivormen (conida en hyfen). In 
Hoofdstuk 3 zijn de resultaten van de studie naar de immunomodulerende invloed van 
Aspergillus conidia en hyfen op een belangrijke groep PRRs, de Toll-like receptoren (TLRs), 
vastgelegd. Een nieuwe immunomodulerende invloed van A. fumigatus conidia werd ontdekt, 
namelijk demping van TLR2- èn TLR4-gemedieerde productie van pro-inflammatoire 
cytokinen, zoals interleukine (IL)-1ß en lL-6. De verminderde TLR2-gemedieerde respons in 
reactie op een secundaire stimulus kon worden toegeschreven aan internalisatie van de 
conidia met de TLR2 receptor tijdens fagocytose. Daarentegen toonde de andere groeivorm, 
A. fumigatus hyfen, een tendens tot selectieve remming van de TLR4-gemedieerde 
secundaire respons met verminderde productie van IL-6 en tumor necrosis factor-alpha. Het 
immunomodulerende effect van hyfen op de TLR4-gemedieerde secundaire respons bleek 
gedeeltelijk beïnvloed door participatie van de mannose receptor (MR). Opheldering van de 
hieraan ten grondslag liggende moleculaire mechanismen is onderwerp van toekomstig 
onderzoek. Al met al ondersteunen deze resultaten onze eerdere aanwijzingen dat hyfen, de 
invasieve groeivorm, de TLR4-gemedieerde respons dempen waardoor een anti­
inflammatoire T-helper 2 respons optreedt. Deze drift van een pro-inflammatoire naar een 
anti-inflammatoire afweerreactie die op de morfologische transformatie van conidia naar hyfe 
volgt is ten faveure van de invaderende schimmel.
Na bestudering van de immunomodulerende invloed van de Aspergillus groeivormen werd 
onderzoek verricht naar de contributie van specifieke Aspergillus celwand bestanddelen aan 
dit proces (Hoofdstuk 4). Dit onderzoek bracht een nieuwe immunomodulerende rol aan het 
licht, namelijk die van a-glucan dat net als galactomannan zowel de TLR2- als TLR4- 
gemedieerde afweerreactie dempte. Beta-glucan is een welbekend ligand van PRR Dectin-1. 
Geheel tegen de verwachting in bleek uit ons onderzoek dat ß-glucan de TLR4-respons op 
een secundaire specifieke stimulus onderdrukte. Dit bleek onafhankelijk van de Dectin-1 
receptor plaats te vinden omdat glucan fosfaat, een Dectin-1 antagonist, de ß-glucan- 
gemedieerde remming niet kon voorkomen. Deze observatie komt overeen met de 
bevindingen in Hoofdstuk 3, waarin laminarine (een andere Dectin-1 antagonist) ook niet in
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staat bleek het immunomodulerende effect van A. fumigatus conidia te couperen. Dit 
bevestigt dat TLR2- en TLR4-gemedieerde cytokine inductie onafhankelijk van ß-glucan 
interactie met Dectin-1 kan optreden. Ook betekent dit dat de modus operandi van ß-glucan 
in het proces van immunomodulatie complexer is dan slechts interactie met, en 
signaaltransductie via Dectin-1, en dat andere receptoren mogelijk een rol kunnen spelen. 
Een kandidaat receptor voor ß-glucan zou Complement Receptor 3 (CR3) kunnen zijn of een 
tot op heden nog te identificeren nieuwe receptor. Additioneel verdiepend onderzoek naar de 
interacties tussen PRRs en bovengenoemde Aspergillus PAMPs is wenselijk en kan aan de 
ontwikkeling van nieuwe antifungale middelen bijdragen die enerzijds een direct effect op de 
schimmel sorteren door de celwand te verzwakken en anderzijds tegelijkertijd de 
afweerreactie versterken. Dit effect is reeds aangetoond voor antifungale middelen behorend 
tot de klasse ecchinocandines. Ook draagt dit onderzoek bij aan de rationale ontwikkeling 
van vaccins tegen invasieve schimmel infecties.
In Hoofdstuk 5 werd voor het eerst aangetoond dat melanine op het oppervlak van intacte 
Aspergillus conidia de onderliggende PAMPs, zoals ß-glucan, afschermt. De PAMPs in 
melanine-bevattende conidia werden dientengevolge niet herkent door PRRs, waardoor een 
afweerreactie nagenoeg uitbleef. Aangezien melanine-deficiënte conidia juist een sterke 
cytokinen productie induceerden en gepurificeerd melanine een verwaarloosbaar 
immunogeen effect teweegbracht, kon de conclusie niet anders luiden dan dat melanine een 
maskerende functie heeft. Recentelijk zijn onze bevindingen door een andere 
onderzoeksgroep bevestigd. Vanwege de alomtegenwoordigheid van sporen in het milieu ligt 
het voor de hand dat de afweerrespons van de gastheer bij voorkeur alléén in geval van een 
invasieve infectie intens wordt geactiveerd. Een overmatige pro-inflammatoire afweerreactie 
in afwezigheid van een daadwerkelijke dreiging kan schadelijke gevolgen voor de gastheer 
hebben. Het feit dat het afweersysteem niet tot nauwelijks reageert op melanine kan dus 
adaptatie van de gastheer zijn om onnodige beschadiging van lucht- en longweefsel te 
voorkomen. Echter, vanuit het perspectief van de schimmel is het een afweersysteem 
ontwijkende strategie: doordat de immunogene kenmerken van de conidia door de melanine 
laag worden gemaskeerd kunnen conidia detectie van het afweersyteem voorkomen en 
intracellulair of in niches overleven tot het moment van ontkieming en invasie (Table 1).
Op activatie van het aangeboren afweersysteem volgt proliferatie en differentiatie van A. 
fumigatus specifieke effector CD4 T-cellen behorend tot het cellulaire afweersysteem. 
Enerzijds is bekend dat de afweer tegen A. fumigatus wordt versterkt door interferon-gamma 
(IFN-y) geproduceerd door T-helper type 1 (Th1) CD4 T-cellen. Anderzijds wordt geopperd
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dat de recentelijk gedetecteerde IL-17-producerende CD4 T-cellen (Th17), een cruciale rol 
spelen in de antimicrobiële weerstand door onder meer de rekrutering van neutrofiele 
granulocyten naar de plaats van infectie te coördineren. In Hoofdstuk 6 is het onderzoek 
naar de relatieve contributie van de humane Th1 en Th17 respons in de afweer tegen A. 
fumigatus beschreven. Terwijl stimulatie met A. fumigatus een significante IFN-y productie tot 
gevolg had, was de produktie van IL-17 slechts matig. Het relatieve onvermogen een Th17 
respons op te wekken was een intrinsiek onvermogen en niet het gevolg van de negatieve 
terugkoppeling door Th1 inductie. De humane anti-Aspergillus respons bleek dus meer op de 
Th1 dan op de Th17 cellulaire afweerrespons te berusten. Dit is echter in tegenstelling met 
de resultaten van studies die gebaseerd zijn op een muismodel. Om te bepalen of IL-17 wel 
of geen cruciale rol in de antifungale weerstand van de mens speelt kunnen klinische studies 
en case-reports de doorslag geven. Patiënten met het Hyper IgE syndroom (HIE) of 
chronisch mucocutane candidiasis (CMC) zijn bekend met een verminderde Th17 respons. 
Deze patiënten gaan echter niet gebukt onder invasieve aspergillose en dit wijst op een 
beperkte rol voor IL-17 in de anti-Aspergillus afweerreactie. Hoofdstuk 6 ondersteund deze 
beperkte rol aangezien de hoeveelheid IL-17 in de bronchoalveolaire lavage van patiënten 
met invasieve aspergillose zeer laag was.
Uit in-vitro onderzoek en muismodellen blijkt Dectin-1 de belangrijkste PRR voor de 
herkenning van schimmels via ß-glucan. In Hoofdstuk 7 is het onderzoek naar de klinische 
relevantie van Dectin-1 Y238X polymorfisme -de enig bekende functionele Dectin-1 SNP die 
in verminderde Dectin-1 receptor expressie resulteert- in een cohort van IA patiënten 
beschreven. De resultaten wezen uit dat aanwezigheid van het Dectin-1 Y238X 
polymorfisme in immuungecompromitteerde hematologische patiënten met een verhoogde 
gevoeligheid voor invasive aspergillose gepaard kan gaan. Functionele studie naar het effect 
van het polymorfisme in perifeer bloed mononucleaire cellen (PBMC) en monocyt-afgeleide- 
macrofagen (MDM) toonde aan dat het effect van het polymorfisme per celtype verschilde. 
Dectin-1 deficiënte PBMC reageerden met een afgenomen pro-inflammatoire cytokine 
respons op Aspergillus stimulatie, terwijl de productie van cytokinen door weefselmacrofagen 
(gerepresenteerd door MDM in-vitro) die de eerste lijn in de verdediging tegen Aspergillus 
vormen onverminderd was. Hoewel is gebleken dat Dectin-1 een cruciale rol speelt in de 
afweer tegen invasieve aspergillose in de muis, suggereert onze studie dat het 
afweersysteem van de mens afwezigheid van Dectin-1 weet te compenseren, althans in 
bepaalde celpopulaties zoals de macrofaag. Alternatieve PRR die hiervoor in aanmerking 
komen zijn bijvoorbeeld TLR4 en de MR.
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Wat is een adequate cytokine response tijdens invasieve aspergillose in de mens? Is een 
grote hoeveelheid pro-inflammatoire cytokinen wenselijk of juist niet? Voordat fundamenteel 
onderzoek kan worden vertaald naar een klinische toepassing, waarbij kan worden gedacht 
aan het gebruik van biomarkers, moeten we antwoord vinden op deze basale vragen. Het 
onderzoek beschreven in Hoofdstuk 8 en Hoofdstuk 9 heeft zich hierop gericht en vond 
plaats op materiaal afkomstig van een goed gekarakteriseerd patiënten cohort met invasive 
aspergillose. Uit Hoofdstuk 8 kan worden afgeleid dat de circulerende pro-inflammatoire 
cytokine concentratie verhoogd is op het moment van diagnose, en geleidelijk tijdens 
antifungale therapie afneemt. In tegenstelling tot responderende patiënten waren de 
circulerende IL-6 en CRP concentraties na 1 week antifungale therapie in patiënten met een 
ongunstig klinisch beloop niet gedaald t.o.v. de uitgangswaarde. Wanneer overleven of niet­
overleven als uitkomstmaat werd gehanteerd bleken de niet-overlevenden een significant 
hoger circulerend IL-8 gehalte te hebben. Galactomannan (GMI) is een biomarker en 
diagnosticum voor invasieve aspergillose. In Hoofdstuk 9 is onderzocht of seriële GMI 
bepaling vroeg in het beloop van invasieve aspergillose van prognostische waarde was. De 
resultaten toonden aan dat het karakter van de GMI trend die geassocieerd was met een 
gunstig of ongunstig beloop afhankelijk was van de uitgangswaarde op moment van 
diagnose (GMI < 0,5 of GMI > 0,5). Deze nieuwe gegevens uit Hoofdstuk 8 en 9 plaveien de 
weg voor de inzet van biomarkers die op non-invasieve wijze patiënten kunnen identificeren 
met een mogelijk slechte prognose of respons op antifungale therapie en gebaat zijn bij een 
agressiever antifungaal regime.
Het spreekt voor zich dat het verstandig is biomarkers zoals circulerende cytokinen en 
galactomannan met korte tussenpozen te meten in de doelgroep in de setting van 
prospectieve klinische trials. Niet alleen om bovengenoemde bevindingen te bevestigen, 
maar ook om een verband te kunnen leggen tussen biomarker ‘concentratie’ en 
daadwerkelijk therapiefalen versus klinische deterioratie ten gevolge van het immuun 
reconstitutie syndroom in patiënten met invasieve aspergillose. Daarnaast is recentelijk 
geopperd dat een gedisreguleerde, overmatige, afweerreactie een rol kan spelen in de 
pathofysiologie van invasieve aspergillose. De gegevens uit Hoofdstuk 8 ondersteunen dit. 
Een goede afweerreactie is dus een kwestie van verhouding en timing. Meer kennis van de 
immunologische kinetiek ten tijde van infectie is noodzakelijk alvorens immunotherapie op 
maat te kunnen toegepassen. Het leidt geen twijfel dat ons huidig begrip van de 
afweerreactie tegen invasieve aspergillose een oversimplificatie van de werkelijkheid is. De 
bevindingen in dit proefschrift zijn slechts enkele stukjes van een grote multidisciplinaire 
puzzel die invasieve aspergillose heet. De complexiteit van de humane antifungale
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afweerreactie zal toenemen met de ontdekking van nieuwe receptoren, ligands en wegen 
van signaaltransductie. Ook al is het verkennen van niet in kaart gebrachte 
afweermechanismen nog zo spannend, het is belangrijk het uiteindelijke doel niet uit het oog 
te verliezen: de vertaling van fundamenteel onderzoek naar toepassing in de patiëntenzorg. 
Ik hoop dat dit proefschrift aan dit proces heeft bijgedragen.
‘To study the phenomenon of disease without books (as with research) 
is to sail an unchartered sea, while to study books (and conduct research) 
without patients (in mind) is not to go to sea at all.’
Paraphrased from Sir William Osler 1849~1919
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Shielding stimulatory PAMPs
Example Possible therapeutic strategy
Shielding of ß-glucan in C.albicans 
hyphae
a-1,3 glucan outer layer masks 
immunostimulatory ß-glucan in 
H.capsulatum
Extracapsular glucuronoxylomannan of 
C.neoformans masks surface PAMPs
Disruption of fungal cell wall by use 
of ß-1,3-glucan synthase inhibitors
a-1,3-glucan synthase inhibitor 
Inhibitor of capsule synthesis
Modulation of inflammatory signal
Example Possible therapeutic strategy
Preferential activation of TLR2 over TLR4 
by hyphal forms of C.albicans and 
A.fumigatus
Inhibitor of morphological change
Shedding of decoy
Example Possible therapeutic strategy
Shedding of gpA as decoy by P.jiroveci to 
block MR
Antibodies against gpA
Intracellular persistence
Example Possible therapeutic strategy
Post-phagocytosis persistence of 
C.albicans and immune escape
Use of TLR ligands or immune 
mediators (e.g. IFN-y) to increase 
lysis efficiency of phagosomes
Complement evasion
Example Possible therapeutic strategy
C.albicans binding of Factor H and C4BP Development of opsonizing 
antibodies and opsonins against 
specific pathogens
Table 1 Mechanisms of immune escape by fungal pathogens and potential strategies for therapy (adapted from 
Chai et al Med Myc 2009 and Rappleye & Goldman Trends Immunol 2008)
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We have been most fortunate to have encountered many people whose kindness and help 
have led to us embarking on this journey together in Nijmegen. If this life may be alluded to 
as travelling on a long distance train journey, God is the train driver we invariably do not see, 
but Whom we are deeply aware of His presence as He has been the One guiding us through 
this journey. As fellow passengers board and subsequently alight at each intermediary 
station stop, we have been most charmed to have been recipients of their unassuming 
kindness during our moments of encounter in many ways than one.
This endeavour would have not been a possibility if not for my parents. They have made it 
their utmost duty to provide for their 3 children with the best education opportunities and 
upbringing at the expense of them working so hard. Despite their old age, they had 
supported my decision to come over to Nijmegen, which is half a world away, to further my 
education; when rightfully, I should have been the one looking after them. Papa and Mummy, 
I will like to tell you that I have really missed you for the past 3 years. Parting at the airport is 
always hard. Now that I am a parent myself, I understand what you both have been through 
bringing us up, and I cherish even more, the love which you have unconditionally showered 
on us. Likewise, I am grateful to my sisters, Helen, Elsa and their families who have 
assumed the even greater responsibility of looking after home and my parents during my 
absence from Singapore. I know this has been a demanding 3 years for you.
Putting aside clinicals to start afresh on a path less travelled has not been easy. I had been 
flooded by doubts on ‘what ifs’ as one would have preferred to snuggle up in a comfortable 
niche at the age of 34 years rather than to venture onto the realm of the untested and facing 
the possibility of failure. Prof Paul Ananth Tambyah, who has been my mentor in infectious 
diseases, had been instrumental in encouraging me to take on this new endeavour, which 
now 4 years on, I can now say with much certainty, that I have never regretted taking this big 
step. Paul, thank you - without your initial encouragement, I could not have imagined that I 
can attain this today. Likewise, I am grateful to Prof Benjamin Ong and Prof Lawrence Ho 
who have furbished every possible means of support from the institution to facilitate my being 
here in Nijmegen. This endeavour would not have been a possibility without the funding from 
the Ministry of Health, Singapore, the Agency for Science, Technology and Research 
(A*STAR) and the National University Healthcare System. Just as importantly, my many 
friends and fellow colleagues back in Singapore who have so kindly followed up on the well­
being of my family members while I was away. By doing so, you have given me the peace of 
mind to continue work here as I know my loved ones are being well looked after.
My first acquaintance with Nijmegen was in March 2006 at the CBS Mycology Course in 
Utrecht where I had also first met Dr Alieke Vonk. It was by God’s Providence that when I 
had decided to pursue an interest in fungal immunology, she was well-placed to introduce 
me to the Netea-Kullberg research group. Dear Alieke, your consistent words of support and 
encouragement have always been so reassuring and timely. I know that should I ever 
encounter problems, there is always someone who I can call on, and who will do her utmost, 
together with Farzin, to render assistance. You have come to epitomize perseverance and
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strength which I will continue to uphold. Thank you also for writing the Nederlandse 
samenvatting en discussie in this thesis for me. When I first enquired about joining the 
research group, Alieke had told me in her very own words, that Prof Kullberg and Prof Netea 
are ‘very kind’. We did not realize the extent of this ‘kindness’ and generosity until our arrival 
in Nijmegen. Dear Mihai and Bart-Jan, throughout our stay here, your primary concern have 
always been to ensure that my family is well-settled in and comfortable rather than over work 
matters. Thanks also for taking so much interest in looking after Claire. It is also from 
yourselves that we draw much inspiration in finding motivation and much direction in our 
work. Dear Mihai, your enthusiasm, drive, intelligence and unrelenting optimism is your 
unique hallmark which we are so fortunate to learn from, and which we hope we can emulate 
in life.
My first impression of Prof Jos van der Meer was that of a well-learned man of chivalry. 
Those early impressions proved to be right: in the initial months in Nijmegen when I was 
encountering worrisome problems with paperwork, Jos reassured me, took up my cause to 
higher levels and wrote in to the press. Your vast experience and wisdom will be much 
missed, Jos. The changes and improvements to the group were very much evident after Dr 
Leo Joosten headed the laboratory, who despite his intellect and experience, have always 
been so unassuming to me. To Dr Andre van der Ven too, who has always paid special 
attention to Claire’s welfare: we are indeed grateful to you.
I realize that the environment in which research is being conducted has an immense bearing 
on output. Under the guidance of Jos, Mihai and Leo, the AIG group is a fertile ground for 
mental stimulation and exchange of ideas, while still keeping research ‘fun and exciting’. 
When I first joined, I was fortunate to have Matthew, Bart, Tim, Berry, Jeroen, Evelien, Meta 
and Hector who facilitated my initiation. Both Matthew and Bart have been most generous in 
sharing their experiences with me and always made me feel comfortable in their company. 
As the group grew in size and strength, I found much joy working in the company of fellow 
colleagues who are all extremely driven and from whom I have learnt a lot: Theo, Marije, 
Rinke, Gerben, Quirijn, Edwin, Nico, Sanne, Diana, Suzanne, Johannake and Marcel. Also, 
the many student interns and visitors who spent time with us, including Kis, Karlijn, Marlo, 
Eleni and Oana. My first room-mate was Calin, who, together with his wife, Delia, always had 
a ear for my queries and worries. With Frank, our exchange of ideas in the room have always 
been exciting and an inspiration to me, and to Monique, through our frequent conversations, 
we have come to know each other better. Amongst friends and colleagues, of special 
mention is James : you have indeed been a gracious friend : you have always been so willing 
to share and I have learnt a lot from you. Beyond work, I still remember how you, without any 
hesitation, lent us your car during the time of Claire’s pregnancy in winter to ease our travel 
concerns. We will certainly miss you and Beryl. The analysts, with their vast experience, form 
the backbone in overseeing the quality of output from the research group. Ineke, Trees, 
Liesbeth, Cor, Anneke, Heidi, Helga, Magda and Johanna have been instrumental in 
imparting to me the basic skills given my lack of prior laboratory training. Dear Magda, Ineke, 
Cor and Johanna, you have all been especially kind to me for which I’ll remember. Despite 
my limited competence in the Dutch language for which I am embarrassed, every effort was
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made to accommodate me in the various activities of the group. I am truly appreciative of 
these gestures.
I have also learnt that research is at its strongest when there is collaboration and free 
exchange of ideas. Many of the works here would not have been a possibility without the 
generous help of friends and collaborators outside the AIG group. In the course of work, 
relationships are formed, especially one being with Dr Steven Teerenstra, my statistician who 
has become more of a friend. Dear Steven, thank you for always being so obliging. I am 
always mindful of the immense efforts and those extra hours which you have put in. Drs 
Adilia Warris and Stefanie Henriet remain close associates from whom I continue to learn 
from. Also within Nijmegen, Dr Alessandra Cambi, Ben Joosten, Richard Huijbens and 
Renoud Marijnissen (from NCMLS), Drs Nicole Blijlevens and Walter van der Velden 
(Hematology), I remain grateful to you for your help and advice in my publications. To Prof 
Paul Verweij and Dr Peter Donnelly: you have taught me much about translating knowledge 
about Aspergillus back to the bedside. Of particular mention is Ton Rijs: you have never said 
‘no’ to any of my requests for help; thank you so much. To Dr Mark de Boer from Leiden, we 
have hit off right in the beginning and have enjoyed working with each other. I hope that we 
can continue this cooperation. I will also like to extend my appreciation to my fellow 
collaborators: Dr Jean-Paul Latgé (Institut Pasteur), Drs Johan Maertens and Katrien Lagrou 
(Leuven, Belgium), Drs June Kwon-Chung and Janyce Sugui (NIH, Baltimore), Dr Peter 
Troke (Kent, UK), Drs David Denning and Peter Warn (Manchester, UK), Dr Wendy van de 
Sande (Erasmus), Prof Marc van der Maarel and Ms Jolanda van Munster (Groningen). It 
was too good to be true that I had the pleasure of working with all of you, many of whose 
names I have known even before coming over to Nijmegen.
The Church has been our pillar of support here over the past 3 years. Led by God, we found 
the Dominicuskerk (which offers the only English Catholic service in the city) on the very first 
day of our arrival in Nijmegen. We found our belonging and identity in this small but warm 
parish community of international students which led us looking forward to attending service 
every weekend even in rain or snow. In the initial few months when we encountered hiccups 
with paperwork or whenever we were in need of help, support and comfort were never 
lacking. Prior to coming, we never imagined that we would be blessed to be able to establish 
relationships with the religious in the Dominicus : Fr Joop, Fr Anton, Fr Budi, Sr Yosephine 
and Sr Dona, whom amongst others, all had inspired us spiritually by the way they live their 
lives. To our many friends in the parish: Andy, Octa, Ratna, Andrew, Maria, Irene, Crispino, 
Cezary, Alena and all the Indonesian students, thank you so much for making Clement, 
Claire and I feel so welcomed. We will sorely miss all of you and your warmth.
I will also like to take the opportunity to acknowledge all the help we have received from the 
Chan Family. Meeting up with them always make us feel a sense of home away from home. 
Understanding of our predicament of living alone far away from Singapore, they have always 
been very concerned about our well-being. Likewise, to Jay: we have been blessed to know
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you as a friend and are sincerely grateful for all your kindness. And to Xuehui and Xinghui 
too, we are most fortunate to have you as our friends.
Last but not least, to my beloved wife Claire: you have always stood by my side in good 
times and in bad. Without you, this endeavour would not have been a possibility. You are the 
co-author of my life, and also, the co-author in my publications. Indeed, I know how 
indispensible you have been in tidying up my many manuscripts, the biggest challenge of 
which has been this thesis; whilst still being fully engaged with the running of the household 
and your work. This book has come to symbolize what we can achieve as One. Together, we 
have continued writing new chapters in life, the most precious of which is the gift of Clement 
on 8th February 2009, right here in Nijmegen. Dearest Clement, Daddy and Mummy live our 
life for you and it is through you that we have been so enriched to experience the love as a 
family. Little Clement, you may not be able to recall much in a couple of years’ time, but as 
you continue to grow and will be able to read, this book will serve as a chronicle of the 
memorable time you spent with Mummy and Daddy in this beautiful city of Nijmegen.
Claire and I came to Nijmegen armed with just two big luggage, but now as we leave 
Nijmegen, we have with us, not only Clement and lots of excess baggage, but also new 
perspectives of life which we learned in these three years. As we come to the designated 
stop of our train journey which we have embarked 3 years ago, we are moving on to board a 
new train bound for another destination. But we bring along with us, the graciousness and 
blessings which we have received from fellow passengers of the last train ride, and will hope 
to ‘pass this on’ to others in this next journey.
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